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Summary 
Prion diseases are as yet inexorably fatal diseases affecting the nervous system of humans 
and animals. They rely on the seeded propagation of the “scrapie” form of the prion protein 
(PrPSc) into its cellular counter-part PrPC. PrPC is indispensible for prion disease as animals 
lacking PrPC do not succumb to the disease. Microscopically, prion diseases or transmissible 
spongiform encephalopathies (TSEs) are characterized by rapid neurodegeneration 
accompanied by astrogliosis, microglial activation, spongiform change and deposits of PrPSc. 
Recent research has exposed the dual nature of PrPC: antibodies targeting the C-terminal, 
globular domain of PrPC (PrPC-GD) exert neurotoxic effects resembling genuine prion 
diseases. Antibodies targeting the N-terminal domain (denoted “flexible tail”, PrPC-FT), 
especially those targeting the octapeptide region of PrPC (PrPC-OR), or interstitial deletions of 
PrPC-OR are protective against both toxic PrPC-GD antibodies and prions, suggesting an 
effector function of the N-terminus. However, the precise molecular mechanisms underlying 
PrPC-mediated neurotoxicity remain largely unclear.  
The aims of the experimental work presented in this thesis are threefold. My first goal 
was to establish a robust experimental assay to measure neurotoxicity. Current methodologies 
mainly rely on post hoc immunohistochemistry with neuronal markers resulting in large read-
out variability that can mask experimental effects. Accordingly, I used organotypic slices from 
transgenic mice expressing fluorescence in neuronal subsets that were subjected to sequential 
confocal imaging in vivo. By taking into account baseline differences in slice size and viability, 
I was able to decrease the read-out variability derived from conventionally used post hoc 
analyses. Sequential time-lapse in vivo imaging was successfully employed in the neurotoxicity 
assessment of anti-prion compounds, which facilitated plotting precise dose-response curves 
that would not have been possible by traditional methods.  
The second aim was to investigate the mechanisms of the neurotoxic, monoclonal 
PrPC-GD antibody POM1 that recapitulates the key features of genuine prion diseases such 
as neuronal cells loss, astrogliosis and microglial activation. It is not known, however, whether 
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POM1 neurotoxicity is accompanied by the generation of prions. In fact, passaging of 
homogenates of POM1-treated cerebellar organotypic slice cultures (COCS) into the brains of 
PrPC-overexpressing Tga20 indicator mice did not cause prion disease whereas inoculation of 
Tga20 mice with bona fide prions caused terminal disease after a few weeks. Histological 
examination of POM1-COCS inoculated mice did not show the typical signs of prion disease, 
nor did a real-time quaking induced conversion (RT-QuIC) assay induce the seeding of 
aggregates, leaving me to conclude that POM1 acts downstream of prion replication. In a next 
step, I aimed to determine whether simultaneous stabilization of both PrPC-FT and PrPC-GD 
through the bispecific, POM1/POM2-antibody LVp12 would be effective against prion disease. 
LVp12 exerted neuroprotective effects in prion-infected COCS even after first signs of prion 
pathology were detectable. In contrast, POM2 alone was only beneficial to neurons when given 
directly after prion inoculation, but not when given at later stages. To dissect the underlying 
molecular mechanisms of POM1-induced toxicity, I studied 11 different, mutated single chain 
variable fragments (scFv) of POM1 derived from alanine scanning of POM1 in complex with 
PrPC. In this experiment, scFvPOM1Y57A and scFvPOM1Y104A showed neuroprotection in prion-
infected COCS and further attenuated the activation of prion-induced toxic pathways such as 
the unfolded protein response and microglial activation. Molecular dynamics (MD) simulations 
showed that relaxation of the rigid loop of the prion protein upon wild-type POM1 binding was 
responsible for the induction of toxicity. These findings suggested that scFvPOM1Y57A and 
scFvPOM1Y104A represent dominant-negative immunoreagents of PrPC.  
 In the final step, I addressed the effects of naturally occuring anti-PrP autoantibodies 
in human patients. Antibodies derived from human subjects frequently show superior safety 
profiles and affinity maturation compared to “humanized” hybridomas or synthetic libraries. On 
the other hand, patients suffering from idiopathic neurological disease have a dismal prognosis 
due to prolonged diagnostic work-up and delayed therapy. Considering both the detrimental 
effects of anti-PrPC-GD targeting antibodies and the beneficial effects of anti-PrPC-FT 
antibodies, I opted to isolate high-affinity, therapeutic anti-PrP-autoantibodies from humans 
without neurological disease and to screen human patients with neurological diseases of 
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unknown origin for the presence of toxic anti-PrP-autoantibodies. I was able to identify patients 
with highly anti-PrP reactive blood samples and to establish a bait-gated fluorescent-activated 
cell sorting (FACS) protocol for subsequent single cell sequencing to clone the variable heavy 
and light chain immunoglobulin genes from cognate memory B-cells. Furthermore, I identified 
that the blood of patients suffering from chronic demyelinating inflammatory polyneuropathy 
(CIDP) harbored a heightened anti-PrP response. As PrP deficient mice are prone to develop 
chronic demyelinating polyneuropathy, one might speculate that depletion of endogenous PrP 
in human CIDP patients through anti-PrP autoantibodies would lead to the observed nerve 
pathology.  
 The elucidation of the mechanisms of prion toxicity and the development of new and 
potentially therapeutic compounds against prion disease will open new paths to create 
effective therapy against this still fatal disease.  
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Zusammenfassung 
Die Fehlfaltung des zellulären Prionproteins PrPC führt zu infektiösen und bis jetzt unheilbaren 
Hirnerkrankungen, sogenannten Prionenkrankheiten. Die Ursache von Prionenerkrankungen 
ist die Übertragung des pathologischen, „scrapie“ Prionproteins PrPSc auf das zelluläre 
Prionprotein PrPC. PrPC ist notwendig für die Ausbreitung von Prionenerkrankungen, da Tiere 
ohne PrPC gegen Prionenerkrkanungen resistent sind. Mikrokopisch zeigen sich in 
Prionenerkrankungen oder transmissiblen, spongiformen Enzephalopathien (TSEs) 
charakteristischerweise spongiforme Veränderungen, Nervenzellverlust, Astro- und 
Mikrogliose, sowie pathologische Ablagerungen von PrPSc. Die Gruppe von A. Aguzzi hat den 
zweiseitigen Mechanismus des Prionproteins entdeckt – Antikörper gegen den flexiblen 
Schweif (flexible tail, PrPC-FT) schützen vor Prionenerkrankungen, wohingegen solche gegen 
die globuläre Domäne (globular domain, PrPC-GD) toxisch sind. Diese Ergebnisse suggerieren 
PrPC-FT als Effektor von PrPC-GD induzierter Toxizität, wobei die genauen, molekularen 
Ursachen weitgehend ungeklärt sind. 
 Die wissenschaftlichen Ziele dieser Arbeit bestehen aus drei Teilen. Mein erstes Ziel 
war es, eine robuste Methode zur Messung von Nervenzellverlust in Prionenerkrankungen zu 
entwickeln. Derzeitig verwendete Methoden nutzen vor allem post hoc Immunhistochemie mit 
neuronalen Markern, die in einer grossen Varianz resultieren, welche die experimentell 
gewonnenen Erkenntisse maskieren kann. Um eine spezifischere Messung zu erhalten, habe 
ich in vivo Konfokalmikroskopie in organspezifischen Scheibenkulturen von transgenen 
Mäusen, welche ein fluoreszentes Protein in einzelnen Nervenzellgruppen exprimieren, 
angewendet. Indem ich individuelle Unterschiede bei Beginn der Messungen, wie 
unterschiedliche Scheibengrösse und Viabilität, mit in die Auswertung eingeschlossen habe, 
konnte ich mit meiner neu entwickelten Methode die bisher beobachtete Variabilität signifikant 
vermindern. 
Mein zweites Ziel war es, die Mechanismen des monoklonalen anti-PrPC-GD 
Antikörpers POM1 genauer zu untersuchen. POM1 rekapituliert die histopathologischen 
Charakteristika von Prionenerkrankungen, jedoch ist unklar, ob Behandlung von Hirngewebe 
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mit POM1 auch zu Infektiosität führt. Ich habe Kleinhirnscheiben, welche mit POM1 behandelt 
wurden, in Gehirne von PrPC-überexprimierenden Tga20 Mäuse injiziert. Während Tga20 
Mäuse, welche mit bona fide Prionen infiziert wurden, innerhalb weniger Wochen 
charakteristische Zeichen der Prionenkrankheit entwickelten, blieben mit POM1-behandeltem 
Gewebe injizierte Mäuse über 200 Tage symptomfrei. Dies lies mich schlussfolgern, dass die 
Toxizität von POM1 unterhalb der Prionenreplikation agiert. Um die genauen Mechanismen 
von POM1-induzierter Toxizität zu untersuchen, habe ich genetisch modifizierte Varianten von 
POM1, sowie dessen Bindungsstellen an PrPC untersucht. Ex vivo Versuche an Prionen-
infizierten, organspezifischen Hirnscheiben zeigten, dass die selektive Mutagenese von 
einzelnen Bindungsresiduen der POM1-PrPC Interaktion zur dominant-negativen 
Immunotherapie gegen Prionenerkankungen führte. Diese Therapie agierte unterhalb der 
Prionenreplikation und verbesserte neurotoxische Kaskaden, welche durch 
Prionenerkrankungen ausgelöst wurden. 
In einem dritten Teil habe ich die Folgen und die Nutzbarkeit von humanen 
Autoantikörpern in ausgewählten Erkrankungen gegen das Prionenprotein untersucht. 
Patienten mit Mutationen im PrPC-kodierenden Gen PRNP leiden an einer fatalen 
neurologischen Erkrankung, jedoch werden PRNP-Mutationsträger erst im hohen Alter klinisch 
manifest, obwohl sie ihr Leben lang ein krankheitsassoziertes Protein exprimieren. Dies ist 
hinweisend auf protektive Faktoren und ich glaube, diese Faktoren sind anti-PrPC 
Autoantikörper. Sofern vorhanden, plane ich protektive, humane Autoantikörper aus 
Gedächtnis B-Zellen von PRNP Mutationsträgern zu klonieren und als mögiches, 
therapeutisches Agens gegen Prionenkrankheiten einzusetzen. Patienten mit chronisch-
inflammatorischer, demyelinisierender Polyneuropathie (CIDP) leiden an einer bis jetzt 
ungeklärten Nervenerkrankung. Das Fehlen des Prionproteins in Mäusen führt zu einer 
chronisch-demyelinisierenden Erkrankung und ist heutzutage die einzige, mehrfach bestätige, 
physiologische Funktion von PrPC. Erhöhte Autoantikörper gegen PrPC könnten endogenes 
PrPC abpuffern und einen „quasi-knock out“ hervorrufen. Ich habe eine sensitive und reliable 
Methode entwickelt, mit der sich humane Autoantikörper gegen PrPC detektieren und aus 
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Gedächtnis B-Zellen extrahieren lassen. PRNP-Mutationsträger weisen keine signifikant 
gesteigerte Prävalenz von anti-PrPC Autoantikörpern im Vergleich zu gesunden 
Familienmitgliedern auf. Interessanterweise lässt sich im Alter von PRNP-Mutationsträgern 
eine verminderte Anzahl von anti-PrPC Autoantikörpern feststellen, welche nicht in gesunden 
Familienmitgliedern auftritt. Diese könnte eine Erklärung der späten, klinischen Manifestation 
von PRNP-Mutationsträgern liefern. Des Weiteren zeigten CIDP Patienten eine kräftige und 
spezifische Autoantikörperreaktion gegen PrPC, welche das immunologische Substrat der 
chronischen Demyelinisierung liefern kann. 
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Abbreviations 
 
+/- In the presence and in the absence of 
aa Amino acid 
AAV Adeno-associated virus  
AD Alzheimer’s disease 
AICc Akaike Information Criteria values adjusted for finite sample sizes 
APECED Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy 
APP Amyloid precursor protein 
APPPS1 Double transgenic mice expressing mutated APP and PS1 
APS Autoimmune Polyendocrine Syndrome 
AscA Ascorbic acid 
BLI Bioluminiscence imaging 
bPrPC bovine PrPC  
BSA  Bovine serum albumin 
BSE Bovine spongiforme encephalopathy 
BV421-SA BrilliantViolet421-Streptavidin 
Ca2+ Calcium ions 
cAMP Cyclic adenosine monophosphate 
CC2 Charged cluster 2 region of PrPC  
CDP Chronic demyelinating polyneuropathy 
CGL Cerebellar granule layer 
CHO Chinese hamster ovary 
CIDP Chronic inflammatory demyelinating polyneuropathy 
CJD Creutzfeldt-Jakob’s disease (umbrella term for sCJD, vCJD, iCJD, gCJD) 
CLSM Confocal laser scanning microscopy 
COCS Cerebellar organotypic slice cultures 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
DIV days in vitro   
DNA Deoxyribonucleic acid 
dpe Days post-exposure 
dpi Days post-infection 
Dpl Doppel 
DTT Dithiothreitol 
Edbg Prnp0/0  mouse Edinburgh (Manson et al. 1994) 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced GFP 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDG-PET F-fluorodeoxygluose positron emission tomography 
FFI Familial fatal insomnia 
GBS Guillain-Barré Syndrome 
GdnHCl Guanidine hydrochloride 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescent protein 
gCJD Genetic Creutzfeldt-Jakob’s disease 
GPCR G-protein coupled receptor 
gPrD Genetic prion disease (umbrella term for gCJD, FFI, GSS) 
GSS Gerstmann-Sträussler-Scheinker disease 
H&E Hematoxylin and eosin 
H-bond Hydrogen bond 
HD Huntington’s disease 
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hIgG Human IgG 
HOCS Hippocampal organotypic slice cultures 
hPrP-ATbiotin  biotinylated human PrP-Avitag 
hPrPC Human cellular prion protein 
HRP Horseradish peroxidase 
iCJD Iatrogenic Creutzfeldt-Jakob’s disease 
IgG Immunoglobulin G 
IL-2 Interleukin 2 
IPTG Isopropyl-β-D-thiogalactopyranosid 
IQR Inter-quartile range 
IRB Institutional review board 
KEK-ZH Cantonal Ethics Committee of Zurich (Kantonale Ethikkommission Zürich) 
LB Lysogeny broth 
Luc Luciferase 
MDS Molecular dynamics simulations 
MEMRI Manganese-enhanced magnetic resonance imaging 
mIgG Murine IgG 
mPrPC Murine cellular prion protein 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
NAc N-acetyl cysteine 
NADPH Nicotinamide adenine dinucleotide phosphate hydrogen 
NBH Non-infectious brain homogenate 
NeuN Neuronal nuclei 
Ngsk Prnp0/0  mouse Nagasaki (Sakaguchi et al. 1996) 
Ni-NTA Ni-Nitrilotriacetic acid 
NIR Near-infrared 
NIR-VAD-fmk Near-infrared Valin-Alanine-Aspartate-fluoromethylketone 
NOX2 NADPH oxidase 2 
OCS Organotypic slice cultures 
OGB-1 Oregon Green 488 BAPTA-1 AM 
ORF Open reading frame 
PCR Polymerase chain reaction 
PD Parkinson’s disease 
PE R-phycoerythin 
pE3-17 Pyroglutamylated Aβ3-17 
PerCP Peridinin Chlorophyll Protein Complex 
PERK Protein kinase-like endoplasmic reticulum kinase 
PET Positron emission tomography 
PK Proteinase K 
PNGase F Peptide -N-Glycosidase F 
PPS Pentosan polysulphate 
PS1 Presenilin 1 
Prnp Prion protein gene (murine) 
PRNP Prion protein gene (human) 
PrP Prion protein 
PrPC Cellular prion protein 
PrPC-FT Flexible tail of PrPC 
PrPC-GD Globular domain of PrPC 
PrPC-OR Pctapeptide region of PrPC 
PrPSc Scrapie prion protein 
PTFE Polytetrafluorethylen 
recPrP Recombinant PrP (rhPrP23-231 + rmPrP23-230) 
rhPrP23-231 Recombinant, full-length human PrP, aa 23-231 
RML6 Passage 6 of the Rocky Mountain Laboratory strain mouse-adapted  
 scrapie prions 
  
  
KARL FRONTZEK, 2017 12 
 
ROI Region of interest 
rmPrP23-230 Recombinant, full-length murine PrP, aa 23-230 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT-QuIC Real-time quaking induced conversion 
SBDP Spectrin breakdown products 
ScFv Single chain fragment, variable  
sCJD Sporadic Creutzfeldt-Jakob’s disease 
S.D. Standard deviation 
SDM Site-directed mutagenesis 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sgRNA Single guide RNA 
sFI Sporadic fatal insomnia 
SLE Systemic lupus erythematodes 
SPR Surface plasmon resonance 
TALEN Transcription activator-like effector nuclease 
TLR Toll-like receptor 
TMB 3,3', 5,5;-tetramethylbenzidine 
TOF MS ES Time-of-flight mass spectrometry electrospray 
TSE Transmissible spongiforme encephalopathy 
UHZ University Hospital Zurich 
UPR Unfolded protein response 
UPS Ubiquitin proteasome system 
VAD-fmk Valin-Alanine-Aspartate fluoromethylketone  
vCJD Variant Creutzfeldt-Jakob’s disease 
WT Wild-type 
YFP Yellow fluorescent protein 
ZH1 Prnp0/0 mouse Zurich I (Büeler et al. 1992) 
ZH3 Prnp0/0 mouse Zurich III (Nuvolone et al. 2016) 
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Introduction 
 
The discovery of prions 
Historically, prion disease was first observed in merino sheep in the 18th century.  Excessive 
inbreeding of sheep in an attempt to improve the quality of wool led to an increased number of 
sheep suffering from a disease, in which the animals repeatedly scraped off their fleece against 
fences or rocks, hereafter termed scrapie (Leopoldt 1759; Brown and Bradley 1998). In the 
beginning of the twentieth century, two German neurologists, Hans-Gerhard Creutzfeldt and 
Alfons Maria Jakob, independently coined the term spastic pseudosclerosis to describe a 
neurological syndrome that did not fit into consensus diagnostic criteria (Creutzfeldt 1920; 
Jakob 1921). Their histopathological observations on post-mortem brain tissue, that is, 
neuronal loss and gliosis, are still considered hallmarks of prion diseases (Aguzzi, Barres, and 
Bennett 2013). In recognition of this seminal work, the most commonly observed human prion 
disease is eponymously called Creutzfeldt-Jakob’s disease (Figure 1, CJD). 
 
Figure 1. Microscopically, Creutzfeldt-Jakob’s disease is characterized by marked spongiform 
change and neuronal loss (HE, upper panel, left image), reactive gliosis (GFAP, upper panel, 
middle image) and microglial activation (HLA-DR. upper panel, right image). Bottom images are 
control histographs from a patient without neurological disease. Reprint with permission from 
(Aguzzi, Barres, and Bennett 2013), Rightslink license number 4127060736524. 
.   
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The first experiments demonstrating the disease’s transmissibility were performed by 
the French veterinarians Jean Cuillé and Paul-Louis Chelle, who intracerebrally inoculated 
healthy sheep with brain homogenates of scrapie-infected sheep, which led to disease onset, 
thus confirming the transmissible properties of the scrapie agent (Cuillé and Chelle 1936). 
Vincent Zigas and Carleton Gajdusek (Gajdusek and Zigas 1957) described a distinct 
neurological syndrome, similar to scrapie and CJD in the Fore tribe in Papua New Guinea, 
who practiced ritual cannibalism. Only a few years later the authors were able to successfully 
transmit the disease to chimpanzees using brain tissue from patients with either Kuru or CJD 
(Gibbs et al. 1968; Beck et al. 1969; Gajdusek, Gibbs, and Alpers 1966).  
What is the exact nature of the infectious agent? The long incubation time of scrapie 
and scientific reports on disease-causing, viral nucleic acids (Fraenkel-Conrat and Williams 
1955) led to the emergence of the slow virus (Sigurðsson 1954) hypothesis. However, attempts 
to inactivate the scrapie agent either by formalin (Gordon 1946) or high-dose ultra-violet light 
(Alper et al. 1967) were unsuccessful. In 1967, J.S. Griffith applied a mathematical approach 
to the “protein-only” hypothesis of prion replication, which proved to be pivotal (Griffith 1967). 
Stanley Prusiner, recognizing the significance of Griffith’s hypotheses, concluded that the 
scrapie agent lacked nucleic acid and coined the term prion, a portmanteau derived from 
protein and infection (Prusiner 1982). In fact, Prusiner and co-workers were able to extract a 
relatively proteinase K-resistant protein from scrapie-infected hamster brain (Bolton, McKinley, 
and Prusiner 1982). Shortly thereafter, Patricia Merz and colleagues performed ultrastructural 
investigations on a variety of prion-diseased brains from different mammals and found so-
called “scrapie-associated fibrils” (Merz et al. 1983). Only a few weeks after Merz’ discovery, 
Prusiner and colleagues published their results about the presence of a single  protein,the 
prion protein, PrP with rod-shaped, birefringent particles morphologically similar to amyloid in 
scrapie brains (Prusiner et al. 1983). The birefringent rods consisted of a multitude of PrP 
molecules leading them to the conclusion that amyloid plaques observed in transmissible, 
degenerative neurological diseases might contain prions.  
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Throughout this manuscript, I will use the following terminology: PrPC for the cellular 
prion protein, which is physiologically expressed in tissue; PrPSc, the Proteinase K (PK)-
resistant, disease associated prion protein found in human prionopathies such as CJD and 
other prionopathies such as scrapie; PrP, refers to PrPC and PrPSc, whenever applicable, for 
both forms. Prnp is the genetic designation for the murine gene, PRNP for the respective 
human gene encoding the prion protein. 
 
The prion protein is indispensable for prion disease 
According to the Central Dogma of Molecular Biology, biological information is sequentially 
transferred from DNA to RNA to protein (Crick 1970). In search of the genetic basis of prion 
disease, Charles Weissmann and co-workers isolated a PrP-related gene encoding for the 
scrapie agent (Oesch et al. 1985), while Chesebro almost simultaneously described the 
messenger RNA of PrP (Chesebro et al. 1985). Additionally, no evidence of nucleic acids was 
found in the purified preparations of scrapie prions, strengthening the “protein-only” hypothesis 
(Oesch et al. 1985). 
 Transgenic mice lacking the prion protein gene Prnp were generated, yielding the first 
Prnp0/+ and Prnp0/0 mice (Zurich I, ZH1 (Büeler et al. 1992)). Primary behavioral analyses up 
to an age of seven months did not reveal an overt phenotype (Büeler et al. 1992). When 
challenging Prnp0/0 (ZH1) with prions, Prnp0/0, but not Prnp+/+ or Prnp0/+ were resistant to prion 
disease, strongly arguing in favor of the prion protein as indispensable for prion disease 
(Bueler et al. 1993). Interestingly, serial passaging of brain and spleen homogenates from 
prion-inoculated Prnp0/0 (ZH1) mice into Prnp+/+ CD1 indicator mice showed an almost 
complete loss of infectivity, except when the inoculum was not heated prior to inoculation, 
albeit only very low levels of infectivity could be observed (Bueler et al. 1993). 
 The pivotal experiments of Weissmann and colleagues (Bueler et al. 1993) precluded 
a loss-of-function of PrPC as the cause of prion diseases; however, it was unclear whether 
PrPSc exerted toxic effects or neurotoxicity was induced by another mechanism. Moreover, up 
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to 10-fold overexpression of PrPC compared to wild-type levels in Tga20 animals did not lead 
to a neurological phenotype, making a toxic gain-of-function of PrPC unlikely. Upon grafting of 
Prnp+/+ neural tissue into Prnp0/0 mice and subsequent prion inoculation, a sharply demarcated 
border between pathologically altered Prnp+/+ and unaffected Prnp0/0 tissue was seen 
(Brandner et al. 1996). Moreover, Prnp0/0 host tissue adjacent to Prnp+/+ grafts showed 
widespread PrPSc deposits with no overt pathology suggesting that neurotoxicity is exerted by 
prions in the presence of PrPC through activation of hitherto unspecified intracellular cascades 
(Brandner et al. 1996).  
 
The physiological role of PrPC 
The Prnp0/0 (ZH1) mouse was the first transgenically modified animal for studying the 
physiological effects of the prion protein (Figure 2), with pilot behavioral analyses showing no 
overt phenotype (Büeler et al. 1992). Using Prnp0/0 (ZH1) animals, it became clear that prion 
protein is necessary for prion disease, as Prnp0/0 (ZH1) mice did not succumb to the disease 
(Bueler et al. 1993). Later generated Prnp0/0 mice included, but were not limited to the Prnp0/0 
(Edbg) mice, on a pure 129/Ola background (Manson et al. 1994) and the Prnp0/0 (Ngsk) mice, 
on a mixed 129/Bl6 background (Sakaguchi et al. 1996).  
Figure 2. Structure of PrPC (nomenclature of residues according to murine PrPC). Adgrg6 denotes 
residues involved in binding of Adgrg6, Cu2+ denotes copper binding sites, interaction regions of 
PrPC with Aβ oligomers are indicated above. CHO denotes glycosylation stes. Graph modified 
according to the Creative Commons Attribution Licence 4.0 from (Wulf, Senatore, and Aguzzi 
2017). 
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One inherent lack of studying physiological protein function on the bases on knock-out 
animals was the technique used for generation of Prnp0/0 transgenic mice at that time: typically, 
Prnp0/0 mouse embryonic stem cells were derived from the 129 strain of Mus musculus and 
implanted into pseudopregnant foster mothers from the C57BL/6 strain of Mus musculus 
(Steele, Lindquist, and Aguzzi 2007). Although resulting mixed Bl6129 mice were backcrossed 
> 10 times to (mostly) Bl6 mice to generate Bl6.129 congenic animals, genes flanking Prnp 
may co-segregate during meiotic recombination and lead to mixing of polymorphisms in genes 
additional to Prnp (Gerlai 1996). 
 What is the true phenotype of the Prnp0/0 mouse? Susceptibility to prion disease was 
repeatedly reported to be independent of the Prnp0/0 animal’s host strain. According to the 
prevailing consensus, it is now considered to represent a genuine function of PrPC (Steele, 
Lindquist, and Aguzzi 2007). The possibility of misleadingly observed phenotypes due to 
genetic confounders in knock-out animals of mixed genetic background was already 
mentioned during the characterization of the first Prnp0/0 (ZH1) mouse (Bueler et al. 1993; 
Büeler et al. 1992). Nonetheless, numerous publications emerged that attributed a plethora of 
diverse, e.g. electrophysiological, immunological, neurological phenotypes to the Prnp0/0  mice 
irrespective of genetic bias (Steele, Lindquist, and Aguzzi 2007). The olfactory bulb shows 
strong PrPC expression and Prnp0/0 mice showed abnormal olfactory behavior resembling 
anosmic mice: this altered behavior was observable in mice bred in different genetic 
backgrounds, both pure and congenic (ZH1, Edbg, Ngsk), suggesting a genuine function of 
PrPC (Le Pichon et al. 2009). 
 A chronic demyelinating polyneuropathy (CDP) was seen in animals lacking PrPC at 
around 10 weeks of age (Bremer et al. 2010). This phenotype was confirmed in four different 
Prnp0/0 mouse strains, e.g. ZH1, Edbg, Ngsk and PrnpGFP/GFP, suggesting an authentic Prnp0/0 
phenotype independent of flanking gene polymorphisms (Bremer et al. 2010; Heikenwalder et 
al. 2008). A strictly co-isogenic Prnp0/0 C57BL/6 mouse (termed Zurich III, ZH3) was created 
by means of transcription activator-like effector nucleases (TALEN) (Nuvolone et al. 2016). 
Prnp0/0 (ZH3) animals authentically recapitulated CDP and a polybasic, N-terminal fragment of 
  
  
KARL FRONTZEK, 2017 19 
 
PrPC was found to be a promyelinating agonist of the G-protein coupled receptor (GPCR) 
Gpr126 (Nuvolone et al. 2016; Kuffer et al. 2016). Development of CDP in Prnp0/0 mice 
represents the best characterized phenotype of animals lacking PrPC to date. 
 
A seeding/nucleation model for prion propagation  
What is the disease-causing agent and how do prions replicate? As stated, experimental 
evidence worked against either loss-of-function or gain-of-function of PrPC (Büeler et al. 1992; 
Bueler et al. 1993), intrinsic toxicity of PrPSc was unlikely as well (Brandner et al. 1996). Until 
the beginning of the twenty-first century, the only known molecular differences between PrPC 
and PrPSc were the higher β-sheet content of PrPSc and resistance to PK digestion (Aguzzi and 
Heppner 2000). Historically, prion propagation was believed to occur through a so-called 
„template-assisted“ or „refolding“ conversion of PrPC to PrPSc whereby PrPSc „imposes“ its 
pathological tertiary structure onto PrPC (Aguzzi and Heppner 2000). The conversion reaction 
was anticipated to involve another molecule, provisionally designated “protein X” (Telling et al. 
1995). In the light of the relative innocuousness of PrPSc (Collinge and Clarke 2007), Collinge 
and Clarke postulated the presence of an alternative, smaller and neurotoxic protein, 
designated “PrP-lethal” (PrPL) as the cause of prion-induced neurodegeneration .To date, 
however, no physical definition of either protein X or PrPL exists. Most likely, these proteins 
are non-existent in nature (Aguzzi and Falsig 2012).   
Besides disease-associated protein aggregation in prion disease, ordered protein 
aggregation is considered harmless in physiological processes such as protein crystallization 
(Senisterra and Finerty 2009). In view of the positive correlation of slow clinical manifestation 
with the gradual increase in PrPSc aggregates, Jarrett and Lansbury postulated a model of 
“nucleation-dependent polymerizations” of the prion protein (Jarrett and Lansbury 1993). 
Indeed, a plethora of scientific data has accumulated in favor of disease-causing, small toxic 
oligomers that are generated by nucleation from monomeric proteins (Arosio et al. 2014). In 
the case of prions, mathematical modelling of fragmentation and elongation of PrPSc 
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aggregates precisely align with gathered in vivo data showing a dose-dependent (i.e. PrPC 
expression levels of the host) disease onset (Figure 3, (Knowles et al. 2009; Fischer et al. 
1996)).  
 
This model, however, is not per sé restricted to PrPSc: inoculation of brain extracts from 
human AD patients successfully induced cerebral β-amyloidosis (Meyer-Luehmann et al. 
2006), intracerebral inoculation of synthetic α-synuclein into wild-type mice induced Lewy 
pathology (Luk et al. 2012) and different Tau-strains reproducibly showed prion-like 
propagation upon re-introduction into naïve cells and animals (Sanders et al. 2014). Although 
β-amyloid, α-synuclein and Tau showed cell-to-cell propagation, they were not the causes of 
epidemic diseases such as bovine spongiform encephalopathy (BSE) or Kuru – hence the 
term “prionoids” was coined to better separate them from genuine prions (Ashe and Aguzzi 
2013). 
 
Autoimmunity in human prion diseases 
In humans, prion diseases are mostly of sporadic origin (sporadic Creutzfeldt-Jakob disease, 
sCJD and rarely, sporadic Fatal familial insomnia, sFI), and in 10-15%, of genetic origin 
(genetic CJD, gCJD; genetic Fatal familial insomnia, gFI and Gerstmann-Sträussler-Scheinker 
disease, GSS). Prion diseases acquired through an iatrogenic or dietary update represent a 
Figure 3. Graphic illustration of reaction pathways leading to the generation of protein aggregates, 
e.g. in neurodegenerative disorders. (A) Soluble monomers reacting with each other define primary 
nucleation pathways. (B) Monomer-independent aggregation, e.g. by fragmentation or (C) monomer-
dependent aggreagation delineate secondary aggregation pathways. Reprint with permission from 
(Cohen et al. 2012), Rightslink license number 4127071484123. 
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third group of cases (iatrogenic CJD, iCJD; Kuru; variant CJD, vCJD) (Capellari et al., 2011). 
As previously noted,  human prion diseases are recognized by the histopathological hallmarks 
of spongiform change, neuronal cell loss, astrogliosis, microglial activation and deposits of 
PrPSc (Aguzzi and Falsig 2012). Genetic prion diseases are characterized by mutations in the 
PrPC encoding human gene PRNP (Takada and Geschwind 2013). Two families have been 
reported with several family members affected by CJD but without PRNP mutation, suggesting 
possible risk genes outside of PRNP to be responsible for disease susceptibility (Frontzek et 
al. 2015; Webb et al. 2008). Large genome-wide association studies, however, hitherto failed 
to identify potential risk genes (Mead et al. 2012).  
Naturally occurring autoantibodies have been proposed to play a protective role in a 
variety of neurodegenerative diseases such as Alzheimer’s disease or Parkinson’s disease 
(Bach and Dodel, 2012; Neff et al., 2008). Herein, autoantibodies are suggested to inhibit the 
formation of toxic species of disease-causing proteins amongst others beta-Amyloid and 
alpha-Synuclein (Neff et al., 2008). Genetic prion diseases are exclusively attributed to 
mutations of the prion protein-coding gene PRNP following an autosomal-dominant trait. As in 
their sporadic counterpart, patients show accumulations of aggregated and misfolded PrPSc 
(Mastrianni, 2010). Interestingly, albeit mutation bearers express this pathological protein 
throughout their whole life, clinical symptoms occur almost exclusively in advanced age 
(Takada and Geschwind, 2013). This observation is indicative of protective factors. To this 
end, one study has proposed the presence of autoantibodies against a fragment of the 
common, PrPCA117V mutation in commercially available, pooled plasma preparations (Wei et 
al., 2012). The subsequently isolated autoantibodies were suggested to exert neuroprotective 
effects against the artificial fragment PrP(106-126)A117V (Roettger et al., 2013). However, 
PrPA117V106–126 does not exist in nature, and therefore, such speculations are implausible. 
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The mechanisms of prion toxicity 
What is responsible for neuronal death in prion diseases? Pathologically, brains from humans 
and animals with terminal prion disease show a typical spongiform degeneration that is 
accompanied by widespread neuronal death, astrogliosis, microglial activation and PrPSc 
deposits (Kovacs and Budka 2008). When PrPC is depleted during the early phase of prion-
induced neurodegeneration, a reversal of spongiform changes was observed (Mallucci et al. 
2003). Shmerling and co-workers investigated the phenotypes of animals with mutants of the 
flexible tail of PrPC (PrPC-FT) and observed a cerebellar syndrome with neuronal death in the 
cerebellar granule layer (CGL) in mutants lacking the residues 32-121 (denoted PrP∆E) and 
32-134 (denoted PrP∆F), but not in shorter deletions (Shmerling et al. 1998). Re-introduction of 
a functional PrPWT allele restored neurotoxicity in PrP∆E and PrP∆F mutants pointing to the 
important role of PrPC-FT in mediating PrPC-dependent neurotoxicity (Shmerling et al. 1998).  
 In one study, prion infection was reported to cause dysfunction of the ubiquitin 
proteasome system (UPS) causing a reduction of protein degradation (Kristiansen et al. 2007). 
Mallucci and colleagues observed abrupt cessation in synaptic protein expression in prion-
infected mice when synapse numbers were already decreasing (Moreno et al. 2012). They 
hypothesized that accumulation of unfolded proteins in the endoplasmic reticulum (ER) leads 
to a decrease in translation and observed an increase in expression of BiP/Grp78 (BiP), which 
detects rising protein levels and initiates the unfolded protein response (UPR) (Moreno et al. 
2012). BiP leads to auto-phosphorylation of protein kinase-like endoplasmic reticulum kinase 
(PERK); phosphorylated PERK (PERK-P) phosphorylates eukaryotic translation initiation 
factor, eIF-2α; eIF-2α-P induces expression of ATP4 and CHOP and eventual activation of 
GADD34, which acts in a negative feedback loop to end UPR signaling (Moreno et al. 2012). 
Lentoviral vector-mediated overexpression of GADD34 and oral administration of the PERK 
inhibitor GSK2606414 resulted in a decrease of UPR activation and amelioration of prion 
disease (Moreno et al. 2012; Moreno et al. 2013). 
 When testing a panel of putative anti-prion compounds in cerebellar organotypic slice 
cultures (COCS) (Falsig and Aguzzi 2008), Congo red, pentosan polysulphate (PPS), 
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amphotericin B, porphyrin, suramin, imatinib and E64d conferred neuroprotection against 
passage 6 of the Rocky Mountain Laboratory strain mouse-adapted scrapie prions (RML6) 
prions (Falsig et al. 2012). Congo red was already demonstrated to confer protection against 
prion disease (Caspi et al. 1998), possibly due to hyperstabilization of PrPSc aggregates. 
Furthermore, PPS, porphyrin, amphotericin B, suramin and imatinib also exerted 
neuroprotection through counter-acting prion replication (Falsig et al. 2012). Although 
treatment of prion-infected COCS with the calpain inhibitor E64d led to minimally increased 
PrPSc levels and infectivity, neuroprotection was seen, implying inhibition of pathways 
downstream of prion replication, as was the case in two other calpain inhibitors, e.g. calpeptin 
and MDL-28170 (Falsig et al. 2012). Calpains are cytoplasmic, calcium-dependent proteases 
(Suzuki et al. 2004). Calpain activation leads to cleavage of αII-spectrin (α-fodrin) with 
characteristic spectrin breakdown products (SBDP) of 150 and 145 kDa (SBDP150 and 
SBDP145) (Wang 2000). In prion-infected COCS, but not in COCS inoculated with non-
infectious brain homogenate, SBDP150 and SBDP145 can be observed, indicative of calpain 
activation (Falsig et al. 2012). Anti-prion antibodies, first and foremost those targeting PrPC-
GD, lead to rapid neurodegeneration with histomorphological features resembling genuine 
prion diseases, such as neuronal cell loss, astrogliosis and microglial activation (Sonati et al. 
2013). Interestingly, treatment of COCS with the murine monoclonal anti-PrPC-GD antibody 
POM1 also leads to activation of calpains and subsequent α-fodrin cleavage yielding SBDP150 
and SBDP145 – as was shown in bona fide prions (Sonati et al. 2013; Herrmann et al. 2015).  
Scavengers of reactive oxygen species (ROS) such as ascorbic acid, and N-acetyl cysteine 
ameliorate POM1-induced toxicity, suggesting that ROS production contributes to cell toxicity 
(Sonati et al. 2013). Both cell-permeable and cell-impermeable ROS inhibitors were protective 
in POM1-induced neurodegeneration, indicating extracellular superoxide to be the responsible 
ROS species. Indeed, inhibition of the nicotinamide adenine dinucleotide phosphate hydrogen 
(NADPH) oxidase 2 (NOX2) through the NOX2 inhibitor diphenyleneiodonium chloride led to 
an amelioration of POM1-induced superoxide production (Sonati et al. 2013). Are anti-PrPC-
GD antibody-mediated pathways also seen in mammalian prion diseases? NOX2 activity was 
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observable predominantly around spongiform vacuoles in human brains from CJD patients, 
significantly stronger than in AD controls (Sorce et al. 2014). Mice lacking both copies of Nox2 
showed a delay in prion disease compared to wild-type animals (Sorce et al. 2014), pointing 
to an important role of ROS in mammalian prion diseases.  
Neuronal cell loss in prion diseases  
The histological hallmarks of prion pathology are characterized by spongiform change, 
neuronal cell loss, astrogliosis, microglial activation and deposits of PrPSc (Aguzzi and Heppner 
2000). Early reports suggested morphological alterations resembling apoptosis following prion-
infected cell lines (Schatzl et al. 1997). Conversely, tissue microarrays on a variety of 
chronically infected cell lines did not show an observable cellular reaction (Julius et al. 2008). 
A wealth of controversy prevails regarding the role of caspase-3 in prion-induced neuronal cell 
death. Punctual activation of caspase-3 was reported in immunohistochemical studies of 
cerebella in human CJD patients (Puig and Ferrer 2001) and scrapie-infected mice (Siso et al. 
2002), while another study failed to see activation of caspase-3 in neurons from scrapie-
affected sheep brains (Lyahyai et al. 2006). Thorough biochemical investigations and 
treatment with caspase-3 inhibitors in scrapie-infected mice and RML6-infected COCS; 
however, did not reveal a role of activated caspase-3 in prion disease (Falsig et al. 2012).  
 Further, mainly immunohistochemical studies on post mortem tissue from sCJD 
patients suggested a complex interplay of a variety of apoptosis-related proteins depending on 
the molecular subtype of sCJD (Kovacs and Budka 2010). Inconclusive results have been 
found when correlating mediators of neural degeneration to brain regions of different sCJD 
subtypes (Llorens et al. 2014). Exhaustive studies on the complement system and prions 
revealed a protective effect of a lack of the components C1q, Bf/C2 and C3, as well as 
complement receptors on prion pathogenesis (Klein et al. 2001). Genetic depletion of 
complement receptors was beneficial in a mouse model of chronic wasting disease (CWD) 
(Michel et al. 2012). Accordingly, a subsequently published study suggested that the presence 
of neuronal depositions of activated, terminal complement fragments in human sCJD brains 
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had a similar effect (Kovacs et al. 2004). As complement deposition inhibited the accumulation 
of PrPSc, one can conclude that the protective effect is mediated at the level of prion infectivity 
and propagation, but not on downstream effects such as cell toxicity.  
 As previously stated, activation of calpains, calcium-dependent proteases followed by 
cleavage of α-fodrin and generation of ROS through NOX2 was shown to mediate of toxicity 
of bona fide prions as well as “prion-mimetic”, toxic anti-PrPC-GD antibodies (Sorce et al. 2014; 
Falsig et al. 2012; Herrmann et al. 2015; Sonati et al. 2013). Furthermore, translational 
repression in prion diseases through activation of BiP, PERK and eIF2α is another well-
characterized mechanism of prion-induced toxicity as described above (Moreno et al. 2012; 
Moreno et al. 2013). Taken together, pharmacological and genetic inhibition of the latter two 
pathways, e.g. through ablation of PrPC-FT or antibodies against PrPC-FT, calpain inhibitors, 
ROS scavengers, NOX20/0 mice, PERK inhibitors, overexpression of GADD etc., are effective 
in delaying prion diseases. In addition, they represent the most widely studied and faithfully 
reproducible routes of prion-induced neurotoxicity. 
 
Antibodies against the prion protein 
A pivotal experiment in antibody immunotherapy of prion disease was performed by mixing 
prion protein-specific antiserum with purified prions, which led to reduced prion infectivity 
(Gabizon et al. 1988). Further studies on the effects of antibodies in prion disease were mostly 
limited to in vitro experiments that investigated whether the administered compounds are able 
to abrogate the generation of PrPSc. Subsequently, a plethora of positively tested antibodies 
were tested with the goal of halting the generation of PrPSc – e.g. the monoclonal anti-PrPC 
antibodies (or fragments thereof) D13, D18, 6H4, R1, R2, SAF32, SAF61 (Enari, Flechsig, and 
Weissmann 2001; Peretz et al. 2001; Perrier et al. 2004; Feraudet et al. 2005). These PrPSc-
clearing antibodies were usually administrated to prion-infected cell lines, which posed two 
major obstacles. Firstly, prion replication has to be at least as fast as cell division in chronically 
prion-infected cells, as slower replication rates will lead to cessation of infectivity over time. 
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Secondly, prion infection can decrease the cell’s fitness, again leading to non-infected cells (Li 
et al. 2010). 
The Aguzzi lab was the first to describe the protective effects of systemic expression 
of antibodies against prion disease in vivo (Heppner et al. 2001). Herein, the µ chain of the 
anti-PrPC antibody 6H4 was expressed by transgenesis in Prnp0/0  mice – the 6H4 clone was 
previously shown to successfully and persistently ablate prion infectivity (Enari, Flechsig, and 
Weissmann 2001). Transgenic antibody expression prevented prion disease after 
intraperitoneal inoculation without affecting expression of PrPC suggesting successful passive 
immunotherapy (Heppner et al. 2001). Further reports have confirmed the protective action of 
systemic antibody levels in prion diseases (White et al. 2003; Goni et al. 2005). D13, a 
monoclonal antibody directed against a linear motif between the PrPC-OR and the charged 
cluster 2 region of PrPC (PrPC-CC2) was initially claimed to induce neurotoxicity (Solforosi et 
al. 2004). A second study that established minimal toxic antibody concentrations of anti-PrPC 
antibodies in vivo was also able to recapitulate D13-induced toxicity (Reimann et al. 2016). Of 
concern, however, was another study that concluded that D13 was innocuous, probably due 
to the low-dose regimen tested (Klöhn et al. 2012). D18, a monoclonal anti-PrPC antibody 
targeting regions proximal to and within the α1-helix of PrPC-GD did not show toxic effects in 
a primary study. A subsequent investigation of adenoviral-mediated expression of a single 
chain variable fragment of D18 (AAV-scFvD18) in prion-inoculated mice showed beneficial 
effects of AAV-scFvD18 by delaying disease onset (Solforosi et al. 2004; Moda et al. 2012). 
 
The immunization of Prnp0/0 mice with PrPC yielded a comprehensive set of monoclonal 
anti-PrPC antibodies, termed POM antibodies (Figure 4, (Polymenidou et al. 2008)). Thorough 
investigations of anti-PrPC antibody toxicity showed a bimodal nature of PrPC – eight out of 
Figure 4. Overview of epitope specificities of the POM1 monoclonals. Reprinted from (Polymenidou 
et al. 2008) under the Creative Commons Attributed Licence 4.0.  
  
  
KARL FRONTZEK, 2017 27 
 
twelve anti-PrPC-GD antibodies showed profound neurotoxicity compared to one out of four 
anti-PrPC-FT antibodies. Of note, anti-PrPC-GD-mediated toxicity could be ablated by pre-
incubation with anti-PrPC-OR antibodies or in interstitial deletion mutant mice lacking PrPC-OR, 
pointing to an important role of the PrPC-OR in mediating neurotoxity (Sonati et al. 2013). 
Transcriptional analyses showed changes in similar pathways in anti-PrPC-GD and prion 
toxicity (Herrmann et al. 2015). Highly controversial results were observed when a therapeutic 
effect was attributed to ICSM18, a monoclonal anti-PrPC-GD antibody targeting a 
conformational epitope on the α1-α3 helices of PrPC-GD (Klöhn et al. 2012). ICSM18 targets 
PrPC-GD in close proximity to the epitope of the severly neurotoxic antibody POM1 (Baral et 
al. 2012; Antonyuk et al. 2009). Klöhn et al. reported no drug-related side effects of up to 2 µg 
of ICSM18 upon stereotaxic injections in the brain (Klöhn et al. 2012). Rigorously performed 
dose escalation studies, however, revealed the neurotoxic nature of ICSM18 (Reimann et al. 
2016), which was later confirmed by another group (Wu et al. 2017). Recent reports on the 
preparation of a humanized version of ICSM18 – PRN100 – for use in clinical trials against 
prion and Alzheimer’s disease are unsettling (Klyubin et al. 2014). 
 
Screening techniques for the discovery of novel prion therapeutics 
In spite of intense ongoing research targeting different aspects of prion disease, no effective 
therapy is in sight. A major limiting factor is the dearth of cell lines exhibiting cell-autonomous 
cytotoxicity upon prion infection. Prion-specific phenotypes were described after prion 
inoculation of the neuronal cell line GT-1, resembling spongiform pathology (Schatzl et al. 
1997). Other studies however failed to detect perceivable changes in a panel cultured neuronal 
cells (Julius et al. 2008). A recent work shows early synaptotoxicity in prion-infected 
hippocampal cells expressing PrPC, but not in prion-infected cells from PrP0/0 mice (Sevigny et 
al. 2016). Artificially engineered cell lines bearing interstitial deletion mutants of PrPC such as 
PrP∆105-125 present an antibiotics-induced hypersensitivity that could be restored by the small 
molecule LD7 (Imberdis et al. 2016). The most potent derivative of LD7 was also suggested to 
ameliorate prion-induced synaptotoxicity in hippocampal cells described in (Fang et al. 2016) 
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and to lower PrPSc levels in vitro. Future research has to show whether these changes 
observed in vitro can be successfully translated to cure prion disease in vivo. The Aguzzi lab 
has described an ex vivo slice culture system for cerebellar organotypic slice cultures (COCS) 
that is easily amendable to prion infections and pharmacological manipulation (Falsig et al. 
2008b). Of note, typical prion-induced changes such as the accumulation of PrPSc , astro- and 
microgliosis, spongiform change and neuronal loss can be studied in COCS. What is more, 
compounds conferring neuroprotection ex vivo successfully ablated toxicity in vivo as well 
(Sonati et al. 2013). 
Certain cell types permit efficient prion replication in vitro (Mahal et al. 2007). In order 
to find an inhibitor targeting prion replication, pharmacophores were selected from a computer-
based algorithm to exert a dominant-negative effect onto the alleged PrPC-“Protein X” binding 
site (Perrier et al. 2000). A lead molecule, Cp-60, was shown to efficiently cure cells from PrPSc 
at a half-maximal inhibitory concentration (IC50) of around 20 µM (Perrier et al. 2000). 
Compounds consisting of a tricyclic scaffold such as acridines and phenothiazines have 
demonstrated a favorable blood-brain-barrier penetration and were shown to reduce PrPSc 
levels (Korth et al. 2001). Fittingly, drugs like Quinacrine (derived from acridine) and 
Chlorpromazine (a phenothiazine) that were already established as anti-psychotic drugs and 
anti-malarials were immediately transferred to clinical trials in prion disease (see below). 
Second-generation compounds of the ladder groups were joined via linkers of variable length 
and molecular composition resulting in so-called bis-acridines (May et al. 2003). Optimal 
covalent linkage resulting in the most efficient PrPSc  reduction with acceptable cytotoxicity was 
achieved at a spacer distance of 10 Å with half-maximal effective concentrations (EC50) of 
around 25 nM, yielding a EC50 reduction of one log when compared to first-generation 
compounds such as Quinacrine (May et al. 2003). STI571 (also known as Gleevec or imatinib 
mesylate) emerged as lead compound from a screen targeting several pathways activated in 
prion disease and was later suggested to delay disease onset in prion-infected mice albeit 
lacking the potential to clear PrPSc   (Yun et al. 2007; Ertmer et al. 2004).  
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Taking a so-called “dynamics-based drug discovery” approach, a cavity created by 
several residues in helices B and C of PrPC that demonstrated relatively lower stability during 
high-pressure NMR was targeted by small molecules in order to stabilize the PrPC 
conformation (Kuwata et al. 2007). The most promising candidate from the screen, GN8, 
showed PrPSc reduction in a dose-dependent manner with dissociation constant (KD) of around 
4 µM. A comparison of NMR spectra after chemical shift perturbation showed a connection of 
distant PrPC residues by GN8 suggesting the exclusion of large conformational shifts (Kuwata 
et al. 2007). Conversely, in experiments from another group using equilibrium dialysis of known 
compounds described to bind to PrPC, neither GN8 was able to bind to a human PrP91-231 
fragment, nor did Quinacrine or tetracycline bind to human PrP91-231 after two days of 
equilibration time (Nicoll et al. 2010). The cationic porphyrin Fe(III)-TMPyP [Fe(III) meso-tetra 
(N-methyl-4-pyridyl) porphine], however, was retained in the PrP-containing chamber and 
provided a reduction of 50% of amplified protease-resistant PrPSc  during the protein-misfolding 
cycling amplification (PMCA) assay (Nicoll et al. 2010).  
Rather than aiming at reduction of total PrPSc levels, another study screened 32 
compounds for their propensity to catalyze the formation of larger-order PrPSc species that 
would by themselves reduce the amount of toxic and aggregation prone monomers (Ayrolles-
Torro et al. 2011). One compound, P30, increased the formation of PrPSc dimers and trimers 
in vitro and led to increased survival in prion-infected mice, albeit no higher-order PrPSc species 
were detectable in vivo, leaving the anti-prion mechanism of P30 elusive (Ayrolles-Torro et al. 
2011). In the PrP-fluorescence resonance energy transfer (FRET)-enabled high throughput 
assay (PrP-FEHTA), two antibodies targeting distinct, non-overlapping epitopes on PrPC were 
labelled with either a fluorescence donor or acceptor leading to FRET upon binding to PrPC on 
the cell surface (Karapetyan et al. 2013). Using PrP-FEHTA, the effects on PrPC cell surface 
levels of 1,280 drugs approved for use in humans were screened. Herein, Tacrolimus (a widely 
used immunosupressant) and Astemizole (an antihistamine) were found to efficiently reduce 
PrPSc levels. In prion-infected mice, Astemizole, but not Tacrolimus, led to a strong, but non-
significant extension (p=0.06) of survival time (Karapetyan et al. 2013). Interestingly, when 
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testing a panel of PrPSc lowering drugs, one study did not find any measurable, direct 
interaction between the compounds and PrPC or a direct capacity to disaggregate PrPSc 
suggesting all PrPSc clearing effects to be indirect (Poncet-Montange et al. 2011). 2-
aminothiazoles, another group of PrPSc lowering compounds, showed initial success in 
extending the life-span of prion-infected mice, but eventually led to a fatal neurodegenerative 
syndrome in prion-infected animals treated with the lead compound IND24 . Subpassages of 
their brain homogenates in mice and cells demonstrated drug resistance to IND24. Drug 
sensitivity to IND24 was restored after a treatment pause with vehicle control (Berry et al. 
2013). This study could have a broader implication for monotherapies in prion disease patients.  
 
Live imaging approches in models of neurological diseases 
Neuronal cell death is a commonly shared feature of several neurodegenerative 
diseases, amongst others Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s 
disease (HD) and prion disease (Bredesen, Rao, and Mehlen 2006). The precise, experimental 
determination of neuronal cell loss is important when asking scientific questions addressing 
pathogenetic mechanisms. Robust and sensitive assays are also needed for screening 
putatively neuroprotective or neurotoxic compounds. In AD, pathologically aggregated forms 
of β-amyloid protein and hyperphosphorylated τ (Tau)-Protein are considered causative factors 
of the disease (Scheltens et al. 2016). To date, no effective therapy has been developed for 
patients suffering from AD, emphasizing the acute need for tools that can reliably predict 
neuronal outcome (Sevigny et al. 2016). F-fluorodeoxygluose positron emission tomography 
(FDG-PET) and PET with β-amyloid-specific ligands has gained importance in the clinical 
assessment of diseases from the AD spectrum (Scheltens et al. 2016). A combination of the 
plethora of available transgenic AD mouse and rat models with miniaturized PET, so-called 
microPET, allows precise assessment of plaque load and can be used to monitor therapeutic 
efficacy of novel anti-AD drugs, to date, several novel radiotracers for AD diagnostics have 
been established using microPET (Zimmer et al. 2014).   
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Double transgenic APPPS1 mice bear mutations in both the amyloid precursor protein 
(APP) and presenilin 1 (PS1) leading to overexpression in pathological β-amyloid depositions 
(plaques) and subsequent neuronal dysfunction (Radde et al. 2006). Two different, fluorescent 
reporter proteins expressing animals were used to study the kinetics of β-amyloid plaque 
deposition, neuroinflammation and neuritic dystrophy. Mice bearing APPPS1 mutations and 
expressing of yellow fluorescent protein (YFP) in a subset of cortical neurons (B6C3-YFP mice) 
and mice bearing an APP mutation crossed to mice expressing green fluorescent protein 
(GFP) in microglia were longitudinally imaged in vivo using multiphoton microscopy (Meyer-
Luehmann et al. 2008). Interestingly, after rapid onset of plaques, microglial activation and 
recruitment to β-amyloid plaques were observed and subsequently, neurites became 
dysmorphic, providing unique insights into the temporal evolution of AD neuropathology 
(Meyer-Luehmann et al. 2008). In APPPS1 mice, depositions of β-amyloid plaques preceded 
loss of dendritic spines as was visualized by in vivo two-photon imaging with computational 
reconstruction (Bittner et al. 2012).  
Lipophilic, fluorescent dyes such as Oregon Green 488 BAPTA-1 AM bind to 
intracellular calcium (Ca2+) and shifts in their fluorescence intensity can be used as surrogate 
markers of calcium load (Tada et al. 2014). In vivo two-photon imaging of animals harboring 
AD-causing mutations in APP and PS1 showed reduced spiking, as visualized by OGB-1 
traces. In addition, “hyperactive”, increasingly spiking neurons, especially in close proximity to 
β-amyloid plaques, revealed the bimodal effects of β-amyloid aggregates on neuronal 
excitability (Busche et al. 2008). Live imaging through a cranial window of animals expressing 
GFP under the Thy1 promoter in neocortical neurons (strain GFP-M) was used to study the 
effects of seizures on dendritic morphology (Rensing et al. 2005; Feng et al. 2000). After 
chemically induced seizures through administration of 4-aminopyridine, only minimal 
alterations in dendritic spine morphology could be found (Rensing et al. 2005). Using kainate 
injections for modelling seizures and the same imaging techniques from the aforementioned 
study, contrary results were obtained, i.e., widespread dendritic spine degeneration in the 
acute seizure phase (Zeng et al. 2007).  
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Bioluminiscence imaging (BLI) refers to the detection of light emitted from a 
bioluminiscent source, most commonly generated by an enzyme (e.g., luciferase, luc) and its 
substrate (e.g., luciferin) (Hochgrafe and Mandelkow 2013). Transgenic mice were created 
that contained an inducible, bidirectional expression system for stoichiometric expression of 
human Tau protein mutants and luciferase (Sydow et al. 2011). The tau burden of neurons 
positively correlated with BLI signal and interestingly, when production of Tau protein and 
luminensce was ceased, pathological synaptic alterations induced by pathological Tau 
mutants could be ameliorated (Sydow et al. 2011). Bigenic mice expressing luc under the glial 
fibrillary acidic protein (GFAP) promoter and expressing mutants of human APP were used to 
study reactive gliosis in AD (Watts et al. 2011). BLI signals showed an age-dependent increase 
in β-amyloid plaques overexpressing mice and intracerebral inoculation of AD brains from old 
mice to young mice resulted in an accelerated disease onset, as could be measured through 
rapid elevations of BLI (Watts et al. 2011). Toll-like receptor 2 (TLR2) is strongly upregulated 
in microglial cells upon injury, hence a dual luc/GFP reporter system under the control of a 
murine TLR2 promoter was implemented into a transgenic mouse to study microglial activation 
in brain ischemia in vivo (Lalancette-Hebert et al. 2009). Surprisingly, the authors observed 
biphasic findings, i.e. acute and chronic, microglial response after brain ischemia.  Of note they 
could also observe an activation of microglial cells in the olfactory bulb upon brain injury, 
additional to the site of injury, suggesting the recruitment of olfactory bulb microglial cells in 
ischemic conditions (Lalancette-Hebert et al. 2009). 
 
Imaging prion neurotoxicity in vivo 
Early attempts to investigate prion-induced toxicity by means of live imaging were attempted 
by Negro an co-workers. Specifically, human epithelial carcinoma (HeLa), murine 
neuroblastoma (N2a) and Chinese hamster ovary (CHO) cells expressed bovine PrPC (bPrPC) 
and bovine orthologs of the pathogenic human PrPC mutations D178N/129M and E200K fused 
to GFP (Negro et al. 2001). When comparing the subcellular distribution of the mutant proteins 
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to wild-type, PrPC mutants exhibited a higher fraction of retention in the ER, and to a lesser 
degree in the Golgi apparatus (E200K). However, bovine PrPC mutants did not alter 
significantly from their human counterparts (Negro et al. 2001).  
 In mammalian prion diseases and other neurodegenerative diseases, neuropathology 
is marked by pronounced reactive gliosis, i.e., astrocytes develop a protoplasmic phenotype 
accompanied by a strongly eosinophilic cytoplasm representing the morphological correlate of 
increased protein expression of GFAP and vimentin and others (Singh and Joshi 2017). GFAP 
is not required for prion pathogenesis as mice devoid of GFAP do not exhibit altered disease 
incubation times or deposition patterns of PrPSc upon prion infection compared to their wild-
type counterparts (Tatzelt et al. 1996). A transgenic mouse expressing luciferase (luc) under 
the GFAP promoter, i.e. Tg(Gfap-luc), bioluminescence imaging (BLI, see above) was used to 
determine the kinetics of GFAP activiation in intercerebrally prion-inoculated animals 
(Tamguney et al. 2009). Accumulation of PrPSc could be detected as early as 42 days post-
infection (dpi) while GFAP was detectable at the mRNA level and by BLI at 55 dpi, in 
accordance with prior reports on the temporal evolution of prion disease (Jendroska et al. 
1991). BLI signal was inversely proportional to the infectivity titers used for inoculation and 
assessing prion pathology in Tg(Gfap-luc) mice provided an increase in sensitivity as signals 
on BLI markedly preceded neurological dysfunction. On the other hand, GFAP activation is not 
restricted to prion-induced pathology but also encountered in other pathological processes 
such as trauma, e.g., intracerebral inoculation with dull needles, which results in decreased 
specificity of measuring prion pathology in Tg(Gfap-luc) mice (Singh and Joshi 2017; 
Tamguney et al. 2009). Testing of Compound B, an amyloidophilic compound against prion 
disease in Tg(Gfap-luc) mice showed efficient neuroprotection against mouse-adapted prions, 
but not against human CJD prions, as measured by BLI (Lu et al. 2013).  
A cyanine, near-infrared (NIR) autofluorescent contrast agent was conjugated to 
Valine-Alanine-Aspartate-fluoromethylketone (VAD-fmk, yielding NIR-VAD-fmk), which binds 
to the active site of caspases and allows for live imaging of apoptosis in vivo, (Lawson et al. 
2010; Morita-Fujimura et al. 1999). After intracerebral inoculation with the M1000 prion strain, 
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Tga20 mice were injected with NIR-VAD-fmk and subjected to fluorescence reflectance 
imaging. After 45 dpi, a strong autofluorescence signal was observed in prion-inoculated, but 
not in sham-inoculated animals. On the other hand, although injection of 2 subsequent doses 
of NIR-VAD-fmk did not show observable toxicity, the potential of the compound for repetitive 
imaging was not demonstrated (Lawson et al. 2010). The YFP-H mouse line (Feng et al. 2000) 
expressing YFP predominantly in hippocampal and cortical neurons, has been used for 
studying synaptic spine dynamics in prion disease (Fuhrmann et al. 2007). Repetitive imaging 
through a chronically implanted, cortical window facilitated investigations of early synaptic 
changes in prion-infected mice. Computational modelling of spines yielded unprecedented 
insights into spine dynamics in prion disease, although this in vivo approach is not suitable for 
medium-to high-throughput screenings of putatively neuroprotective anti-prion compounds 
(Fuhrmann et al. 2007). 
In vivo, manganese-enhanced magnetic resonance imaging (MEMRI) impressively 
demonstrated the effects of anti-PrPC antibody-mediated toxicity (Sonati et al. 2013). 
Monoclonal anti-PrPC antibodies targeting the globular domain of PrPC (PrPC-GD) showed 
widespread and rapid neurotoxicity closely resembling genuine prion diseases. Stereotaxic 
injection of the anti-PrPC-GD antibody POM1 demonstrated rapid formation of brain edema 
and subsequent cerebellar atrophy within a few days as was seen by MEMRI (Figure 5, (Sonati 
et al. 2013; Reimann et al. 2016)). Contralateral injection of POM1 pre-incubated with 
recombinant, full-length murine PrPC (rmPrP23-230) was innocuous. Moreover, anti-PrPC-GD 
antibody-mediated toxicity was dependent on the presence of a functional flexible tail of PrPC 
(PrPC-FT), since genetic or pharmacological ablation of PrPC-FT was neuroprotective (Sonati 
et al. 2013). 
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When assessing the dose-dependent toxicity of a variety of anti-PrPC monoclonal antibodies, 
dose-escalation of the anti-PrPC-GD targeting antibody ICSM18 showed hyperintense lesions 
on MEMRI corresponding to pathologically altered hippocampal neurons as observed on H&E 
histology, putting the therapeutic potential of ICSM18 as a potential anti-prion and anti-AD 
therapeutic in question (Klyubin et al. 2014; Reimann et al. 2016). 
 
  
Figure 5. (A) Injection of the neurotoxic anti-PrPC antibody POM1 into the brain of PrPC-
overexpressing Tga20 mice leads to a diffusion restriction 4 days after injection as visualized by 
the hyperintense signal. POM1 injection into Prnp0/0  (ZH1) mice does not elicit toxicity. (B) The 
same animals were re-imaged 11 days post-injection: no diffusion restriction is no longer visible, 
indicating resorption of the acute injury.  
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Part I – Novel in vivo assays to measure prion-induced 
neurodegeneration 
 
Aims of the study 
My goal is to establish a reliable, in vivo live-imaging assay to study neuronal cell loss in prion 
disease. As laid out before, currently available techniques are limited to low-throughput 
methods (MEMRI, imaging of spine dynamics through chronic windows) that do not allow 
medium- to high-throughput screening of putatively neuroprotective compounds (Reimann et 
al. 2016). Furthermore, current screening methods rely mainly on post hoc 
immunohistochemistry using neuronal markers such as neuronal nuclei (NeuN) resulting in a 
large read-out variability (Sonati et al. 2013; Falsig et al. 2012). By exposing hippocampal and 
cerebellar organotypic slice cultures expressing fluorescent reporter proteins in a subset of 
neurons to repeated in vivo confocal laser scanning microscopy (CLSM), I have reduced read-
out variability by taking into account pre-treatment slice viability and inter-slice variability. 
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Results  
Time-lapse confocal imaging of YFP+ CA1 pyramidal neurons in YFP16 HOCS 
confirms neurotoxicity of PrPC-GD targeting antibodies 
In a first step, I determined the contributing background values of my imaging setup (i.e. YFP16 
HOCS on PFTE membranes in slice culture medium) to EYFP reference spectra by recording 
lambda stacks of individual culture components without YFP16 HOCS, herein, when 
measuring cell bodies, background fluorescent did not contribute more than 5% of the total 
recorded signal (Figure 6A).  
 
 
Neurons were counted semi-automatically using IMARIS spots function (Figure 6B) and the 
encompassing volume of counted neurons was calculated using MATLAB convhull function 
(Figure 6C, D). Fluorescent protein expression in YFP16 HOCS was exclusively limited to a 
Figure 6. (A) Lambda stacks of YFP16 HOCS show a contributory noise level of less than 5% for 
assessing cell bodies (blue line) in peak fluorescencence spectrum from YFP reference spectrum 
(dashed line, Invitrogen/Life Technologies, Grand Island, NY, USA) and enhanced YFP (solid black 
line, fluorophore used in these experiments). Enhanced noise ratios are observed for imaging of 
neurites (red line); green line denotes unspecific background region of interest. Semiautomatic 
identification of neuronal cell bodies through IMARIS Spots (C) and graphical visualization of spots 
(D) and computation of encompassing volume through a convex hull (E); axes = [pixel]. Scale bar = 
100 µm. 
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subset of CA1 pyramidal neurons as was confirmed by YFP-NeuN double staining on 
immunohistochemistry (mean Pearson’s r=0.58 ± 0.09 for colocalized YFP+/NeuN+ pixel, n=7, 
Figure 7A).  
 
 
To determine long-term viability of repeated recordings of YFP16 HOCS, slices were imaged 
during 5 weeks after dissection starting from 5 days in vitro (DIV5). Semi-automated counts of 
absolute YFP+ neurons per slice obtained throughout the recorded time period were 
normalized to baseline YFP+ neuron counts of each corresponding slice (i.e. DIV5). YFP+ 
neurons did not significantly decrease throughout the recorded time period when compared to 
baseline (Figure 7B) and semi-automated counting of YFP+ hippocampal CA1 pyramidal 
neurons showed less read-out variability than the ratio of cell to total YFP+ encompassing 
volume (p<0.05 in 3 of 4 comparisons, F-test of equality of variances, Figure 7C). Repetitive 
imaging allowed re-tracing of the same neuronal population over several time points (Figure 
Figure 7. (A) Upper drawing: Schematic depiction of YFP+ CA1 pyramidal neurons in YFP16 HOCS. 
Lower panel: Post hoc immunostainings for cell nuclei (H33342) and neuronal nuclei (NeuN) of YFP16 
HOCS with subsequent colocalization analysis for YFP+/NeuN+ positive pixels showed a high 
correlation (grey pixels, lower right image, Pearson’s r=0.58 ± 0.09). Scale bar = 100 µm. (B) Time-
course analysis of untreated YFP16 HOCS showed no significant spontaneous neurodegeneration 
over 5 weeks (one-way ANOVA with Dunnett’s post-test, n.s. [not significant]). (C) Counting of absolute 
neurons showed significantly reduced read-out variability than YFP+ neurons-to-encompassing volume 
ratio (p<0.05 in 3 of 4 comparisons, F-test of equality of variances). (D) YFP16 HOCS allowed for re-
tracing of identical neuronal populations and individual neurons in confocal imaging (maximum 
intensity projections from the same YFP+ slice, upper panel) as well as in three-dimensional point 
reconstruction (lower panel). Upper panel: scale bar = 100 µm, lower panel: axes are given in [µm].  
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7D, upper panel). Also, three-dimensional neuronal cell distribution was reconstructed using 
MATLAB that also allowed re-tracing of single neurons from reconstructed point clouds (Figure 
1D, lower panel).  
I have crossed YFP16 mice (harboring 2 wild-type alleles of Prnp) to PrPC overexpressing 
Tga20 mice, yielding YFP16Tga20/- mice that allow for sensitive investigation of neurotoxic anti-
PrPC-GD antibodies (Fischer et al. 1996). YFP16Tga20/-  HOCS were treated with a full-length 
([67 nM], 10 days) or a Fab1-fragment ([67 nM], 6 days), respectively, of the PrPC-GD targeting 
antibody POM1. Anti-prion protein antibodies pre-incubated with rmPrP23-230 at molar excess 
([134 nM]) were used as negative controls.   
 
Slices were always imaged once at baseline and then every other day (full-length POM1, 
POM1) or every day (Fab1-fragment of POM1, Fab1POM1) using confocal time-lapse 
Figure 8. Upper graph: Time-lapse confocal imaging of YFP16Tga20/- HOCS treated with POM1 in the 
presence and absence (+/-) of rmPrP23-230 shows significantly reduced YFP+ CA1 pyramidal neurons 
from 8 dpe, p<0.01 (one-way ANOVA with Sidak’s post hoc test). Treatment was initiated after 
recording of baseline (i.e. dpe 0) and then re-added on days 2, 4, 6 and 8. Lower panel: Maximum 
intensity projections of imaged z-stacks demonstrate significant neurotoxicity of full-length POM1. 
Scale bars = 100 µm.   
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microscopy. Treatment of YFP16Tga20/-  with the PrPC-GD targeting monoclonal antibody POM1 
(Figure 8) and its Fab1 fragment (Figure 4) showed severe neurotoxicity after only a few days 
 
 
of treatment initiation (p<0.01 on day 8 for POM1, n=5, vs. POM1+ rmPrP, n=6, and p<0.05 
on day 2 for Fab1POM1 vs. Fab1POM1 + rmPrP, n=9 for both treatment groups) that was 
sustained in both treatment schemes until the end of the imaged period.  
Slice-based reconstruction of neuronal loss in YFP16 HOCS treated with PrPC-GD 
targeting antibodies  
Best curve estimates for reconstruction of single-slice based neuronal cell loss during the 
recorded time-course were assessed by the calculation of Akaike Information Criteria values 
adjusted for finite sample sizes (AICc) in 9 different curve estimation models (Table 1).  
Figure 9. Upper graph: Time-lapse confocal imaging of Tg(YFP16:tga20tg/wt) HOCS treated with a 
Fab1-fragment of POM1 +/- rmPrP shows markedly accelerated neurotoxicity, as soon as 2 dpe 
(p<0.05, one-way ANOVA with Sidak’s post hoc test) that was sustained until the end of the imaged 
time-frame, i.e. 6 dpe. Treatment was initiated after recording of baseline (i.e. dpe 0) and then re-
added on days 2, 4, 6 and 8. Lower panel: Maximum intensity projections of imaged z-stacks 
demonstrate significant neurotoxicity of Fab1POM1 Scale bars = 100 µm. §: 1 HOCS was not 
readable on 5 dpe due to a technical error. 
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Table 1. Curve estimation equations used for modelling neurodegeneration (k = 
regression constant, λ = regression coefficient, t = time constant, u = upper boundary value). 
 
Linear  
Logarithmic  
Inverse  
Compound  
Power  
S-curve 
 
Growth 
 
Exponential  
Logistic  
 
Table 2. Modeling neurodegeneration in YFP16 HOCS by comparison of ∆I from different 
AICc values (see Methods). 
Table 2a. ∆i values from control treated (i.e. (Fab1)-POM1 + rmPrP23-230) slices (k=2 for every 
model, RSS = residual sum of squares, n=14). 
Model RSS ∆i 
Linear 622.556 771.3091 
Logarithmic 593.521 748.9662 
Inverse 654.746 749.5849 
Compound 0.232 0 
Power 0.353 4.719 
S-curve 0.520 23.3895 
Growth 0.228 0 
Exponential 0.745 0 
Logistic 1.608 233.3304 
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Table 2b. ∆i values for (Fab1)-POM1 treated slices (n=13). 
Model RSS ∆i 
Linear 835.849 654.2637 
Logarithmic 862.468 634.1705 
Inverse 1090.613 660.4375 
Compound 0.442 0 
Power 0.789 47.036 
S-curve 1.215 89.9362 
Growth 0.438 0 
Exponential 1.198 0 
Logistic 2.038 100.9743 
 
Strikingly, both groups showed the lowest AICc values for compound, growth and simple 
exponential equations, so we chose neuronal loss to be modeled by a compound function with 
a simple equation (Tables 1+2). This resulted in a good fit of the model as expressed through 
the root mean square error RMSE = 0.26 ± 0.2 (n=29). Individualized slopes of neuronal loss 
were reconstructed using a compound fit (Figure 10).  
 
The regression coefficients showed a significant difference when comparing (Fab1-)POM1 
treated slices and their control treated counterparts (POM1+rmPrP 0.95 ± 0.04, n=6, versus 
Figure 10. Individualized slice-based 
slopes of neuronal loss were 
reconstructed using a compound fit for 
both POM1 in the presence or in the 
absence of rmPrP23-230 (+/- rmPrP, upper 
graph) and Fab1POM1 +/- rmPrP (lower 
graph) treated slices. 
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POM1 0.81 ± 0.09, n=5, p<0.05; Fab1POM1+rmPrP 0.92 ± 0.08, n=9, versus Fab1POM1 0.68 
± 0.10, n=8, p<0.001; one-way ANOVA with Sidak’s post hoc test, Figure 11). Interestingly, a 
significant difference was observed when comparing the regression coefficients between 
HOCS treated with POM1 and Fab1POM1 (p<0.05) while regression coefficents between 
(Fab1-) POM1+rmPrP treated HOCS did not differ significantly (one-way ANOVA with Sidak’s 
post hoc test, Figure 11). These findings also point towards an accelerated neurodegeneration 
through the Fab1-fragment of POM1 when compared to the whole antibody. 
 
 
Figure 11. Regression coefficients from curve estimation models showed a significant difference 
when comparing (Fab1-)POM1 treated slices to their control treated counterparts (i.e. through 
pre-incubation with rmPrP23-230). Regression coefficients of neuronal cell loss in Fab1POM1 
treated HOCS were also significantly reduced when compared to treatment with the whole 
antibody. * p<0.05, *** p<0.001; one-way ANOVA with Sidak’s post hoc test. 
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Time-lapse imaging of YFP16 HOCS reduces read-out variability compared to post hoc 
morphometry 
In order to compare the newly established in vivo imaging of YFP16 slices to the commonly 
employed post hoc NeuN morphometry, I challenged non-fluorescent HOCS from Tga20 mice 
with an identical treatment regimen, fixed and stained HOCS at defined time points (Figure 
12). As previously reported, the NeuN-immunopositive area of (Fab1-)POM1 treated HOCS 
was normalized to the average of control-treated slices, here (Fab1-)POM1 treated HOCS with 
pre-incubated full-length rmPrP23-230 (Falsig et al. 2012). Tga20 HOCS treated three times with 
Fab1POM1 showed significant neurotoxicity after 6 days on NeuN morphometry when 
compared to those with pre-incubated rmPrP23-230 (p<0.01, Fab1POM1+rmPrP23-230 [n=10] vs. 
Fab1POM1 [n=11], paired two-tailed t-test, Figure 13A). Tga20 HOCS treated with POM1 +/- 
rmPrP23-230 did not show any significant neuronal cell loss after 10 days of treatment comparing 
to the whole treatment course (one-way ANOVA with Dunnett’s post hoc test). In contrast, 
Figure 12. Treatment schemes used for read-out comparison of live-imaging versus post hoc NeuN 
immunolabeling. Black horizontal lines denote 1 treatment group, red arrows indicate imaged time 
points, and black arrows administration of treatment. *Here for all treatment groups n=8, except for 
POM1 treatment for 6 days, n=10 (middle bar). 
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YFP16Tga20/-  animals showed a significant neurotoxicity after 8 dpe (days post-exposure) 
(Figure 13). The discrepancy of this finding seems noteworthy since PrPC protein levels in 
Tga20 mice are around 10-fold higher when compared to wild-type mice than those of Tga20+/- 
Figure 13. (A) Treatment of Tga20 HOCS with Fab1POM1 for 6 days resulted in significantly  
decreased NeuN+ cells as determined by NeuN morphometry (p<0.01, Fab1POM1+rmPrP, n=10, vs. 
Fab1POM1, n=11, paired two-tailed t-test). Left panel: representative fluorescent micrographs of NeuN 
immunolabeled HOCS counterstained with Hoechst 33342, 6 dpe. Scale bars = 500 µm. (B) 
Fluorescent micrographs (top panel) of POM1 +/- rmPrP treated Tga20 HOCS showing post hoc NeuN 
immunolabeling (scale bars = 500 µm). NeuN morphometry of the recorded time-course resulted in 
high read-out variability and did not show a significant neurotoxic effect of POM1-induced neurotoxicity 
(lower left graph) although an end-point based comparison (i.e. after 10 days) resulted in significantly 
decreased NeuN+ area in treated HOCS (p<0.05, paired two-tailed t-test) (lower right graph).  
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showing around 6- to 7-fold higher expression levels of PrPC than wild-type animals, pointing 
towards an increased sensitivity of YFP16 HOCS (Fischer et al. 1996). A post hoc two-group 
endpoint comparison (i.e. 10 dpe only) between POM1 and POM1+rmPrP did in prion protein 
levels show a significant neurotoxic effect (p<0.05, paired two-tailed t-test, Figure 13B).   
 Prnp0/0 mice do not succumb to prion disease or anti-PrPC-GD antibody-mediated 
toxicity (Sonati et al. 2013; Bueler et al. 1993). I crossed YFP16 mice with Prnp0/0 (ZH1) mice, 
yielding YFP16ZH1/ZH1. 14 days of treatment with a single-chain fragment of the variable 
domains (scFv) of POM1 (scFvPOM1) showed profound toxicity in YFP16Tga20/- (p<0.01, 
scFvPOM1 [n=8] vs. scFvPOM1+rmPrP23-230 [n=8], one-way ANOVA with Dunnett’s post hoc 
test), but not in YFP16ZH1/ZH1 HOCS (p<0.01, scFvPOM1 in YFP16Tga20/- [n=8] vs. scFvPOM1 
in YFP16ZH1/ZH1 [n=9], one-way ANOVA with Dunnett’s post hoc test, Figure 14A). Likewise, on 
post hoc NeuN immunohistochemistry, scFvPOM1 showed neurotoxicity in YFP16Tga20/- 
(p<0.01, scFvPOM1 [n=8] vs. scFvPOM1+rmPrP23-230 [n=8], one-way ANOVA with Dunnett’s 
post hoc test), but not in YFP16ZH1/ZH1 HOCS (p<0.001, scFvPOM1 in YFP16Tga20/- [n=8] vs. 
scFvPOM1 in YFP16ZH1/ZH1 [n=9], one-way ANOVA with Dunnett’s post hoc test, Figure 14B).  
 
Figure 14. (A) Treatment with scFvPOM1 leads to significant neurotoxicity in YFP16Tga20/-, but not 
in YFP16ZH1/ZH1 HOCS. (B) Post hoc staining of YFP16Tga20/- and YFP16ZH1/ZH1 HOCS with NeuN 
shows PrPC-dependent toxicity of scFvPOM1, as YFP16ZH1/ZH1 HOCS do not show a reduction of 
NeuN+ area when compared to YFP16Tga20/- HOCS. * p<0.05, ** p<0.01, *** p<0.001; one-way 
ANOVA with Dunnett’s post hoc test. 
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To further test read-out variability of YFP16 HOCS, I tested compounds known to ablate anti-
PrPC-GD mediated toxicity, such as the anti-PrPC-FT antibody POM2, the ROS scavenger 
ascorbic acid (AscA) and the calpain inhibitor calpeptin (Herrmann et al. 2015). Treatment for 
12 days of YFP16Tga20/- with scFvPOM1 in combination with scFvPOM2 resulted in amelioration 
of neurotoxicity (p<0.05, scFvPOM1 [n=8] vs. scFvPOM1+scFvPOM2 [n=8], one-way ANOVA 
with Dunnett’s post hoc test, Figure 15A), while post hoc NeuN stainings of the same slices 
did not reveal a significant difference (p>0.05, scFvPOM1 [n=8] vs. scFvPOM1+scFvPOM2 
[n=8], one-way ANOVA with Dunnett’s post hoc test, Figure 15B). 
Likewise, treatment with 50 µM calpeptin (p<0.001, scFvPOM1 [n=12] vs. 
scFvPOM1+Calpeptin [n=9], one-way ANOVA with Sidak’s post hoc test, Figure 16A) or 2.5 M 
ascorbic acid (p<0.001, scFvPOM1 [n=10] vs. scFvPOM1+AscA [n=10], one-way ANOVA with 
Sidak’s post hoc test, Figure 16C) demonstrated ablation of scFvPOM1-mediated toxicity as 
was observed by live imaging of YFP16 HOCS (Figures 16A+C), but not post hoc NeuN 
staining (Figures 16B+D).  
 
Figure 15. Treatment with scFvPOM2 ablates scFvPOM1-induced toxicity in time lapse imaged 
YFP16Tga20/- HOCS (A), but not in post hoc NeuN stained HOCS (B). * p<0.05, ** p<0.01, *** p<0.001; 
one-way ANOVA * p<0.05, ** p<0.01, *** p<0.001; one-way ANOVA with Dunnett’s post hoc test.  
with Dunnett’s post hoc test   
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OCS have been shown to faithfully replicate prion pathology (Falsig et al. 2012). In a last step, 
I investigated the read-out variability of the neuroprotective agent ascorbic acid in RML6-
infected YFP16Tga20/-  HOCS. As early as 28 days post inoculation (dpi), I could observe 
significantly increased YFP+ neurons when comparing RML-inoculated slice alone to RML 
Figure 16. Treatment with the calpain inhibitor calpeptin (A), as well as with the ROS scavenger 
AscA (C) ameliorates scFvPOM1-induced toxicity in time lapse imaged YFP16Tga20/- HOCS (A), but 
not in post hoc NeuN stained HOCS (B+D). * p<0.05, ** p<0.01, *** p<0.001; one-way ANOVA * 
p<0.05, ** p<0.01, *** p<0.001; one-way ANOVA with Sidak’s (A+B) / Dunnett’s (C+D) post hoc test.   
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plus AscA-treated HOCS. This treatment effect was sustained until the end of the investigated 
time-period (p<0.05, RML [n=7] vs. RML+AscA [n=8], one-way ANOVA with Dunnett’s post 
hoc test, Figure 17A). Conversely, post-hoc staining of imaged YFP16Tga20/-  HOCS on 48 dpi 
with NeuN did not reveal any treatment effect (Figure 17B).  
 
 What is the overall performance of the live-imaging assay when compared to NeuN 
morphometry? A statistical evaluation of differences of variance between all n=28 treatment 
groups showed superiority of live imaging in YFP16 HOCS to NeuN morphometry in n=15 
comparisons, equal read-out variability in n=12 and inferiority of YFP16 HOCS live imaging in 
n=1 comparisons, showing significantly reduced read-out variability of my novel live imaging 
assay in over 50% of cases. 
 
Discussion and outlook 
In this current study I present a novel fluorescence-based live-imaging assay for long-term 
imaging of a small neuronal subset in hippocampal organotypic slice cultures. I show that this 
assay reliably reproduced the previous findings of neurotoxic antibodies targeting the globular 
domain of the cellular prion protein, PrPC-GD, with increased read-out sensitivity in over 50% 
Figure 17. Treatment of RML-infected and NBH control HOCS with the ROS scavenger ascorbic 
acid showed significant disease amelioration in YFP16Tga20/- HOCS on 42 and 49 dpi (p<0.05, RML 
[n=7] vs. RML+AscA [n=8], one-way ANOVA with Dunnett’s multiple comparison test) while post 
hoc NeuN morphometry on YFP16Tga20/- HOCS stained on 49 dpi did not show any observable 
treatment effects (B). * p<0.05, one-way ANOVA with Dunnett’s post hoc test.  
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of the compared groups. The cerebellar organotypic slice culture (COCS) assay was shown to 
faithfully reproduce prion pathology ex vivo. This discovery allowed convenient 
pharmacological manipulation and eventually paved the way to demonstrate that PrPC-
antibody induced neurotoxicity is mediated through its flexible tail (Falsig et al. 2008a; Falsig 
et al. 2012). These observations in PrPC-dependent neuronal cell death have been 
complicated through heightened read-out variability using NeuN morphometry from post-hoc 
immunolabeled COCS. Due to the lack of a suffiently labeled number of YFP+ neurons in 
COCS from YFP16 mice, I chose HOCS as an ex vivo model for PrPC-dependent POM1-
induced neurotoxicity (Feng et al. 2000).  
I crossed YFP16 mice with PrPC-overexpressing, Tga20 mice that serve as a sensitive 
indicator of prion-induced pathology (Fischer et al. 1996), yielding YFP16Tga20/- mice. Treatment 
of YFP16Tga20/- with the monoclonal anti-PrPC-GD antibody POM1 showed significant toxicity 
after 8 dpe (Figure 13), while longitudinal assessment with post hoc, immunohistochemical 
stainings in HOCS did not show any significant effects (Figure 13). High read-out variability in 
NeuN stained HOCS did not show significant results in multiple testing since an end-point 
comparison reached statistical significance (Figure 13). Further comparisons of POM1 in PrPC-
overexpressing versus Prnp0/0 HOCS, as well as rescue of POM1 toxicity through POM2, 
calpeptin and ascorbic acid showed significantly reduced read-out variability in YFP16 HOCS 
in over 50% of all treatment groups. Significant inferiority of YFP16 COCS to post hoc 
morphometry was seen in 3.6% of cases.  
What is the reason for the inferiority of post hoc NeuN morphometry in terms of read 
out variability? In the experiments performed here, large read-out variability obscures 
significant differences in multiple testing regimens. Furthermore, the downside of repetitive 
imaging of YFP16 HOCS is its increased toxicity. In addition,  re-staining of HOCS after several 
rounds of imaging might obscure the true effects of gene knock-outs and pharmacological 
compounds. On the other hand, lowered read-out sensitivity in YFP16Tga20/- HOCS was 
unrelated to relatively lower expression levels of cellular prion protein: brains from YFP16Tga20/- 
mice show 6- to 7-fold higher PrPC expression levels when compared to wild-type, while Tga20 
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mice show around 10-fold higher PrPC expression levels compared to wild-type. I believe this 
observation underscores the sensitivity of my assay and suggests that the CA1 area is an early 
target in PrPC-mediated neurotoxicity (Fischer et al. 1996). 
Consistent with previous findings, Fab1 and Fab2-fragments of globular domain 
targeting PrPC-antibodies showed more accelerated neurotoxicity than their full-length 
immunoglobulin counterparts (Sonati et al. 2013). I was able to reproduce this finding in 
hippocampal slices by showing that treatment of YFP16Tga20/- HOCS with Fab1POM1 resulted 
in significant neuronal loss after only 2 dpe when compared to treatment with full-length POM1 
(Figures 3+4). Since YFP-expression was limited to a small subset of hippocampal CA1 
pyramidal neurons, those areas could be re-traced during each imaging time point. This in turn 
allowed the construction of neurodegenerative slopes with a high goodness of fit assuming an 
compound equation (Tables 1+2, Figures 5+6). Lastly, the comparison of computed neuronal 
loss decay rates further underlined the accelerated neurodegeneration induced by Fab1-
fragments of POM1 and added valuable information to the mechanisms of PrPC-antibody 
dependent neurotoxicity (Figure 16). When screening putatively neuroprotective or -toxic 
compounds in neurodegenerative diseases, high read-out variability may stall efforts to 
identifyinteresting drugs that may broaden knowledge about deregulated pathways during 
disease. I show here that the semi-automated counting of time-lapse imaged YFP+ HOCS adds 
50% to read-out sensitivity when compared with identical treatment schemes using already 
established methods such as post-hoc NeuN morphometry.  
Neuronal cell death is a commonly shared and pathognomonic hallmark amongst 
several neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s, 
Huntington’s and prion disease (Bredesen, Rao, and Mehlen 2006). To assess neuronal loss 
in an experimental setup, a variety of commercially available tools and reagents exist; for 
instance through the addition of (not necessarily neuron-specific) chemicals that are either 
taken up or excluded by the cells depending on their viability in the culture system of interest, 
i.e. primary neuronal cultures, organotypic slice cultures etc. These compounds, including 
Trypan blue and Propidium iodide, are then quantified using conventional light or fluorescent 
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microscopy (Giordano et al. 2011). Although they are widely established and their application 
is rather cheap, they are always end-point based and lack the ability to directly measure the 
kinetics of cell death over a longer time span. Another - but also indirect - approach to study 
neuronal cell death by pre-labeling the cells with cell-permeable acetoxymethylester (AM)-
conjugated dyes such as calcein AM. However, interpretation may be hampered by 
spontaneous cellular release of the dye after incorporation leading to reduced read-out 
sensitivity (Giordano et al. 2011).  
Previous live imaging techniques to evaluate neurodegeneration in prion diseases 
entail bioluminescence imaging (BLI) using Tg(Gfap-luc) animals expressing luciferase under 
the GFAP promoter, i.e., exploiting reactive gliosis as a surrogate marker of prion pathology 
(Tamguney et al. 2009). BLI is a non-invasive method to longitudianally study 
neurodegeneration that has been shown to provide a sensitive, preclinical readout in prion-
inoculated Tg(Gfap-luc) mice. On the other hand, reactive gliosis is a non-specific reaction of 
the central nervous system to a variety of injuries and can lead to false-positive results (Singh 
and Joshi 2017). High-resolution imaging of dendritic spine turnover dynamics through a 
cranial window in mice expressing fluorescently marked neurons yielded unprecedented 
insights into early prion pathogenesis. However, the invasive nature of animal surgery and 
imaging, is unlikely to be suitable for parallel screening of several compounds (Fuhrmann et 
al. 2007). Manganese-enhanced magnetic resonance imaging (MEMRI) was demonstrated to 
be a sensitive indicator of toxic anti-PrPC antibodies allowing calculation of dose-response 
curves (Sonati et al. 2013; Reimann et al. 2016). A major drawback of MEMRI, however, are 
the side effects of chronic Mn2+ administration leading to PD-like symptoms questioning the 
suitability of MEMRI for longitudinal studies (Silva and Bock 2008). Admittedly, my novel live-
imaging based assay may be more expensive and more time-consuming than previous end-
point based assays with the need for intercrosses with the genotype of interest, organotypic 
slice cultures, repetitive imaging, and high-resolution microscopes for live-imaging. 
Conversely, I believe that this approach may provide valuable information on neurotoxicity 
screening applications by gathering pharmacokinetic data and reduction of false-negative 
  
  
KARL FRONTZEK, 2017 53 
 
results through increased read-out sensitivity. Further optimizations of the assay might include 
minituarization of the assay, e.g., by using fragments of fluorescent OCS to increase 
throughput, since I have already shown that a small subset of neurons is enough for sentitive 
screening.  
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PART II - The globular domain of the prion protein induces 
prion neurotoxicity through increased relaxation of its β2α2 
loop 
 
Aims of the study 
Antibodies and single-chain variable fragment (scFv) targeting certain epitopes of the prion 
protein PrPC are acutely neurotoxic. Transcriptional and proteomic analyses indicate that their 
toxicity closely recapitulates that of prion infections, suggesting that these antibodies mimic 
the docking of prions to PrPC. Toxicity is mediated by the flexible tail of PrPC, implying that 
antibody binding triggers an allosteric transition within  PrPC. Here I report that POM1 firstly 
does not induce prion replication and secondly imposes a strict spatial constraint on the 
flexibility of the β2-α2 loop of PrPC without appreciably distorting its overall structure. To assess 
the functional consequences of this constraint, each one of the POM1 residues interacting with 
PrPC was replaced with alanine. Single chain variable fragments of the resulting 11 individual 
mutants were found to be toxic (S32A, D52A, W94A, Y101A), innocuous (D55A), or protective 
(Y57A, Y104A) to naïve and prion-infected cerebellar organotypic slice cultures (COCS). Toxic 
mutants induced acute neuronal loss and astrogliosis that, as with their parental antibody 
POM1, was prevented by antibody scFvPOM2 against the amino terminus of PrPC. Protective 
mutants attenuated microgliosis and activation of the unfolded protein response, and 
suppressed the toxicity of both scFvPOM1 and infectious prions. Molecular dynamics 
simulations showed that protective mutations led to a relaxation of the β2-α2 loop. Besides 
implying loop rigidity as a mediator of prion toxicity, these investigations have led to the 
discovery of dominant-negative immunoreagents binding to PrPC and quenching prion toxicity. 
These structural insights provide a well-defined pathway towards the development of 
efficacious antiprion drugs.   
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Results 
The neurotoxic anti-PrPC antibody POM1 does not elicit prion replication 
In order to investigate the possible generation of prions by the neurotoxic, anti-PrPC-GD 
targeting antibody POM1, I treated PrPC-overexpressing Tga20 COCS with either scFvPOM1 
(400 nM) or with scFvPOM1 (400 nM) preincubated with a molar excess of rmPrP23-230 (600 
nM) for control. This treatment was maintained over 10 days with three medium changes per 
week; scFvPOM1 was replaced with each medium change. NeuN immunofluorescent 
stainings, which identify neurons, showed widespread neuronal degeneration in COCS treated 
with scFvPOM1, but not in COCS treated with antibody that had been preemptively blocked 
with rmPrP23-230 (Figure 18A). To clarify whether this effect was induced by the aggregation of 
PrP, I analyzed pooled COCS homogenates treated with either scFvPOM1 (n=8) or 
  
  
KARL FRONTZEK, 2017 56 
 
scFvPOM1 + rmPrP23-230 (n=5) for PrPSc, an isoform of PrP that is partially resistant to 
proteinase K (PK) and is universally employed as a surrogate marker for prion infectivity 
(Figure 18B). Pooled slice homogenates from scFvPOM1-treated (n=8) and 
(scFvPOM1+rmPrP23-230)-treated (n=5) Tga20 COCS were analyzed by Western blotting and 
were found to be devoid of PrPSc. In contrast, PK digestion of prion-containing brain 
homogenate (RML6 = passage 6 of the Rocky Mountain Laboratory strain mouse-adapted 
scrapie prions), which served as positive control, showed the typical diagnostic shift towards 
a smaller PK-resistant core with un-, mono- and diglycosylated PrPSc.  
The murine neuroblastoma cell line CAD5 is highly susceptible to prion infection and 
serves as a sensitive bioassay for prion propagation (Enari, Flechsig, and Weissmann 2001). 
I therefore spiked cell culture media of exponentially growing CAD5 cells with RML6 prions, 
non-infectious brain homogenate (NBH), or homogenates from COCS that had been exposed 
to scFvPOM1 or scFvPOM1+rmPrP23-230- (6–12 ng protein of total homogenate in 1 mL of cell 
culture media). After 4 days of culture, I lysed the CAD5 cells and assessed PrPSc by Western 
blotting. No PrPSc was detectable in CAD5 cells inoculated with COCS homogenates exposed 
to either scFvPOM1 or scFvPOM1+rmPrP23-230. In contrast, RML6 prion-infected CAD5 cells 
displayed the typical pattern of PrPSc on Western blots (Figure 18C). 
To investigate the possible presence of prions in POM1-treated COCS in more detail, 
Manuela Pfammatter (Institute of Neuropathology, University Hospital Zurich) assessed the 
prion propagation activity of antibody-treated Tga20 COCS homogenates using the real-time 
quaking induced conversion assay (RT-QuIC) (Atarashi et al. 2011). The RT-QuIC allows 
sensitive detection of PrPSc based on prion-catalyzed cyclic amplification of misfolded PrP. 
Homogenates of COCS treated with scFvPOM1 or scFvPOM1+rmPrP23-230 as well as COCS 
Figure 13 (page 56). (A) Chronic treatment of COCS with scFvPOM1 induced profound 
neurodegeneration. Instead, no neurodegeneration was observed in COCS exposed to scFvPOM1 
pre-incubated with rmPrP23-230. *** p<0.001, unpaired, two-tailed T-test. Scale bar = 500 μm. (B) 
Pooled slice homogenates of scFvPOM1-treated (n=8 slices) or (scFvPOM1+ rmPrP23-230)-treated 
Tga20 COCS (n=5 slices) did not show PK-resistant species after digestion as is typically observed 
in RML6 brain homogenate (n=1). (C) No PrPSc was observed after inoculation of the highly PrPSc-
susceptible cell line CAD5 with pooled scFvPOM1-treated COCS homogenates. CAD5 cells were 
successfully infected with RML6 as shown by the typical “diagnostic shift” of PK-digested RML6 with 
un-, mono- and diglycosylated PrPSc bands. RML6 brain homogenate served as a positive control 
(left band pair).  
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homogenates treated with NBH- and RML6 were spiked into the RT-QuIC reaction mixture 
and amplified for 70 hours. Neither scFvPOM1-treated nor (scFvPOM1+rmPrP23-230)-treated 
COCS homogenates induced de novo PrP aggregate formation in the RT-QuIC assay. In 
contrast, RML6-treated COCS homogenates induced aggregation after an initial lag phase of 
about 24 hours (Figure 19A). 
The failure to detect PrPSc suggests that exposure to toxic GD ligands does not induce PrP 
aggregation. However, the sensitivity of the assays employed is not very high. Moreover, GD 
ligands may conceivably induce PK-sensitive PrP aggregates which may still be infectious 
(Head et al. 2013). Finally, cell-based assays suffer from the differential susceptibility of 
Figure 19. (A) RT-QuIC analyses failed to reveal de novo PrPSc aggregation when seeded with 
scFvPOM1 or (scFvPOM1+rmPrP23-230)-treated Tga20 COCS homogenates. NBH- and RML6-
treated Tga20 COCS homogenates were used as negative and positive controls for prion-catalyzed 
amplification of aggregated PrP, respectively. RT-QuIC reactions were performed in quadruplicates 
for each sample. (B) Tga20 mice inoculated with pooled slice homogenates of scFvPOM1-treated 
(n=6 mice) or (scFvPOM1+rmPrP23-230)-treated tga20 COCS (n=6 mice) stayed healthy for at least 
200 days after inoculation. tga20 mice infected at high dose (n = 4 mice) or low dose (n = 5 mice) 
with RML6 succumbed to prion disease at 55 ± 2 (mean ± s.d., high dose) and 95 ± 5 (high dose) 
days, respectively. 
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individual cell lines to specific prion strains, which is unpredictable and may lead to false-
negative results (Mahal et al. 2007). 
To overcome these limitations, I tested the transmissibility of pathology from antibody-
treated COCS to PrPC-overexpressing Tga20 mice that serve as sensitive indicators of prion 
infectivity (Fischer et al. 1996; Blattler et al. 1997). COCS treated with scFvPOM1 or 
scFvPOM1+rmPrP23-230 (1%, 18 μg total brain homogenate in 30 μl) were inoculated 
intracerebrally (i.c.) into Tga20 mice. In control experiments (performed non-synchronously 
with mice of the same genotype and age), Tga20 mice were i.c. inoculated with RML6 at high 
dose (1%, 36 μg total brain homogenate, corresponding to 3 x 106 median lethal dose [LD50] 
units and low dose (0.0001%, 3.6 pg total brain homogenate, corresponding to 3 x 
102 LD50 units). RML6-infected mice showed the characteristic clinical signs of terminal prion 
disease (e.g. progressive ataxia, rolling gait) at 55 ± 2 (high dose) and 95 ± 5 days (low dose, 
Figure 19B). Tga20 mice inoculated with homogenates from scFvPOM1 or 
scFvPOM1+rmPrP23-230 treated COCS, as well as non-inoculated control mice, did not develop 
any signs of disease within an observation period of 200 days (Figure 19B). 
Immunohistochemical analysis of brain sections from RML6-inoculated mice showed 
prominent and classical signs of prion disease, such as spongiform changes, neuronal cell 
loss, astrogliosis, and microglial activation (Figure 20). In contrast, none of these signs were 
observed in mice treated with scFvPOM1 COCS homogenate, scFvPOM1+rmPrP23-230 COCS 
homogenate, or non-inoculated mice (Figure 20). Western blots of brain homogenates from 
RML6-infected mice showed the molecular weight shift typical of PrPSc after PK digestion 
(Figure 21). No PrPSc was detected by Western blotting in brain homogenates from mice 
inoculated with scFvPOM1-COCS, (scFvPOM1+recPrP23-230)-COCS, or NBH. 
 
 
Figure 20 (page 55). Brain sections from terminally sick mice (high dose RML6, lowest row) revealed 
typical signs of prion disease such as spongiform change (H&E), astrogliosis (GFAP), microgliosis 
(IBA1) and PrPSc deposition (SAF84). None of these features were observed in Tga20 mice inoculated 
with scFvPOM1-COCS, (scFvPOM1+rmPrP23-230)-COCS, or in untreated mice. Scale bar = 50 μm. 
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Figure 21. PK-digestion of brain homogenate from a terminally sick Tga20 mouse revealed relative 
protease resistance. The residual PrPSc showed a typical diagnostic shift in its molecular weight. 
Neither untreated, scFvPOM1-COCS inoculated (n=3 brain homogenates) nor (scFvPOM1+rmPrP23-
230)-COCS inoculated (n=3 brain homogenates) Tga20 mice showed detectable PrPSc. 
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Generation and binding studies of scFvPOM1 mutants  
X-ray crystallography of Fab1POM1 in complex with human PrPC resulted in precise 
determination of binding sites (Table 3, (Baral et al. 2012)). In order to dissect the toxic effects 
of the PrPC globular domain (PrPC-GD) binding antibody POM1 the Luca Varani lab (IRB 
Bellinzona) has performed single-alanine scanning mutagenesis of all known binding sites 
resulting in 11 individual mutants that were subsequently expressed as single-chain variable 
fragments and purified, mutagenized scFvPOM1 antibodies (scFvPOM1Mut) migrated as a 
single band around 25 kDa in SDS-PAGE (scFv, Table 4 and Figure 22, (Baral et al. 2012)). 
Mutagenesis of POM1Asn92 was omitted since alanine scanning did not yield a significant impact 
on binding energy. 
 
Human 
PrPC 
Fab1POM1 Human PrPC Fab1POM1 
Fab1POM1 light chain  Fab1POM1 heavy chain 
Gly142 Tyr96 His140 Trp33 
Ser143 Asn92 His140 Tyr101 
Asp144 Ser32 Gly142 Tyr104 
Asp144 Ser91 Asp147 Tyr104 
Asp144 Tyr50 Lys204 Tyr57 
Asp144 Asn92 Arg208 Asp52 
Tyr145 Asn92 Arg208 Asp55 
 
 Gln212 Asp55 
Table 3. Interaction sites of Fab1POM1 in complex with human PrPC, as determined by X-ray 
crystallography, modified from (Baral et al. 2012) 
Figure 22. 
Silver staining 
of purified 
scFvPOM1Mut 
(expressed as 
mutated amino 
acids) and 
scFvPOM1WT 
(WT) shows 
migration of 
scFv antibodies 
at around 25 
kDa in SDS-
PAGE. Dashed 
bars indicate 
cropping of gel. 
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 Surface plasmon resonance (SPR) measurements performed by Marco Bardelli (Group 
Luca Varani, IRB Bellinzona) yielded binding characteristics of scFv parental antibodies and 
scFvPOM1Mut (Table 4). Herein, no or low-affinity binding in W33A and S91A mutants (KD > 
1µM), medium-affinity binding in D52A, D55A, Y57A, Y50A, W94A and Y96A mutants (KD = 
100 nM – 1 µM) and high-affinity binding (KD < 100 nM) in Y101A, Y104A and S32A mutants 
was observed (Table 4).  
To determine whether scFvPOM1Mut could effectively inhibit binding of the wild-type 
maternal antibody (scFvPOM1WT) to rmPrP23-230, Tiziana Sonati (Institute of Neuropathology, 
University Hospital Zurich) performed Förster Resonance Energy Transfer (FRET) using 
recombinant, full-length mouse PrP23-230 (rmPrP23-230), the allophycocyanin (APC) labelled, 
monoclonal anti-PrP antibody POM3 (APC-POM3, binding residues aa 95-100 (Polymenidou 
et al. 2008)) and an europium (Eu) labelled scFvPOM1WT (Eu-scFvPOM1WT). All scFvPOM1Mut 
antibodies, as well as scFvPOM1WT, but not the off-target small molecule 400-B1 (Lilly) 
successfully showed binding to rmPrP23-230, as was seen by a dose-dependent decrease of 
maximal NET FRET signal (Figure 23A). The concentration needed for half-maximal 
displacement (half-maximal inhibitory dose ID50) signifcantly correlated with antibody affinity 
as measured by SPR (Spearman r=0.86, p<0.01, Figure 22B).  
scFvPOM1 
antibody  Ka [1/nMs] Kd [1/s] KD [nM] 
location on 
POM1 
hPrPC 
binding site 
 Wild-type 4.78 x 104 3.16 x 10-4 5.08   
 W33A  no binding no binding no binding CDR_H1 loop H140 
 D52A  3.34 x 105 4.56 x 10-2 103 
C
D
R
_H
2 loop 
R208 
 D55A  1.05 x 105 3.67 x 10-2 372 R208, Q212 
 Y57A  7.7 x 104 3.15 x 10-2 406 K204 
 Y101A  6.26 x 104 7.14 x 10-4 11.5 
C
D
R
_H
2 
loop 
H140 
 Y104A  3.61*104 2.09*10-4 8.79 G142, D147 
 S32A  6.36 x 104 5.95 x 10-4 9.98 CDR_L1 loop D144 
 Y50A  5.7 x 104 8.17 x 10-3 313 CDR_L2 loop D144, Y145 
 S91A  1.34 x 104 1.85 x 10-2 1430 
C
D
R
_L3 loop 
D144 
 W94A  3.08 x 105 2.7 x 10-2 201 hydrophobic enviroment§ 
 Y96A  6.24 x 104 7.4 x 10-3 123 G142 
Table 4. Binding characteristics of scFvPOM1 and scFvPOM2 parental antibodies and scFvPOM1 
mutants as determined through SPR. Ka = association rate constant, Kd=dissociation rate constant, KD 
= equilibrium dissociation (binding) constant, CDR = complementary-determining region, L/H 1-3 = CDR 
1-3 of antibody light/heavy chains. § Trp94 was described to create a hydrophobic environment for 
POM1-hPrPC binding. 
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Toxic scFvPOM1Mut antibodies faithfully recapitulate scFvPOM1WT toxicity that can be 
ablated by the PrPC-OR binding antibody POM2 
At 400 nM, the Aguzzi lab has shown scFvPOM1WT to induce severe neurotoxicity in PrPC-
overexpressing, Tga20 cerebellar organotypic slices cultures (COCS), conversely, COCS 
derived from Zurich 1 Prnp knock-out mice are resistant to POM1-induced toxicity (Sonati et 
al. 2013). Initial toxicity assessment of the mutagenized scFvPOM1 variants was performed 
through exposure of COCS derived from both Tga20 and Prnp0/0 (ZH1) at a concentration of 
400 nM for 14 days (Figure 23A). Expectedly, scFvPOM1WT led to rapid and profound 
neurodegeneration as reflected by low levels of cells stained positive for neuronal nuclei 
(NeuN, Figures 24A+B). ScFvPOM1WT-like toxicity, i.e. a rapid decrease of NeuN+ area 
compared to untreated Tga20 COCS, was also observable in scFvPOM1S32A, scFvPOM1Y50A, 
scFvPOM1D52A, scFvPOM1S91A, scFvPOM1W94A, scFvPOM1Y96A and scFvPOM1Y101A (Figures 
18A+B). Innocuity, i.e. unchanged levels of NeuN+ area, was observed in scFvPOM1W33A, 
scFvPOM1D55A, scFvPOM1Y57A and scFvPOM1Y104A (Figures 24A+B) although I believe the 
findings to be irrelevant in the case of scFvPOM1W33A as it does not show any measurable 
biophysical binding on SPR (Table 4).  
Figure 23. (A) All scFvPOM1Mut and unlabelled 
scFvPOM1WT showed binding on FRET, as is shown by a 
dose-dependent decrease in maximal NET FRET of 
scFvPOM1Mut, the non-PrPC binding small molecule 400-B1 
does not lead to a diminished FRET signal. FRET is elicited 
by simultaneous binding of APC-POM3 and Eu-
scFvPOM1WT. (B) Plotting KD (as derived from SPR) versus 
IC50 (as derived from FRET) shows a significant correlation 
(Spearman r=0.86, p<0.01). scFvPOM1W33A did not show 
any binding on SPR and was thus not included in this 
analysis 
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Figure 24. (A) Left panel: Treatment of Tga20 COCS with scFvPOM1WT, scFvPOM1D52A, 
scFvPOM1Y101A, scFvPOM1S32A, scFvPOM1Y50A, scFvPOM1S91A, scFvPOM1W94A and scFvPOM1Y96A 
leads to rapid and significant neurodegeneration when compared to untreated COCS, while treatment 
with scFvPOM1W33A, scFvPOM1D55A, scFvPOM1Y57A and scFvPOM1Y104A do not show significant 
toxicity. Right panel: Neither scFvPOM1WT nor scFvPOM1Mut show significant toxicity in Prnp0/0  (ZH1) 
COCS. * p<0.05, *** p<0.001, one-way ANOVA with Holm-Sidak’s post-hoc test. (B) Representative 
micrographs of NeuN-stained Tga20 COCS treated with scFvPOM1 wild-type (WT) and scFvPOM1Mut 
antibodies. Scale bar = 500 µM. 
 
  
  
KARL FRONTZEK, 2017 64 
 
The toxicity of (scFv-) POM1WT is dependent on the presence of PrPC, as Prnp0/0 mice do not 
show neurodegeneration and toxicity can be ablated by pre-incubation of the antibody with 
rmPrP23-230 (Sonati et al. 2013). Furthermore, POM1WT-induced neurotoxicity is histologically 
characterized by neuronal cell loss, astrogliosis and microglial activation (Sonati et al. 2013; 
Herrmann et al. 2015). In a next step, I was wondering whether the high-affinity and toxic 
scFvPOM1 mutants scFvPOM1S32A and scFvPOM1Y101A share similar pathways as their 
scFvPOMWT counterpart. Pre-incubation of 400 nM of scFvPOM1WT, as well as scFvPOM1S32A 
and scFvPOM1Y101A  with molar excess (600 nM) of rmPrP23-230 significantly ameliorated 
neuronal cell loss, as was illustrated by increased NeuN+ area (Figure 25A+B).  
 
Also, pre-incubation of scFvPOM1WT and high-affinity scFvPOM1Mut with molar excess of 
rmPrP23-230 led to ablation of reactive gliosis (as was assessed by post hoc GFAP 
Figure 25. The toxicity of the high-affinity scFvPOM1Mut antibodies scFvPOM1S32A and scFvPOM1Y101A 
is PrPC-dependent, as pre-incubation of antibodies with rmPrP23-230 leads to amelioration of NeuN+ cell 
number ((A) confocal fluorescent micrographs of NeuN-Alexa488 stained Tga20 COCS, (B) statistical 
assessment). Scale bar = 100 µm, *** p<0.001, one-way ANOVA with Sidak’s post hoc test.  
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immunohistochemistry, Figure 26A+C) and microgliosis (as assessed by post hoc F4/80 
immunohistochemistry, Figure 26B+D) as was induced by the toxic antibodies.  
 
Figure 26. ScFvPOM1WT, as well as the high-affinity scFvPOM1Mut antibodies scFvPOM1S32A and 
scFvPOM1Y101 induce reactive gliosis (GFAP, (A) and (C)) and microgliosis (F4/80, (B) and (D)) that 
can be ablated by pre-incubation of antibodies with rmPrP23-230. Scale bar = 100 µm, * p<0.05, *** 
p<0.001, one-way ANOVA with Sidak’s post hoc test.  
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The neurotoxicity of POM1WT is dependent on a functional PrPC-OR, as genetic ablation of 
PrPC-OR or anti-PrPC-OR antibodies, such the monoclonal mouse antibody POM2 inhibit 
POM1WT-induced toxicity (Sonati et al. 2013). When I added 400 nM scFvPOM2 to 200 nM of 
scFvPOM1S32A, neurotoxicity after 10 dpe was significantly ablated (p<0.05, scFvPOM1S32A 
[n=9] vs. scFvPOM1S32A + scFvPOM2 [n=9], one-way ANOVA with Sidak’s post hoc test, 
Figure 27). The same was observed for scFvPOM1WT (p<0.001, scFvPOM1WT [n=9] vs. 
scFvPOM1WT + scFvPOM2 [n=9], one-way ANOVA with Sidak’s post hoc test, Figure 27).  
 
 
  
Figure 27. Neurotoxicity of scFvPOM1WT, but also scFvPOM1S32A is ameliorated by pre-incubation 
with scFvPOM2 in Tga20 COCS. (A) Fluorescent micrographs of post hoc NeuN 
immunohistochemistry, (B) NeuN morphometry of (A). * p<0.05, ** p<0.01, *** p<0.001, one-way 
ANOVA with Sidak’s post hoc test.  
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POM1Y57A and POM1Y104A are innocuous and neuroprotective mutants of POM1 
During my initial screen of the 11 scFvPOM1Mut antibodies, I observed innocuity of the mutants 
scFvPOM1W33A, scFvPOM1D55A, scFvPOM1Y57A and scFvPOM1Y104A (Figure 24), although 
scFvPOM1W33A did not show any binding on SPR, and very weak binding on FRET 
measurements (Table 4, Figure 23), and hence was not followed up. To determine the minimal 
dosis of scFvPOM1WT needed in Tga20 COCS to exert significant neurotoxicity, i.e. the optimal 
dosage to test whether scFvPOM1Mut can ablate the toxic effects of scFvPOM1WT, I exposed 
Tga20 COCS to 67, 33.5, 20 and 6.7 nM of scFvPOM1WT over 2 weeks in the presence and 
absence of molar excess of rmPrP23-230: on post-hoc NeuN morphometry, 67 nM of 
scFvPOM1WT were needed to exert significant toxicity (p<0.001, scFvPOM1WT [67 nM] vs. 
scFvPOM1WT [67 nM] + rmPrP23-230 [100 nM],  Figure 28).  
 
In order to investigate possible neuroprotective effects of the innocuous mutants, I inoculated 
Tga20 COCS with RML6 prions and non-infectious brain homogenate (NBH) and started 
treatment with scFvPOM1Mut on 21 dpi, on 45 dpi, slices were formalin-fixed and stained with 
NeuN to assess neurodegeration. Treatment with scFvPOM1D55A at 400 nM for 24 days was 
well tolerated, as was illustrated by unchanged NeuN+ cells in NBH-inoculated, Tga20 COCS, 
Figure 28. 67 nM scFvPOM1WT for 14 
days are necessary to induce significant 
neurotoxicity in Tga20 COCS.  
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treatment of RML-inoculated Tga20 COCS with scFvPOM1D55A, however, did not result in 
rescue of RML-mediated neuronal cell loss (Figure 29).  
 
When adding scFvPOM1Y104A to RML-infected, Tga20 COCS on 21 dpi at 400 nM, post hoc 
NeuN immunohistochemistry on 45 dpi showed a significant increase in prion-infected COCS 
treated with scFvPOM1Y104A compared to untreated COCS (p<0.001, RML Tga20 COCS [n=6] 
vs. RML+scFvPOM1Y104A [n=7], one-way ANOVA with Dunnett’s post-hoc test, Figure 30A+B), 
also, chronic treatment with scFvPOM1Y104A NBH-infected Tga20 for 24 days did not reveal 
observable toxicity (Figure 30A+B). Moreover, scFvPOM1Y104A also ablated scFvPOM1WT 
toxicity, albeit at threefold molar excess, i.e. 400 nM of scFvPOM1WT versus 1200 nM of 
scFvPOM1Y104A (p<0.01, scFvPOM1WT [n=6] vs. scFvPOM1WT + scFvPOM1Y104A [n=6], one-
way ANOVA with Dunnett’s post hoc test, Figure 30C+D).  
ScFvPOM1Y57A was added to RML-infected Tga20 COCS on 10 and 21 dpi and slices 
were harvested on 45 dpi. On NeuN morphometry, addition of scFvPOM1Y57A on both 
timepoints resulted in increased NeuN+ areas when compared to RML alone (Figure 31A+B).  
Figure 29. Treatment of prion-infected, Tga20 COCS with scFvPOM1D55A does not ameliorate prion-
induced neurodegeneration. (A) Fluorescent micrographs of Tga20 COCS with post hoc NeuN 
immunohistochemistry, (B) NeuN morphometry of (A). n.s. not significant, *** p<0.001, one-way 
ANOVA with Dunnett’s post-hoc test. Scale bar = 500 µm. 
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SPR measurements revealed the KD of scFvPOM1Y57A to be 79.9-fold weaker than the KD of  
scFvPOM1WT (5.08 nM scFvPOM1WT vs. 406 nM scFvPOM1Y57A, Table 4). Hence, any 
effective competition of scFvPOM1WT by scFvPOM1Y57A will need 79.9-fold molar increase of 
the latter compound, i.e., 5353.3 nM of scFvPOM1Y57A at a minimal toxic concentration of 
scFvPOM1WT 67 nM. I hence exposed Tga20 and Prnp0/0 (ZH3) COCS to increasing 
concentrations of scFvPOM1Y57A to assess the maximum tolerable dosis. A single treatment of 
1200 nM already induced significant neurotoxicity in Tga20 COCS as was observable by 
Figure 30. (A+B) Treatment of RML-inoculated Tga20 COCS with scFvPOM1Y104A leads to 
amelioration of neuronal cell loss. (C+D) Addition of scFvPOM1Y104A ([1200 nM]) to scFvPOM1WT-
treated ([400 nM]) Tga20 COCS prevents neuronal loss. ** p<0.01, *** p<0.001, one-way ANOVA 
with Dunnett’s post hoc test (A+B: all groups versus RML, C+D: all groups versus scFvPOM1WT). 
Scale bar = 500 µm.  
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decreased NeuN levels on western blot (Figure 31C+D). 2400 nM of scFvPOM1Y57A in Prnp0/0  
(ZH3) COCS did not result in observable toxicity making off-target effects unlikely (Figure 
31C+D). I concluded that a competition experiment of scFvPOM1WT with scFvPOM1Y57A was 
not feasible to due unfavorable binding affinities.  
 
 
Figure 31. (A+B) Fluorescence micrographs and NeuN morphometry quantification of Tga20 
COCS, addition of scFvPOM1Y57A was protective against RML when given both on 10 and 20 dpi. 
(C+D) Western blot and densitometric analysis of Tga20 and Prnp0/0 (ZH3) COCS treated with 
increasing amounts of scFvPOM1Y57A showing good tolerability of 400 nM, but not 1200 nM or 
2400 nM in Tga20 COCS, while 2400 nM of scFvPOM1Y57A in Prnp0/0  (ZH3) COCS did not show 
toxicity, suggesting a PrPC-specific effect. * p<0.05, ** p<0.01, *** p<0.001, one-way ANOVA with 
Sidak’s post hoc test. Scale bar = 500 µm.   
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The neuroprotective scFvPOM1 mutants Y57A and Y104A restore levels of ROS 
enzymes and the UPR independent of PrPC or PrPSc levels 
As laid out before, prion infection leads to activation of reactive oxygen species and microglia 
activation(Sorce et al. 2014), when adding scFvPOM1Y104A to prion-infected Tga20 COCS, a 
decrease in NOX2 levels can be seen (Figure 32A), also, when adding scFvPOM1Y57A, 
microglial activation was attenuated as illustrated by lowered levels of Iba1 (Figure 32B).  
 
Activation of the unfolded protein response leading to translational repression is commonly 
observed in prion disease, as is the production of ROS and activation of microglia (Moreno et 
al. 2012; Aguzzi, Barres, and Bennett 2013; Sorce et al. 2014). To assess whether the 
aforementioned, neuroprotective scFvPOM1 mutants Y57A and Y104A ameliorated toxic 
cascades, NBH- and RML-inoculated Tga20 COCS were treated with either scFvPOM1Y57A or 
scFvPOM1Y104A (400 nM, starting at 21 dpi) until 45 dpi, then COCS were lysed and subjected 
to western blot. Upon activation of the unfolded protein response, phosphorylated eIF-2α leads 
to activation of ATF-4, which in turn leads to activation of CHOP (Moreno et al. 2012) – 
Figure 32. (A) NOX2 levels are significantly reduced in RML-infected Tga20 COCS by 24 days of 
treatment with scFvPOM1Y104A, when adding scFvPOM1Y57A to RML-infected COCS, microglial 
activation is significantly reduced (B). * p<0.05, ** p<0.01, unpaired, two-sided T-test.  
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treatment with protective scFvPOM1Mut led to a restoration of ATF-4 levels (scFvPOM1Y57A, 
Figure 33A, and scFvPOM1Y104A, Figure 33B) and CHOP levels (scFvPOM1Y104A, Figure 33C).  
 
Figure 33. (A) Treatment of RML-inoculated Tga20 COCS with the scFvPOM1Mut Y57A leads to an 
attenuation of the UPR, as is reflected by lower ATF-4 levels. An arrow at 48 kDa denotes ATF-4, 
CAD5+TG: as a positive control, the murine neuroblastoma cell line CAD5 was treated with 0.5 M 
of Thapsigargin for 24h. (B+C) Treatment of RML-inoculated Tga20 COCS with scFvPOM1Y104A 
leads to attenuated levels of ATF-4 (B) and CHOP (C). * p<0.05, ** p<0.01, unpaired, two-tailed T-
test. 
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Binding of antibodies to surface receptors can lead to substantial receptor endocytosis 
and degradation (Yarden and Tarcic 2013).In the case of scFvPOM1Mut , this could lead to a 
protective effect due to lowered PrPC levels and not due to binding to a toxicity-inducing epitope 
on PrPC. In order to assess whether the protective scFvPOM1Mut antibodies Y57A and Y104A 
lead to a downregulation of PrPC expression, Tga20 COCS were treated for 7 days with 
scFvPOM1Y57A and scFvPOM1Y104A in the presence and absence of molecular excess of 
rmPrP23-230. COCS were lysed and a sandwich ELISA using POM19 (absorbed to a polystyrene 
plate) and biotinylated POM3 (for detection) was employed to measure total PrPC levels - 
treatment with either scFvPOM1Mut antibody did not lead to downregulation of PrPC (Figure 34).  
 
 
 
 
 
 
 
 
 
I then wanted to know whether neuroprotective scFvPOM1Mut antibodies are protective due to 
reduction of PrPSc levels. I inoculated Tga20 COCS with NBH and RML, respectively, and 
added scFvPOM1Y57A and scFvPOM1Y104A on 21 dpi for 24 further days, on 45 dpi, I lysed the 
COCS and assessed PrPSc levels by proteinase K digestion of COCS lysates and western blot 
with the monoclonal anti-PrPC antibody POM1. Densitometric analyses of PrPSc did not reveal 
a decrease in PrPSc after treatment with scFvPOM1Y57A or scFvPOM1Y104A suggesting 
protection through binding to an epitope not involved in prion replication (Figure 35).  
Figure 34. Chronic treatment (7 days, 400 nM) of 
Tga20 COCS with either scFvPOM1Y57A or 
scFvPOM1Y104A in the absence or the presence of 
molar excess of rmPrP23-230  did not lead to reduced PrPC 
levels as was measured in a POM3/POM19 sandwich 
ELISA.   
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Establishing models to study relaxation of the PrPC-β2α2 loop  
Molecular dynamics simulations (MDS) on POM1 mutants in complex with PrPC performed by 
Marco Bardelli and Luca Varani (IRB Bellinzona) showed an almost complete overlap with the 
in vivo findings presented in this work. POM1WT, when in complex with human PrPC (hPrPC), 
Figure 35. Treatment of RML-inoculated Tga20 COCS with scFvPOM1Y57A (A) or 
scFvPOMY104A (B) does not lead to decreased PrPSc levels.  
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POM1(Y57) forces the intercalation of a hydrogen bond (H-bond) between hPrPC(R208) and 
hPrPC(H140), leading to a relaxation of the β2α2 loop. When hPrPC is free in solution, 
hPrPC(R208) points towards hPrPC(Q212). POM1 with a Y57A substitution (POM1Y57A) does 
not form a H-bond at hPrPC(R208-H140) in MDS, and as mentioned, abolished infectious prion 
toxicity in vivo (Figure 31). POM1D52A was not able to disrupt binding of hPrPC(R208-H140) in 
MDS resulting in neurotoxicity, a finding that was confirmed in vivo (Figure 24). On the contrary, 
another innocuous antibody mutant such as scFvPOM1D55A also disrupted the H-bond 
formation in MDS, but was not protective against prions in vivo (Figure 29), probably due to 
insufficient dosage. The binding of the other protective mutant scFvPOM1Y104A occurs via the 
more N-terminal residue hPrPC(K204), although specific MDS have not been performed yet. 
 To study the effects of POM1 toxicity onto the β2α2 loop in mPrPC (aa 165-175), I 
aimed to generate three PrPC mutants.Firstly, alanine mutagenesis of mPrPC(R207), 
corresponding to hPrPC(R208), should abolish POM1 toxicity upon binding to PrPC. Secondly, 
replacing glutamine mPrPC(Q211) by a negatively charged residue, e.g., glutamate, was 
suggested to attract mPrPC(R207) away from mPrPC(H139) (the murine equivalents of 
hPrPC(R208-H140)) in MDS. Thirdly, by forcing a disulfide bridge between mPrPC(R207-H139) 
with a mPrPC(C207-C139) mutant, I aimed to simulate the H-bond between mPrPC(R207-
H139) as created by POM1 in MDS.  
In the first step, I assessed whether the intended mutants, i.e. mPrPR207A, mPrPQ211E 
and mPrPI138C-R207C showed correct membranal presentation, glycosylation and conformational 
orientation. To express the mutants on a pure Prnp0/0 background, I first knocked-out Prnp in 
the murine neuroblastoma cell line CAD5 by means of CRISPR/Cas9. To avoid expression of 
abberant or truncated versions of PrPC or deletion of the splice acceptor site that would lead 
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to pathological overexpression of Doppel (Dpl) mRNA (Moore et al. 1999), I used single-
stranded guide RNA (sgRNA) cloned into the MLM3636 plasmid aiming at a protospacer 
adjacent motif (PAM) site in the signal peptide of Prnp (Figure 36A). Cells were co-transfected 
with MLM3636 and the hCas9 plasmid followed by transient antibiotic selection.  
Subsequently, 7 clones were manually picked, expanded and subjected to further 
characterization. Cells were lysed and PrPC levels were measured by POM1/POM2 sandwich 
ELISA. Herein, 7 CAD5 Prnp0/0 candidate clones #A6, #C2, #C6, #C12, #H7, #H9 and #H12 
all showed near-zero PrPC levels comparable to the established Prnp0/0 cell line HPL (p>0.05, 
one-way ANOVA with Dunnett’s post hoc test, Figure 36B, (Kuwahara et al. 1999)). 5 clones 
were further assessed on western blot for detection of PrPC, where no detectable PrPC levels 
could be observed (Figure 36C), suggesting a successful knock-out of PrPC in all 5 Prnp0/0 
candidate clones. DNA was extracted from expanded cells of clones #C2 and #C12 and the 
mutagenized region was sequenced by PCR amplification of the open reading frame (ORF) of 
Prnp. Amplified products were cloned into the pCR-Blunt II-TOPO plasmid (Invitrogen) and at 
10 colonies per clone were studied by sanger sequencing. Herein, #C2 showed four different 
mutations, i.e., three deletions and one insertion, while #C12 showed two different deletions 
proximal to the PAM (Figure 36D). These results indicate multiploidy to be more likely in #C2 
than in #C12, hence all further experiments are performed with the CAD5 Prnp0/0 clone #C12.  
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Figure 36. (A) Design of sgRNA for CRISPR/Cas9 mediated generation of CAD5 Prnp0/0  cells. A PAM 
in the coding sequence of the signal peptide was chosen. (B+C) ELISA of 7 candidate CAD5 Prnp0/0  
clones showed similar PrPC levels compared to the established Prnp0/0 cell line HPL, 5 of which were 
further assessed by PrPC western blot, confirming lack of PrPC expression (C). (D) Sanger sequencing 
of PCR amplified Prnp ORF showed n=4 different mutations in #C2 and n=2 different mutations, 
labelling according to (A). The splice acceptor site is unaffected in both of the constructs. 
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CAD5 Prnp0/0 were stably transfected with empty plasmid (CAD50/0) and plasmids 
expressing mPrPWT (CAD5WT), mPrPR207A (CAD5R207A), mPrPQ211E (CAD5Q211E) and mPrPR207C-
I138C (CAD5R207C-I138C). In order to assess correct membranal expression of mutants I performed 
immunhistochemical analyses of CAD5 cells with POM1 and POM19, with the former expected 
to lose binding in PrnpMut and the latter to retain binding due to its more C-terminal epitope 
(Sonati et al. 2013). Expectedly, POM1 
binding was only seen in CAD5WT but not 
in the empty plasmid, mPrPR207A, 
mPrPQ211E and mPrPI138C-R207C expressing 
cells (Figure 37A). Conversely, POM19 
binding was retained on the cell 
membrane in all cells except CAD50/0 
(Figure 37B). These findings suggest that 
although the POM1 binding site is 
abolished, PrPMut is correctly presented 
on the membrane with preservation of the 
conformational, POM19 epitope.   
 
 
Figure 37. The POM1 epitope is retained 
in CAD5WT, but not in CAD5R207A, 
CAD5Q211E and mPrPR207C-I138C (A). 
Conversely, POM19 detects both PrPWT 
and mutated isoforms (B). Scale bar = 20 
µm.  
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PrPC exists in di-, mono- and unglycosylated forms (Aguzzi, Baumann, and Bremer 2008). In 
order to assess whether mutated PrP variants are correctly glycosylated, I performed digestion 
of cell lysates with Peptide -N-Glycosidase F (PNGase F), cleaving N-linked oligosaccharides 
between the innermost GlcNAc and asparagine residues (Maley et al. 1989). Prion protein 
wild-type and mutants showed a shift from partially glycosylated to fully unglycosylated 
proteins after PNGase F digestion on western blot, indicating correct glycosylation (Figure 38).  
 
POM monoclonals target a variety of conformational epitopes on PrPC (Polymenidou et 
al. 2008).  Accordingly, I wanted to know whether I could further explore the conformational 
status of newly generated prion protein mutants, especially to study the alterations in rigidity 
of the β2α2 loop of PrPC as was seen in MDS. To this end I performed immunohistochemical 
stainings using the anti-PrPC-β2α2 loop targeting antibody POM5 and included a third PrPC-
GD antibody, i.e. POM8, to further elucidate the conformational stability of the mutants. POM1 
and POM19 served as controls. On immunhistochemistry, CAD5WT, CAD5R207A, CAD5Q211E and 
CAD5R207C-I138C were detectable by POM19, as described before (Figure 37), further 
Figure 38. Western blot with the anti-PrPC antibody POM2 of cell lysates in the presence and in the 
absence of PNGaseF shows a shift from partially glycosylated (- PNGaseF) to fully unglycosylated (+ 
PNGaseF) prion protein in both wild-type and mutants, but not in control plasmid transfected CAD5 cells. 
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membrane-associated immunopositivity was seen in all cells (except CAD50/0) by POM8, 
showing retention of the POM8 epitope on the α1-α2 helices of PrPC-GD (Figure 39). 
Interestingly, POM5, which is a conformational antibody to the rigid β2α2 loop, did not bind to 
CAD5R207C-I138C strengthening the conformational alterations observed in MDS. Furthermore, 
the POM5 epitope was not detectable in CAD5Q211E as well, suggesting conformational 
changes in CAD5Q211E exceeding those seen in MDS (Figure 39).  
 
  
Figure 39. Retention of the conformational POM1, POM5, POM8 and POM19 epitopes is only 
observable in CAD5WT. The POM1 epitope is ablated in all prion protein mutants, while POM19 and 
POM8 epitopes are also retained in CAD5R207A, CAD5Q211E and CAD5R207C-I138C. Conformational 
alterations in the β2α2 loop, as detected by loss of POM5 immunhistochemistry were seen in 
CAD5Q211E CAD5R207C-I138C. Scale bar = 20 µm.    
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In a last step, I was wondering whether I could chronically infect CAD5R207A, CAD5Q211E and 
CAD5R207C-I138C cells with RML prions as was described before (Enari, Flechsig, and Weissmann 
2001) to study the effects of the mutants on prion propagation. I inoculated the cells with RML6 
prions and split them three times 
every 3-4 days. I performed 
proteinase K digestion of cell 
lysates collected immediately 
before inoculation and after the 
last cell passaging. Herein, brain 
homogenate of RML6 infected 
mice showed the typical 
molecular “shift” towards the PK-
resistant core (Figure 40). 
CAD5WT cells were susceptible to 
chronic prion infection. 
CAD5R207C-I138C cells showed a 
faint PK-resistant band without 
the typical di-, mono- and 
unglycosylated prion protein 
isoforms before, but not after 
inoculation (Figure 40). Due to 
the variability of PK resistance at 
the low PK concentrations used, 
I believe this is rather due to protein aggregation than generation of PrPSc, which is usually 
resistant to concentrations of 100-500 µg/ml of PK (McKinley, Bolton, and Prusiner 1983).  
 
 
 
Figure 40. CAD5WT, but not CAD5R207A, CAD5Q211E or 
CAD5R207C-I138C cells are susceptible to chronic prion 
infection, as is illustrated by the presence of a PK-resistant 
“core” in CAD5WT infected cell lysates (lower panel). 
CAD5R207C-I138C cells show a faint PK-resistant fraction in the 
pre-inculated lysates (upper panel), probably indicating 
moderate protein aggregation. 
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The bispecific POM1/POM2 antibody LVp12 is protective against prion diseases 
In light of previous reports and the results shown in this chapter, I believe PrPC-mediated 
toxicity is induced by an “inducing” site on PrPC-GD and its execution is dependent on a 
functional PrPC-FT (Reimann et al. 2016; Herrmann et al. 2015; Sonati et al. 2013). 
Conversely, a major drawback of the anti-PrPC-FT antibody POM2 is its limited therapeutic 
potential, i.e. POM2 is only protective against prion disease when given directly after 
inoculation, but not when pathology is already visible (Figure 41).  
 
To investigate whether concomitant blockage of PrPC-FT and PrPC-GD was beneficial 
against prion diseases, Marco Bardelli and Luca Varani (IRB Bellinzona) created a bispecific 
antibody consisting of both scFvPOM1 and scFvPOM2, termed LVp12 (Figure 42A). When 
adding LVp12 at 67 nM to RML-infected Tga20 COCS on 21 dpi, neuronal cell loss is 
significantly reduced, indicating higher efficacy of binding to both PrPC-FT and PrPC-GD than 
to PrPC-FT alone (Figure 42B+C).  
Figure 41. Treatment of RML-infected Tga20 COCS with 335 nM of the anti-PrPC-FT antibody POM2 
leads to a significant amelioration of neuronal cell loss when given directly after inoculation, i.e. 1 dpi 
(p<0.05, one-way ANOVA with Dunnett’s post hoc test), but not when pathology is already visible, 
i.e. 21 dpi. N.s. not significant, * p<0.05, *** p<0.001, one-way ANOVA with Dunnett’s post hoc test. 
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Figure 42. (A) Scheme of LVp12: scFvPOM1 and scFvPOM2 are joined via (GGGGS)4 
linkers. (B) NeuN and DAPI histochemistry of LVp12 treated, Tga20 COCS showing rescue 
of RML-induced neurotoxicity by LVp12. Scale bar = 500 µm (C) NeuN morphometry of (B). 
** p<0.01, *** p<0.001, one-way ANOVA with Dunnett’s post hoc test. 
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Discussion and Outlook 
The neurotoxic antibody POM1 mimics typical prion pathology with spongiform change, 
neuronal loss, astrogliosis, and microglial activation, and transcriptomic perturbations similar 
to those observed in prion diseases (Herrmann et al. 2015). It was shown before that prion 
toxicity or protection is dependent on the identity of the PrPC epitopes recognized by each 
antibody (Sonati et al. 2013). Antibodies targeting the PrPC globular domain are predominantly 
neurotoxic, whereas those targeting the flexible tail are largely protective (Sonati et al. 2013). 
FT-dependent protection through the OR-binding antibody POM2 is independent of prion 
replication, since it preserves neurons without reducing the accumulation of PK-resistant 
PrPSc (Herrmann et al. 2015). PrPC mutants devoid of the octapeptide repeat domain do not 
confer POM1 susceptibility to Prnp-deficient COCS, confirming that the FT is a crucial effector 
of neurotoxicity (Sonati et al. 2013). 
The scrapie prion protein PrPSc is defined through its resistance to enzymatic digestion 
by proteases and is commonly used as a surrogate marker for the presence of infectious prions 
(Aguzzi and Weissmann 1997).It is unclear, however, if and to what extent prion mimetics such 
as the monoclonal antibody POM1 are able to induce prions. I have shown in the first part of 
this chapter that POM1 treatment of COCS does not lead to the generation of infectious prions. 
In view of the pivotal importance of this question, I have employed a set of orthogonal 
methodologies including a cell bioassay, real-time quaking induced conversion (performed by 
Manuela Pfammatter), and a sensitive bioassay utilizing PrPC-overexpressing transgenic mice. 
Because of technological limitations, the docking of infectious PrPSc oligomers to 
membrane-resident normal PrPC has never been observed directly. However, such docking 
represents a plausible basis for the phenomenon of prion toxicity. Accordingly, prions damage 
only neurons that express PrPC on their surface, whereas Prnp-negative neurons do not 
undergo degeneration even after chronic, long-term exposure to prions (Brandner et al. 1996). 
I therefore submit that the docking of POM1 may mimic the process by which prions dock onto 
PrPC. Consequently, I predict that compounds conferring protection against POM1 may have 
a high likelihood of being protective against infectious prions–a prediction that has been 
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verified experimentally with a number of compounds (Herrmann et al. 2015). By extension, 
POM1 toxicity seems to represent a promising model of prion toxicity that might allow for 
screening prion-protective compounds without the need of advanced biosafety measures. 
The induction of toxicity independent of infectivity suggests the existence of a toxicity-
inducing epitope of PrPC that may be accessible to both neurotoxic antibodies and infectious 
prion seeds. The conformational POM1-epitope in the α1-α3 region of PrPC could represent 
such a site, since additional monoclonal antibodies other than POM1 targeting residues in 
close proximity also induce neurotoxic effects (Reimann et al. 2016; Wu et al. 2017). To 
precisely pin down the important residues involved in PrPC-GD mediated toxicity, I have 
assessed the effects of POM1 mutants carrying single alanine mutants of residues involved in 
PrPC-binding as was observed in MDS (Table 4) resulting in 11 different scFvPOM1 mutants. 
Biophysical charaterization of the mutants has shown antibodies of different binding affinities, 
spanning KD values of > 2 logs. High-affinity toxic antibodies showed activation of pathway 
similar to their wild-type, parental antibody, i.e., microgliosis and astrogliosis (Figures 25, 26) 
as well as execution of toxicity through PrPC-FT, since scFvPOM1S32A toxicity was ablatable 
by the anti-PrPC-OR antibody POM2 (Figure 27).  
I have found two mutants, scFvPOM1Y57A and scFvPOM1Y104A that ablated 
neurotoxicity induced by both the anti-PrPC-GD antibody POM1 (scFvPOM1Y104A) and prions 
(scFvPOM1Y57A and scFvPOM1Y104A, Figures 30, 31). Of note, treatment with scFvPOM1Y57A 
and scFvPOM1Y104A was successful when first signs of prion pathology were already visible, 
i.e. on 21 dpi in RML6-inoculated Tga20 COCS. This finding contrasts with the neuroprotective 
anti-PrPC-OR antibody POM2, that is only therapeutic when given directly after prion 
inoculation, but not in later stages (Figure 41). Protective mutants attenuated the production 
of the reactive oxygen species producing enzyme NOX2 and microglial activiation (Figure 32), 
as well as the unfolded protein response (Figure 33). Low-binding affinity of scFvPOM1Y57A 
and toxicity of scFvPOM1Y57A at a dose of 1.2 µM precluded rescue experiments of anti-PrPC-
GD toxicity with scFvPOM1Y57A (Figure 31).  
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How do anti-PrPC-GD antibodies lead to protection against prion disease? Treatment 
of RML-infected COCS with either scFvPOM1Y57A or scFvPOM1Y104A does not lead to a 
reduction of PrPSc, hence their mode of action is most likely located downstream of prion 
replication (Figure 35). Chronic treatment with scFvPOM1Y57A or scFvPOM1Y104A does not lead 
to reduction of PrPC levels, either, excluding lowered PrPC “substrate” to be a cause of reduced 
toxicity (Figure 34). These findings point towards protective scFvPOM1Mut antibodies to act as 
dominant-negative immunoreagents binding to PrPC and quenching prion toxicity.  
 Molecular dynamics simulations on human PrPC showed that, when free in solution, 
R208 was free in solution, upon binding to POM1, R208 formed a H-bond with H140 leading 
to relaxation of the β2-α2 loop, implying loop rigidity as a mediator of prion toxicity. The β2-α2 
loop (“rigid loop”) spans aa 165-175 in the murine prion protein carrying a strictly conserved 
tyrosine at residue 169 (Kurt et al. 2014). Modification of as little as three amino acids in the 
rigid loop, was shown to profoundly alter the properties of interspecies transmission. In fact, 
transgenic mice carrying the a triple mutation of Y169G, S170N and N174T were completely 
resistant to mouse and chronic wasting disease prions (Kurt et al. 2014). I created CAD5R207C-
I138C cells carrying a mutated form of PrPC mimicking decreased β2-α2 rigidity, as observed in 
MDS (Figure 37). Indeed, binding of the monoclonal anti-PrPC-β2-α2 antibody POM5 was 
ablated in CAD5R207C-I138C, but not in CAD5WT cells, strengthening the observations made in 
silico (Figure 39). Furthermore, protection by scFvPOM1Y57A against prions and neurotoxicity 
of scFvPOM1D55A was predicted by MDS and has proven true ex vivo (Figure 24, 31).  
Based on predictions made in silico, I further generated the allegedly protective mPrPC 
mutants PrPC(R207A) and PrPC(Q211E). Both mutations were intended to ablate binding to 
the supposed “toxicity inducer” domain of PrPC-GD, i.e., the conformational epitope of POM1 
and similar toxic anti-PrPC-GD antibodies, amongst others ICSM18 and D18 (Wu et al. 2017; 
Reimann et al. 2016; Solforosi et al. 2004). Stable expressing PrPC mutants showed correct 
membranal expression (Figure 37), correct glycosylation (Figure 38) and adequate 
conservation of the conformational POM8 and POM19 epitopes, as well as, the expected  loss 
of POM1 recognition (Figures 37, 39). Unexpectedly, the prion protein mutant of CAD5Q211E 
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was no longer recognizable by the anti-PrPC-β2-α2 antibody POM5, suggesting conformational 
deregulation in vitro that was not predicted in silico, leaving the pathogenic significance of a 
mPrP(Q211E) elusive (Figure 39). Of note, stabilization of both PrPC-FT and PrPC-GD through 
a bispecific POM1/POM2 antibody had profound impact on amelioration of neuronal cell loss 
in RML-infected COCS and was efficient when given at low doses and in late stages of the 
disease (Figure 42). This observation contrasts with the anti-PrPC-FT antibody POM2 that has 
to be applied directly after inoculation to exert significant, protective effects (Figure 41). These 
findings are of significance when translating protective anti-PrPC antibodies into clinical trials, 
as the most commonly prevalent prion disease in humans, i.e. sporadic CJD, is usually only 
diagnosed when clinical symptoms appear – in contrast to lesser prevalent,  inherited forms of 
prion disease (Takada and Geschwind 2013). 
 There are potential criticisms of my study. Firstly, I did not show the beneficial effects 
of any of the antibodies in vivo, e.g. in prion-infected mice. In vivo experiments with scFv 
antibodies are usually applicable when scFv are administrated locally, e.g. through a osmotic 
mini-pump, since they are cleared from the circulation after a few minutes after injection. As 
osmotic mini-pumps are implanted for several weeks into the animal’s ventricles at 37°C, the 
aggregation-prone scFv will eventually lose their biological function (Tiziana Sonati and Uli 
Hermann, personal communication). Systemic administration of holo IgG antibodies is in my 
opinion the most feasible approach, although this has been hampered by as yet low antibody 
yields from recombinant protein production. Secondly, the mechanistic data presented is 
mostly derived from MDS in silico. In fact, some predicitions such conformational stability of 
CAD5Q211E and exertion of neuroprotective effects of scFvPOM1D55A (probably due to low 
dosage regimen) could not been reproduced in vitro or ex vivo, respectively. Furthermore, the 
allosteric changes upon POM1 and prion binding to PrPC were not yet observed in NMR 
spectroscopy (Sonati et al. 2013), probably due to higher-order changes in tertiary and 
quarternary structure.  
 In the future, I am planning to confirm the neuroprotective effects of POM1Y57A and 
POM1Y104A in vivo by systemic administration of IgG1 antibodies into prion infected mice. 
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Preliminary data by Marco Bardelli and Luca Varani have shown interaction of a N-terminal 
residue, i.e. Y127, with the C-terminal domain of PrPC upon binding to POM1. I am currently 
cloning and producing 2 of 3 of the above-mentioned PrP-mutants (i.e. R207A and R207C-
I138C) plus the mPrP(Y127F) mutant coupled to a fluorophore as adeno-viral expressed 
plasmids that can be used for transduction of Prnp0/0 COCS to assess the impact of these 
mutations on POM1 and prion-induced toxicity. Further experiments include dose-escalation 
tests of the protective POM1-derivatives (POM1Y57A, POM1Y104A and LVp12) to assess 
innocuity and test rescue of other downstream pathways by protective antibodies, such as 
calpains, cleavage of alpha-fodrin and reactive oxygen species. One could also speculate that 
a bispecific antibody consisting of both POM2 and POM1Y57A could provide a highly effective 
compound against prion disease.  
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Part III - Human autoantibodies against the prion protein in 
health and disease 
 
Aims of the study 
There is compelling evidence that anti-PrPC-FT antibodies may be therapeutic in human prion 
diseases and eventually in other neurodegenerative diseases involving PrPC such as AD 
(Herrmann et al. 2015; Chung et al. 2010). Furthermore, antibodies derived from human 
subjects frequently show superior safety profiles and affinity maturation compared to 
“humanized” hybridomas or synthetic libraries. They have already shown great therapeutic 
promise in the case of the anti-amyloid β antibody Aducanumab (Sevigny et al. 2016) and in a 
range of autoimmune and inflammatory diseases through naturally occurring interferon-
gamma neutralizing autoantibodies (Meyer et al. 2016), among others.  
Genetic prion disease patients express a pathological form of the prion protein 
throughout their entire life, clinical symptoms occur, however, almost exclusively in advanced 
age (Takada and Geschwind, 2013). This is indicative of protective factors. Here, I posit that 
such factors may consist of antibodies against prions that are responsible for the long clinically 
silent period of gPrD patients. Over time, however, the overproduction of PrPSc in PRNP 
mutation carriers may overwhelm the defense afforded by such antibodies.  
CIDP is a rare, chronic neuropathy of uncertain etiology (Hanewinckel, Ikram, and Van 
Doorn 2016).  Prnp0/0 mice independent of the genetic background develop a chronic 
demyelinating polyneuropathy (CDP). After several months, Prnp0/0 animals develop 
characteristic walking disturbances that manifest in typical demyelinating changes in 
peripheral nerves, such as macrophage invasion, breakdown of myelin proteins (Bremer et al. 
2010). Recently, the G-protein coupled receptor Adgrg6/GPR126 has been demonstrated to 
depend on a functional PrPC-FT signaling to maintain myelin integrity (Kuffer et al. 2016). I 
postulate that patients harboring anti-PrPC-FT autoantibodies develop a chronic demyelinating 
neuropathy through sequestering of soluble PrPC-FT by autoantibodies. 
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 In search of both toxic and protective autoantibodies against PrPC I will perform 
autoantibody screenings of gPrD and CIDP patient cohorts with subsequent clinical 
correlations and clone paired heavy and light chains of human antibodies from cognate 
memory B cells. Crucially, access to patient clinical history will ensure selection of 
autoantibodies for minimal toxicity and allow the correlation of clinical histories with 
autoantibody levels. Human-derived antibodies generated in this study will represent safe and 
efficacious new drug candidates compared to murine, humanized or human antibodies 
obtained by current immunization or peptide display approaches. Completion of the proposed 
activities will lead to the development of effective antibodies against these fatal disorders. 
Further, the discovery of toxic anti-PrPC autoantibodies responsible for CIDP will vastly 
broaden our understanding of this still elusive disease and provide immediate treatment 
options for these patients. 
 
Results 
Establishing a screening platform to detect and extract anti-PrPC autoantibodies in 
human blood 
Enzyme-linked immunosorbent assays are sensitive assays that can be used in medium- and 
high-throughput screenings. I chose an indirect ELISA that would allow me to present the 
antigen of interest, i.e. human PrPC, via a linker protein absorbed to the test plate, in order to 
reduce protein denaturation through direct absorption of the protein of interest resulting in 
reduced detection specificity and sensitivity (Figure 43A, (Kim and Herr 2013)). 
In order to establish a robust positive control for anti-PrPC autoantibody screenings, I 
created humanized versions of the monoclonal murine anti-PrPC antibodies POM1 and POM2 
(Polymenidou et al. 2008), hereafter termed HuPOM1 and HuPOM2 for human and MuPOM1 
and MuPOM2 for murine counter-parts. To this end I have grafted their variable light and heavy 
chains onto human kappa (κ) and gamma (γ1) constant domains: light and heavy chains of 
POM1 and POM2 cloned into pFUSE2-CLIg-hK, for light chains, or pFUSE-CHIg-hG1 (both 
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Invivogen), for heavy chains, respectively. IgG1 constant heavy chains were designed as 
L234A and L235A (“LALA”) mutants to reduce Fcγ and complement binding (Hessell et al. 
2007) (Figure 43B).  
 
HEK293 PRNP0/0 #H1 cells were co-transfected with a ratio of 3:2 = light:heavy chain plasmids 
and stably selected with Blasticidin and Zeocin, cell supernatants were collected and purified 
by affinity chromatography using protein G sepharose (HuPOM1+HuPOM2) and Ni-NTA resin 
(HuPOM1, Figure 44A). Analyses of purified antibodies showed binding of both HuPOM1 and 
HuPOM2 to rmPrP23-230 as well as to rhPrP23-231 (Figure 44B). Expectedly, HuPOM1 bound to 
the PrPC-GD fragment rmPrP121-230, but not to rmPrP23-120 and vice versa (Figure 44B).  
Figure 43. (A) Schematic depiction of the anti-PrPC autoantibody ELISA: avidin (here: Streptavidin) is 
adsorbed onto microtiter plates and bound by a site-specificbiotinylated antigen (here: rhPrP23-231 C-
terminally tagged with a biotinlyated AviTag peptide. Autoantibodies are bound to immobilized prion 
protein and detected via a horseradish peroxidase (HRP)-conjugated secondary antibody. Image 
courtesy of Adriano Aguzzi. (B) Scheme of humanized POM1 and POM2 antibodies, denoted HuPOM1 
and HuPOM2, respectively. Murine, variable light and heavy chains are grafted onto their human 
constant light (κ) and gamma (γ1) counterparts. Constant heavy chains bear to L-to-A substitutions 
(L234, L235A; “LALA” mutation) to ablate complement and Fcγ binding. Constant heavy chains are 
tagged by 6x histidines. 
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To test whether my assay would detect all human IgG (hIgG) isoforms, i.e. hIgG1-4, I 
tested single hIgG1-4 isoforms derived from multiple myeloma patients and pooled murine IgG 
(mIgG) against the HRP-conjugated anti-human IgG antibody. Herein, the anti-hIgG antibody 
Figure 44 (A) SDS-PAGE of Ni-NTA purified HuPOM1 stained with InstaBlue (left panel) and silver 
stained SDS-PAGE of protein G sepharose purified HuPOM2 shows strong bands at 150 kDa under 
oxidative and heavy (50 kDa) and light (25 kDa) chain bands under reducing (+ 2-mercaptoethanol, 
2-ME conditions). (B) Direct ELISA of HuPOM1/2 shows specific binding of HuPOM1 to MuPrP121-230 
without overt binding to MuPrP23-110 and vice versa.  
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specifically reacted with all hIgG1-4 isoforms, but not rabbit (Figure 45A) or murine IgG (Figure 
45B).  
 
I have generated a full-length human PrP23-231 with a C-terminal AviTag, a 15 aa linker 
tag with a central lysine, i.e. GLNDIFEAQKIEWHE, which, upon co-transfection with the biotin 
ligase BirA in E. coli undergoes site-specific biotinylation in vivo (Fairhead and Howarth 2015) 
in order to facilitate native and conformationally correct presentation of hPrPC. A gBlock (IDT) 
containing rhPrP23-231, a GSGS linker and the AviTag was cloned into the BamHI and EcoRI 
sites of the pRST-Mini-T plasmid as described before (Figure 46A (Zahn, von Schroetter, and 
Wuthrich 1997; Sonati et al. 2013)). Co-transfection of E. coli with pRST-Mini-T.rhPrP23-231-
Figure 45. All hIgG1-4 isoforms are detected in the anti-PrPC autoantibody ELISA. (A) Western blot 
of 10 ng of protein per lane shows specific reactivity of the anti-hIgG antibody to all hIgG1-4 isoforms, 
but not to rabbit IgG. (B) Human IgG1-4, pooled hIgG and pooled mIgG were absorbed onto a 
polystyrene microtiter plate at c=20 µg/mL and detected using a anti-hIgG antibody, herein all 
hIgG1-4 isoforms and pooled hIgG, but not mIgG were detected.  
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AviTag and the pBirAcm plasmid containing BirA led to efficient in vivo biotinylation, yielding 
hPrP-ATbiotin (Figure 46B). Proteomic analysis by time-of-flight mass spectrometry electrospray 
(TOF MS ES, performed by the Functional Genomics Center at the University of Zurich) 
showed two clear peaks according to the estimated molecular weight, namely native hPrP-AT 
and biotinylated hPrP-ATbiotin (Figure 46C). 
Figure 46. (A) Scheme of the expression plasmid of hPrP-AT (B) Western blot of purified and in vivo 
biotinylated hPrP-ATbiotin, native rhPrP23-231 and biotinylated POM19 shows hPrP-ATbiotin, but rhPrP23-231 
is not detectable by both Streptavidin and POM1. Recombinant proteins are loaded at 300 ng (left band) 
and 100 ng (right band). (C) TOF MS ES shows the correct size of biotinylated and unbiotinylated hPrP-
ATbiotin after Ni-NTA resin purification of in vivo biotinylated hPrP-AT.  
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The magnitude of anti-PrPC autoantibody reactivity is expressed as the negative 
decadic logarithm of the half-maximal inflection point of the binding curve [-log10(EC50)], as was 
calculated by an automated 4-point logistic regression fitter (by Georg Meisl, Cambridge). In 
order to test the specificity of my generated antibodies and further experimentally dervied hits 
from human plasma, I was wondering whether pre-incubation of rhPrP23-231 with both HuPOM1 
and HuPOM2 would lead to a decreased anti-PrPC reactivity. Both HuPOM1 and HuPOM2 
were pre-incubated with 300 nM of either rhPrP23-231 or murine, scrambled PrPC-N1 (rmPrP23-
110, see also (Kuffer et al. 2016)) in 1% TopBlock in 0.1% PBS-T at 4°C for 1 hour and then 
tested on the anti-PrPC ELISA. A right-shift of the binding curve, i.e. weakend binding to hPrP-
ATbiotin was observed upon pre-incubation with rhPrP23-231, but not scrambled PrPC-N1, 
suggesting successful competition (Figure 47).  
 
In order to clone the cognate memory B-cell variable heavy and chain light repertoire, I 
established a protocol using bait-gated fluorescent activated cell sorting (FACS) in which hPrP-
Avitag is tetramerized through binding to a Streptavidin-Fluorophore leading to increased 
avidity of B-cell binding (Figure 48A). Reportedly, a fraction of hybridoma cells not only 
secretes antibodies but also expresses membrane-bound antibodies (Seifert et al. 1992). To 
test the specificity of my bait-gated approach, I stained POM1 hybridoma cells (Polymenidou 
et al. 2008) with the lipophilic dye DiI (Invitrogen) and the anti-Cytokeratin 8/18 (CK8/18) 
Figure 47. Pre-incubation with 300 nM of rhPrP23-231, but not scrambled PrPC-N1 with HuPOM1 (left 
panel) or HuPOM2 (right panel) leads to a right-shift of the binding curve indicating specific 
competition of the soluble against the immobilized antigen. 
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hybridoma cell line UCD/PR10-11 (ATCC) with the lipophilic dye DiO (Invitrogen) in a 1:1 ratio 
(Figure 48B) and incubated with a complex of hPrP-ATbiotin and Streptavidin-BV421. No 
DiO+/BV421+ cells, but a large fraction of DiI+/BV421+ cells were seen, indicating specific 
binding of the POM1 hybridoma cells to the hPrP-ATbiotin/Streptavidin-BV421 complex (Figure 
48C). 
 
Anti-PrPC autoantibodies in genetic prion disease patients 
Sequencing of the PRNP ORF from blood samples of genetic prion disease patients was 
performed using Sanger Sequencing at the Institute of Molecular Pathology (University 
Figure 48. (A) Scheme of tetrameric Streptavidin-BV421 bound to hPrP-ATbiotin. B= biotin, 
BV=brilliant violett 421. (B) Gating strategy for POM1 hybridomas stained with DiI and UCD/PR10-
11 hybridomas stained with DiO. (C) Mixing of DiI+ and DiO+ cells with a complex of hPrP-
ATbiotin/Streptavidin-BV421 complex shows specific binding in POM1, but not in anti-CK8/18 
hybridoma cells.  
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Hospital Zurich). Prior to sequencing, I established a protocol for the inactivation of prions from 
blood samples while maintaining DNA integrity (Figure 49).  
 
A total of n=112 patients was genotyped in the frame of the study (detailed baseline 
characteristics, see Table 5). 54% (n=60) of individuals were PRNPWT, i.e., unmutated family 
members, and 46% (n=52) of participants carried a non-synonymous PRNP mutation.  
 
 Median (IQR) n 
Median 
(IQR) n 
data 
available  
in % 
p-value 
 PRNPWT PRNPMut   
# of 
patients 
 60  52 112  
demographics   
age [y] 36 (28-54) 51 
43 
(33-
64.5) 
49 89 0.12* 
female  29  26 86 0.93§ 
p.129 polymorphism   
M/M  8  27 85 <0.001§ 
M/V  34  22   
V/V  4     
non-synonymous mutations   
E200K  -  48 100  
D178N  -  4   
clinical data   
gPrD 
symptoms 
   10 100  
Figure 49. For PRNP genotyping, whole blood was diluted in PBS and proteinase K was added to 
dissociate cells. To deactivate prions, 5M GdnGCl + 1% Triton X-100 (Tx100) at pH=5 were added 
and incubated for 24 hours at room temperature. Further DNA elution was performed using Qiagen’s 
Blood and Tissue DNeasy kit.  
Table 5. Summary of the investigated gPrD cohort. IQR = inter-quartile range. * two-tailed, 
unpaired t-test § Chi-Square test 
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PRNPMut patients were almost exclusively E200K (92%, n=48) mutations and in a minor 
fraction D178N (8%, n=4) mutations. Nineteen percent (n=10) of PRNPMut patients were 
symptomatic when blood was drawn for the study. Demographic data provided by the 
participating institutions for all patients included age at phlebotomy (available for 89%, n=100) 
and gender (available for 89%, n=100). PRNPMut patients were significantly more likely to 
harbor Met/Met at p.129 that PRNPWT individuals (p<0.001, 55% PRNPMut versus 17% 
PRNPWT, Chi-square test, Table 5). 
Screening of venous blood from n=103 genotyped patients for IgG autoantibody reactivity 
against PrPC did not yield significant differences between PRNPMut and PRNPWT (Figure 50A). 
Clinical symptoms in PRNPMut patients did not affect anti-PrPC autoantibody levels when 
compared to asymptomatic PRNPMut patients (Figure 50B), neither did p.129 polymorphisms 
(Figure 50C). No gender-specific effects were observable (Figure 51D). When correlating the 
age at phlebotomy with anti-PrPC autoantibody titers, the titers of PRNPMut patients significantly 
decreased during aging (Pearson r=-0.41, p<0.01) while those of PRNPWT patients remained 
stable (Figure 51E), independent of age per groups at baseline (Table 5). A second 
phlebotomy was performed in n<20 PRNPMut patients (due to data protection of PRNPMut 
patients the exact number cannot be disclosed). Comparison of titers did not yield a significant 
change (paired, two-tailed T-test, Figure 51F). 
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Figure 51. (A) In blood from PRNPWT versus PRNPMut 
individuals, no differences in anti-PrPC autoantibody titer were 
seen between the groups. Autoantibody titers were not 
influenced in PRNPMut patients by clinically silent or manifest 
patients (B), by p.129 polymorphism for both patient groups (C) 
or by gender (D). Titers remained stable in PRNPWT individuals 
during ageing (E, left panel) but significantly decreased in 
PRNPMut patients (E, right panel). Solid lines=mean ± 95% 
confidence intervals (dashed lines) (F) Follow-up 
phlebotomies of < 20 patients did not reveal changes in anti-
PrPC autoantibody titer over the observed time period. Solid 
and dashed lines indicate mean decrease and +/- S.D., 
respectively (horizontal line denotes median, box IQR and 
whiskers minimum and maximum, respectively).   
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Anti-PrPC autoantibodies in CIDP patients 
Prnp0/0 mice suffer from chronic demyelinating polyneuropathy (Nuvolone et al. 2016; Bremer 
et al. 2010; Kuffer et al. 2016), similar to chronic inflammatory demyelinating polyneuropathy 
(CIDP), a rare neuropathy seen in human patients, the etiology of which remains largely 
elusive (Hanewinckel, Ikram, and Van Doorn 2016). If antibodies in human blood were to 
sequester soluble PrPC, inadequate pro-myelinating signaling of GPR126 would lead to a 
Prnp0/0-like, demyelinating phenotype. I have received n = 100 plasma samples from CIDP 
patients from a variety of hospitals in France (Jerome Devaux, CNRS, Marseille). The median 
age of the patients was 60 years (inter-quartile range 49-68), n=35 patients were of female 
gender. Control groups included patients with autoimmune polyendocrinopathy candidiasis 
ectodermal dystrophy (APECED), also called autoimmune polyendocrine syndrome type 1 
(APS1), a rare autoimmune disease caused by mutations in the autoimmune regulator (AIRE) 
gene (Kisand and Peterson 2011). In APS-1 patients, AIRE mutations lead to a failure to 
eliminate autoreactive T cell pools with the subsequent development of  autoimmunity (Kisand 
and Peterson 2011). These patients display a broad autoantibody profile against many 
antigens (Hayday 2013). Guillain-Barré Syndrome (GBS) is an acute peripheral neuropathy 
and often considered to be the acute counterpart of CIDP (Wijdicks and Klein 2017). Lastly, 
patients with systemic lupus erythematosis (SLE) suffer from a chronic autoimmune syndrome 
sharing pathogenic features with CIDP patients, e.g. terminal complement activation (Quast et 
al. 2016).  
 Anti-PrPC autoantibody titers did not significantly correlate with patient age (Figure 52A) 
or gender (Figure 52B). Autoantibody titers showed good inter-assay correlation when testing 
blood on plates with directly absorbed rhPrP23-231 versus Streptavidin-linked hPrP-ATbiotin 
(Spearman’s r = 0.55, 95% confidence interval 0.37-0.69, p<0.001, Figure 52C). When testing 
patient blood from CIDP patients against unbiotinylated rhPrP23-231, CIDP patients exhibited a 
strong reactivity compared to unselected hospital patients from the University Hospital of 
Zurich (p<0.001, mean -log10(EC50) 1.87 ± 0.33 CIDP vs. 1.38 ± 0.22 UHZ controls, two-tailed, 
unpaired, t-test, Figure 53A). CIDP autoantibody titers were not different from SLE patients, 
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but significantly elevated to APS1, GBS, Sepsis, PRNPMut patients and their PRNPWT family 
counterparts (Figure 53B). As any strong reactivity could be due to artificial polyreactivity of 
the blood samples, I tested n=42 CIDP patient blood samples against biotinylated, 
pyroglutamylated Aβ3-17 (pE3-17, a gift from Prof. H.-U. Demuth, (Nussbaum et al. 2012)) as well 
as against Streptavidin, biotin, BSA and uncoated plates alone to exclude unspecific binding 
(Figure 53C). Binding of CIDP blood samples against hPrP-ATbiotin was significantly stronger 
than all other conditions tested (p<0.001, hPrP-ATbiotin versus all other conditions, one-way 
ANOVA with Dunnett’s post hoc test, Figure 53C). Lastly, I tested total IgG levels in CIDP, 
SLE, APS1, 2, 4 and UZH patients, herein, no significant differences were seen (Figure 53D). 
Figure 52. No correlation was seen between the age of CIDP patients and anti-PrPC autoantibody 
titer (A), nor did I see a difference in antibody titers in regards to gender of the patients (B). (C) 
When correlating titers in two different assays, i.e. directly absorbed rhPrP23-231 versus Streptavidin-
linked hPrP-ATbiotin, a good correlation was observed (Spearman’s r=0.55, p<0.001). 
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Figure 53. (A) CIDP patients show strong anti-PrPC reactivity compared to patients randomly selected 
from the University Hospital of Zurich, *** p<0.001, two-tailed, unpaired t-test. (B) CIDP patients 
showed significantly elevated anti-PrPC autoantibody titers compared to patients suffering from APS1, 
GBS, Sepsis as well as PRNPMut mutation carriers and their PRNPWT family members. No significant 
difference is seen between SLE and CIDP patients. N.s. not significant, * p<0.05, ** p<0.01, *** 
p<0.001, one-way ANOVA with Dunnett’s post hoc test. (C) Reactivity of CIDP blood is significantly 
higher when compared to the biotinylated protein pE3-17, as well as against Streptavidin, biotin and 
BSA alone and when compared to uncoated test plates *** p<0.001, one-way ANOVA with Dunnett’s 
post hoc test. (D) No significant differences are observed in total IgG levels from randomly selected 
UZH patients, as well as SLE, CIDP and APS1, 2, 4 patients. 
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Discussion and Outlook 
I have successfully established an enzyme-linked immunosorbent assay (ELISA) to detect 
anti-PrPC autoantibodies in human blood. Herein, recombinantly expressed, site-specificy 
biotinylated hPrP-ATbiotin is immobilized via Streptavidin to microwell test plates (Figure 43B), 
as antigens directly absorbed to polystyrene plates are more prone to denaturation (Kim and 
Herr 2013). Humanized versions of the monoclonal anti-PrPC antibodies POM1 and POM2 
served as positive controls (Figure 43A). Importantly, the assay was able to detect all human 
IgG1-4 isoforms (Figure 45).  
Genetic prion diseases (gPrD) are rare, neurodegenerative diseases that rely on the 
autosomal-dominant inheritance of mutations in the ORF of the PrPC coding gene PRNP 
probably le. Although gPrD patients carry a mutated version of PrPC throughout their lifetime, 
they usually become clinically manifest at a later age, indicative of protective factors (Takada 
and Geschwind 2013). Anecdotal reports of successfully treated cases of gPrD and other 
prion diseases have been published.  However, randomized, controlled, double-blind clinical 
trials of patients with prion disease have hitherto failed to yield therapeutic compounds 
(Geschwind et al. 2013; Geschwind 2014). It has recently been found that PrPC-GD 
antibody-mediated toxicity is exerted through the engagement of PrPC-FT, as no toxicity was 
observed in mice expressing a shortened variant of the PrPC-FT (Sonati et al. 2013). 
Importantly, blockade of the FT by antibodies is beneficial in three models of prion toxicity, 
e.g. toxic GD antibodies, prion infection, and mice expressing a toxic PrP variant (Sonati et 
al. 2013; Herrmann et al. 2015), implicating the FT as the PrP-effector module of neuronal 
death. But the role of PrPC in inducing cellular neurotoxicity might not be restricted to prion 
disease. Several reports have suggested the potential of antibodies against PrPC to prevent 
Aβ-mediated toxicity in vitro and in vivo (Chung et al. 2010; Resenberger et al. 2011; Klyubin 
et al. 2014). 
 Importantly, naturally occurring monoclonal antibodies represent novel therapeutic 
molecules for neurologic disorders such as multiple sclerosis, Parkinson’s disease, AD, 
amyotrophic lateral sclerosis. Naturally occurring antibodies have potentially functional activity 
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with higher safety profile and are reactive to self-proteins, altered self-components, or foreign 
antigens. It is postulated that human autoantibodies targeting misfolded pathogenic proteins 
serve as surveillance molecules to eliminate toxic aggregates before they can elicit a 
deleterious response (Szabo, Relkin, and Weksler 2008). Such antibodies might neutralize the 
activity of oligomers and/or facilitate the clearance of deposited aggregates via microglia 
uptake. A successful example of human-derived antibodies is represented by Aducanumab 
(currently in phase III clinical trial), targeting a conformation epitope of aggregated Aβ and 
derived from healthy, aged donors who were cognitively normal (Sevigny et al. 2016). At early 
phases of clinical trial is HIgM22, targeting myelin and oligodendrocytes and promoting central 
nervous system repair in animal studies (Wootla et al. 2015). 
 In this study, I have established a workflow from screening the blood from gPrD patients 
to bait-gated, single-cell sorting of cognate memory B-cells that I plan to use for sequence 
extraction and production of endogenous, affinity-maturated antibodies (Figure 48). 
Unfortunately, I was not able to detect any differences in anti-PrPC autoantibody titers between 
gPrD patients and PRNPWT family members. Furthermore, no significant association was found 
between gender, clinically silent or manifest gPrD patients or over time. Of note, gPrD patients 
exhibited decreased anti-PrPC autoantibody titers than did their PRNPWT counterparts 
independent of age – suggesting a gPrD-specific effect rather than age-dependent 
immunosencesce. In rodent models of gPrD, mutated prion protein forms birefringent amyloid 
and proteinase K resistant PrPSc (Hsiao et al. 1994). One could speculate that anti-PrPC 
autoantibodies in gPrD patients bind to pathologically aggregated PrPSc preventing 
neurological symptoms to occur. Over time, the immune system is overwhelmed by the amount 
of PrPSc produced and patients become symptomatic.  
 It will be interesting to find out whether gPrD and control patients target different 
epitopes of PrPC. As disease-causing mutations predominantly occur in PrPC-GD, one might 
speculate that these mutations lead to generation of “neo”-epitopes that cause autoimmunity. 
Furthermore, I am planning to test the blood of gPrD patients for autoantibodies against 
aggregated forms of PrPC (Swietnicki et al. 2000). In a last step, one could think of testing the 
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patient’s autoreactivity against recombinant, human, mutated prion protein, although the 
biosafety implications are rather worrisome. 
 In the second part of this chapter, I have begun to investigate the possibility of disease-
causing, anti-PrPC autoantibodies in CIDP patients. CIDP is a rare, chronic neuropathy of 
uncertain etiology (Hanewinckel, Ikram, and Van Doorn 2016). Antibodies against a plethora 
of nodal and paranodal proteins have been suggested to be involved in CIDP pathogenesis, 
such as neurofascin 140 and 155, contactin-1 and contactin-associated protein 1, although the 
disease still lacks trackable biomarkers (Delmont et al. 2017). In my investigations, CIDP 
patients showed strong responses against native and biotinylated PrPC, in addition, anti-PrPC 
autoantibody titers were significantly higher than those in the “acute” form of CIDP, i.e., 
Guillain-Barré syndrome as well as other chronic inflammatory states such as sepsis and the 
monogenic autoimmune disease APS (Figure 53A+B). The CIDP signal was specific to PrPC 
as CIDP blood reacted significantly less to a fragment of pyroglutamylated Aβ (pE3-17), the anti- 
pE3-17 reactivity was only slightly higher than the IgG immuneresponse against streptavidin, 
biotin and BSA alone (Figure 53C). SLE patients share pathogenic pathways with CIDP 
patients, such as a dysregulated complement system (Quast et al. 2016). In my assay, the 
anti-PrPC autoantibody titers of SLE were similar to those of CIDP patients (Figure 53B). 
Although not significant, probably due to the low number of patients tested, IgG levels were 
around 30% higher in SLE patients (Figure 53D) possibly leading to an overall higher anti-IgG 
reactivity.  
 Rigorous studies in Prnp0/0 mice of different genetic backgrounds have established a 
chronic demyelinating polyneuropathy to represent a true phenotype of animals lacking PrPC. 
After several months, Prnp0/0 animals develop characteristic walking disturbances that manifest 
in typical demyelinating changes in peripheral nerves, such as macrophage invasion, 
breakdown of myelin proteins (Bremer et al. 2010). These changes were not caused by 
neuron-specific, but Schwann cell-specific knock-out of PrPC suggesting a receptor in need of 
PrPC or fragment thereof to exert pro-myelinating functions (Bremer et al. 2010). Recently, the 
G-protein coupled receptor Adgrg6/GPR126 has been demonstrated to depend on functional 
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PrPC signaling to maintain myelin integrity (Kuffer et al. 2016). PrPC is binding through its N-
terminal polybasic stretch KKRPKPG to GPR126, in fact, a 27 aa, the KKRPKPG-containing 
PrP23-50 fragment was sufficient to induce cAMP responses via GPR126 in zebrafish (Kuffer et 
al. 2016). 
 What is the possible pathogenic mechanism of anti-PrPC autoantibodies in CIDP 
patients? In human blood, PrPC is most abundantly found in the plasma fraction (MacGregor 
et al. 1999) and – independent of the organ - subjected to α- (at aa 110/111) and β-cleavage 
(at the C-terminus of PrPC-OR) yielding PrPC-FT fragments accessible to GPR126-mediated, 
pro-myelinating signaling. One might speculate that an increased prevalence of anti-PrPC 
autoantibodies, preferably to N-terminus of PrPC, could sequester pro-myelinating signals 
resulting in a functional Prnp0/0. If this were true, systemic administration of PrP23-50 would 
provide an immediate treatment option for CIDP patients.  
To strengthen my hypothesis, I plan to perform epitope mapping on CIDP 
autoantibodies by ELISA using truncated PrPC fragments, amongst others PrPC-FT and PrPC-
GD. Further experiment such as competition of autoantibody reactivity by addition of 
recombinant prion protein to blood samples and cell-based assays are planned to validate the 
presence of anti-PrPC autoantibodies in CIDP patients. Blood from a second CIDP patient 
cohort is needed to cross-validate my findings. Although the CIDP samples investigated here 
come from different centers across France, possible confounders in sample preparation could 
lead to a sampling bias. Lastly, I believe the gold standard to verify the presence of anti-PrPC 
autoantibodies in CIDP patients is their cloning from cognate memory B-cells as presented in 
Figure 48, purification and subsequent injection into rodents in order to elicit a CIDP-like 
syndrome. 
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Materials and Methods 
 
Animals and PCR genotyping  
Prnp0/0 (ZH1) and Tga20+/+ mice were generated on a mixed 129Sv/Bl6 background, Prnp0/0 
(ZH3) mice were generated on a pure C57BL/6J background (Aller et al. 2003; Büeler et al. 
1992; Fischer et al. 1996; Nuvolone et al. 2016). F1 generation animals were used for further 
ex Embryos for injection of thy1 driven YFP expression were obtained from matings between 
(C57BL6/J and CBA) F1 hybrids and transgenic founders were backcrossed to C57BL6/J mice 
resulting in the YFP16 mouse line (Feng et al. 2000). A 2-primer PCR was used to genotype 
the YFP allele (primers oIMR1258 and oIMR1260, see appendix a)). All animal studies were 
performed in accordance with local ethics guidelines and with permission by the responsible 
institutional animal care committee, namely the Animal Welfare Committee of the Canton of 
Zurich (permit numbers 200/2007, 41/2012, 90/2013 and ZH040/2015).  
Animal survival study, inoculation of prions and scFvPOM1-treated brain tissue 
Prion inoculations were performed under isofluorane anesthesia and, mice were monitored 
every other day after prion inoculations. Scrapie was diagnosed when ataxia, limb weakness, 
front leg paresis or rolling were observable and mice were subsequently euthanized by CO2 
inhalation. At necropsy, brains were halved either snap-frozen in liquid N2 or fixed in 4% 
formalin. The time elapsed from prion inoculation to the terminal stage of disease was defined 
as incubation time for the survival study. All brain and COCS homogenates were diluted in 
0.32 M sucrose in demineralized water before inoculation. 3 months-old tga20 mice were 
inoculated in the right frontal lobe at 1% (36 μg protein in 30 μL, corresponding to 3 x 106 LD50 
units, high dose) and 0.0001% (3.6 ng protein per animal, corresponding to 3 x 102 LD50 units, 
low dose) of RML6 homogenate, and 1% (18 μg protein in 30 μL) of COCS homogenate. The 
protein concentrations in brain homogenates used for inoculation are in agreement with 
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previously reported protein concentrations of infectious and non-infectious brain homogenates 
(Basu et al. 2007). No unexpected deaths were observed during the animal experiments 
reported. 
Antibodies  
POM monoclonal antibodies were created as described in (Polymenidou et al. 2008). Single-
chain variable fragment antibodies of POMs were created through purification of inclusion 
bodies from E. coli on a Ni-NTA column as reported in (Sonati et al. 2013). Fab2POM fragments 
were generated through pepsin digestion and purified on a protein A column as described in 
(Sonati et al. 2013). Purified, mutagenized scFvPOM1 antibodies were generously provided 
by Luca Varani (Institute of Biomecial Research, Bellinzona).  
For creation of humanized POM1 and POM2 antibodies (hPOM1 and hPOM2), murine 
variable light chains were ordered as gBlocks (IDT) gene fragments and PCR amplified using 
Q5 high-fidelity DNA polymerase (New England Biolabs) according to the manufacturer’s 
guidelines prior to restriction enzyme digestion. Variable + constant heavy chains were ordered 
in EcoRV cloning sites in pUC57-Kan expression vectors (Genscript, see sequences below). 
Heavy and light chain gene blocks included a Kozak initiation sequence and a IL-2 signal 
peptipe for efficient secretion. Gene blocks of the heavy chain were modified by inclusion of a 
L234A and L235A mutation (“LALA”) in the constant heavy region 2 and contained a C-terminal 
6xHis-Tag. PCR-amplified products were excised from agarose gels and double digested with 
the restriction enzymes AgeI and BsiWI (variable light chain) and EcoRV and MscI (heavy 
chain). For antibody expression, digested light and heavy chain vectors were inserted into the 
corresponding restriction sites of pFUSE2.CLIg-hK (light chain) and pFUSE2.CHIg-hG1 
(heavy chain, both Invivogen) yielding the plasmids pFUSE2.CLIg-hK.POM1, pFUSE2.CLIg-
hK.POM2, pFUSE2.CHIg-hG1.POM1 and pFUSE2.CHIg-hG1.POM2. Prior to insertion of the 
heavy chain gene block, a site-directed mutagenesis was performed at the MscI2594 restriction 
cleavage site of pFUSE2.CHIg-hG1 using QuikChange II Site-Directed Mutagenesis Kit 
(Agilent) with primers MscI(2594)-fwd and MscI(2594)-rev (see appendix a)) according to the 
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manufacturer’s guidelines. HEK293(Prnp0/0) monolayer cells were transfected using 
Lipofectamine 2000 (Invitrogen) in plain OptiMEM medium (Invitrogen) with the corresponding 
immunoglobulin light and heavy chain expression plasmids at a ratio of light:heavy=3:2 
according to the manufacturer’s guidelines. Medium was changed 24 h after transfection to 
standard culture medium. 48 h after transfection, pFUSE2 transfected cells were selected 
using 5 µg/ml Blasticidin (Invitrogen) and 50 µg/ml Zeocin (Invitrogen). Prior to medium 
collection for antibody purification, FBS in culture medium was exchanged by Ultra-low IgG 
FBS and Ultra-low IgG FBS content in culture medium was sequentially decreased to 0% with 
every medium change (i.e. 10 % -> 5 % -> 1 % -> 0 %). HEK293(Prnp0/0) supernatants were 
stored at -20°C until purification. Affinity chromatography was performed on protein G resin 
using ÄKTA protein purification system ÄKTAprime (GE Life Sciences), antibody elution was 
undertaken using 0.2 M glycine, pH=2.7. Antibody eluates were pooled and protein 
concentration was determined using bicinchoninic acid assay (Pierce). Purity of antibodies was 
determined using SDS-PAGE gel stained with InstaBlueTM Ultrafast Protein Stain (Sigma-
Aldrich) and SilverXpress Silver Staining Kit (Thermo Fisher Scientific) according to the 
manufacturer’s guidelines. For detection of correct human IgG-Fc expression, 50 ng of purified 
antibody were loaded on SDS-PAGE in the presence and in the absence of 200 mM 
Dithiothreitol (DTT) and blotted onto a nitrocellulose membrane. Human IgG-Fc was detected 
by a goat anti-human IgG Fc𝜸𝜸-specific HRP-conjugated polyclonal anti-IgG antibody (1:4’000, 
Jackson ImmunoResearch). 
Cell lines and generation of stable cell lines 
The human embryonic kidney cell line HEK293 was purchased by ATCC. The HEK293 
PRNP0/0 cell line clone #H1 was generously provided by Mario Hermann. The CAD5 cell line 
is a prion-susceptible subclone (Mahal et al. 2007) of Cath.a-differentiated cells (Qi et al. 1997) 
and was generously provided by Charles Weissmann.  
For CRISPR/Cas9-aided generation of CAD5 knock-out cells, mouse Prnp sgRNA was 
designed using the web-based tools http://crispr.mit.edu/ and 
  
  
KARL FRONTZEK, 2017 110 
 
http://zifit.partners.org/ZiFiT/CSquare9GetOligos.aspx (last access on May 15th 2017). The 
sgRNA expression plasmid MLM3636 was a gift from Keith Joung (Addgene plasmid # 43860, 
www.addgene.org). For annealing of single-stranded DNA oligomers of sgRNA (Oligo4 F and 
Oligo4 R, sequences are listed in appendix a)) for subsequent cloning into the MLM3636 
plasmid the following ligation reaction was prepared: 10 µl Oligo4 F [100 µM], 10 µl Oligo4 R 
[100 µM], 10 µL of NEB Buffer 2.1 (New England Biolabs), 70 µl ddH2O. Reaction mix was 
heated for 4 min at 95°C on a heating block ThermoStat (Eppendorf), then the heating block 
was turned off and the reaction was allowed to proceed for 30 min on the block and was then 
put at 4°C. Golden Gate assembly (Engler, Kandzia, and Marillonnet 2008) was used in order 
to clone the double-stranded DNA Oligomers into the MLM3636 plasmid, using the following 
reaction: 
 
 
This reaction was put on a thermocycler using the following conditions: 
temperature duration cycles 
37°C 5 min 
10 x 
16°C 10 min 
37°C 15 min  
80°C 5 min  
amount name 
150 ng MLM3636 plasmid 
1 µl double-stranded oligomer ligation mix 
2 µl NEB T4 ligase buffer (New England Biolabs) 
13.25 µl  ddH2O 
1 µl Esp3I (New England Biolabs) 
1 µl T4 ligase (New England Biolabs) 
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The ligated plasmid MLM3636(sgRNAmPrnp) was subsequently transformed into DH5α 
chemically competent E. coli cells (Invitrogen) and plasmid purification was undertaken using 
Plasmid Maxi Kit (Qiagen). CAD5 cells were co-transfected using the MLM3636(sgRNAmPrnp) 
plasmid and the hCas9 plasmid (hCas9 was a gift from George Church, Addgene plasmid # 
41815, (Mali et al. 2013)) dissolved in Lipofectamine 2000 (Invitrogen). After selection of 
transfected cells with Geneticin (Invitrogen), single colonies were picked and expanded. For 
sequencing, DNA was extracted from cells using DNeasy Blood & Tissue Kit (Qiagen). PCR 
amplification with Q5 high-fidelity DNA polymerase was undertaken using the primers Prn-ko 
F1 and P10 rev. After PCR clean-up using NucleoSpin Gel and PCR Clean-up kit (Macherey-
Nagel), blunt-end PCR fragments were cloned into Zero Blunt TOPO PCR Cloning Kit (Thermo 
Fisher Scientific) and Sanger Sequencing (Microsynth) was performed to identify mutated Prnp 
sequences. Western Blot and ELISA was undertaken to confirm Prnp0/0 as described below. 
Unless mentioned otherwise, clone #C12 was used for all experiments. 
Generation of stably transfected CAD5 cells with the murine Prnp mutants R207A, Q211E and 
R207C-I138C was done based on CAD5 Prnp0/0 cells (clone #C12). The pcDNA3.1(+) plasmid 
harboring Prnp (pcDNA3.1-PrnpWT) between the EcoRI and XhoI restriction sites was a gift 
from Valeria Eckhardt. Generation of PrPR207A, PrPQ211E and PrPR207C-I138C was undertaken 
using one-step (R207A, Q211E) or two-step (R207C-I138C) site-directed mutagenesis with 
the QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer’s 
guidelines. Empty and Prnp-expressing pcDNA3.1(+) plasmid variants were transfected into 
CAD5 Prnp0/0 using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
guidelines. Cells were selected with 0.5 mg/ml of Geneticin (Invitrogen) for at least 14 days 
prior to experiments.   
pCAG.SypI-hPrP-IRES-GFP was a gift from Vijay Chandrasekar, pCAG.DsRed was a gift from 
Connie Cepko (Addgene plasmid # 11151, (Matsuda and Cepko 2004)). Prior to transfection, 
pCAG.SypI-hPrP-IRES-GFP and pCAG.DsRed were linearized by AgeI restriction enzyme 
digestion (New England Biolabs). Transfection into HEK293 cells was performed using 
linearized pCAG.SypI-hPrP-IRES-GFP and pCAG.DsRed plasmids mixed with Lipofectamine 
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2000. Selection of brightest GFP- or DsRed-expressing cells, respectively, was undertaken by 
operator-based sorts on a FACSAria III 5L (BD Biosciences) at the Flow Cytometry Facility at 
the University of Zurich.  
HEK293 cells were maintained in DMEM/F12 medium (Invitrogen) with 10% fetal bovine serum 
(Invitrogen), 1% GlutaMAX (Invitrogen) and 1% Penicillin/Streptomycin (Invitrogen). CAD5 
cells were maintained in OptiMEM, phenol-red free medium (Invitrogen) with 10% fetal bovine 
serum (Invitrogen), 1% GlutaMAX (Invitrogen) and 1% Penicillin/Streptomycin (Invitrogen). 
Cell lines were kept in a standard cell incubator (37°C, 5% CO2, 95% humidity) and the culture 
medium was exchanged three times weekly. 
Chemicals  
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. All DNA 
oligonucleotides were synthesized by Microsynth. 
Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were performed in multi-well plates, namely 384-well Spectraplates HB (Perkin Elmer). 
For the detection of non-avidin linked, directly absorbed proteins, 1 µg of protein was dissolved 
per 1 ml of PBS and 20 µl of the PBS-protein solution was coated per well at 4°C overnight. 
Plates were washed three times in in PBS + 0.1% Tween-20 (0.1% PBS-T) and 80 µl per well 
of 5% skim milk (Migros) in 0.1% PBS-T was added to block nonspecific reactivity. After 2 h 
incubation at room temperature, blocking solution was discarded and blood samples were 
added usually at 1:100 starting dilutions (or as stated) in 1% skim milk in 0.1% PBS-T and 
incubated for 1.5 h at 37°C. Plates were washed five times and secondary anti-human IgG 
antibody (goat anti-human IgG Fc𝜸𝜸-specific HRP-conjugated polyclonal anti-IgG antibody 
(1:4’000, Jackson ImmunoResearch)) or anti-mouse IgG antibody (polyclonal HRP-conjugated 
goat anti-mouse IgG (1:4’000, Jackson ImmunoResearch)) and incubated for 1 h at room 
temperature. Plates were washed again 3 times in 0.1% PBS-T and 20 µl of the chromogenic 
HRP substrate 3,3', 5,5;-tetramethylbenzidine (TMB, Life Technologies) was added in each 
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well, after 5 minutes of incubation at room temperature, chromogenic reaction was stopped by 
addition of 20 µl of 0.5 M H2SO4  and absorbance was read at 𝜆𝜆=450 nm on a EnVision plate 
reader (Perkin Elmer). When coupling proteins through a biotin-avidin linker, 20 µl of the avidin-
based protein was absorbed per plate well at 1 µg per 1 ml of PBS overnight at 4°C. The plate 
was washed three times with 0.1% PBS-T and blocked for 1 hour with 5% TopBlock (Fluka) in 
0.1% PBS-T at room temperature. The biotinylated protein was added in molar excess 
dissolved in 0.1% PBS-T and incubated for 1 h at room temperature. The plate was washed 
three times in 0.1% PBS-T, further blocking with skim milk and addition of samples and 
antibodies was undertaken as described above.  
For measuring PrPC levels from cell and OCS lysates, 384-well Spectraplates HB were coated 
with 400 ng/ml POM1 (or POM19) in PBS at 4°C overnight. Plates were washed three times 
in 0.1% PBS-T and blocked with 80 µl per well of 5% skim milk in 0.1% PBS-T for 1.5 h at 
room temperature. Blocking buffer was discarded and samples and controls were added 
dissolved in 1% skim milk in 0.1% PBS-T for 1 h at 37°C. 2-fold dilutions of rmPrP23-230, starting 
at a dilution of 100 ng/ml in 1% skim milk in 0.1% PBS-T were used as calibration curve. 
Biotinylated POM2 (or biotinylated POM3) was used to detect PrPC (200 ng/ml in 1% skim milk 
in 0.1% PBS-T), biotinylated antibody was detected with Streptavidin-HRP (1:1’000 in 1% skim 
milk in 0.1% PBS-T BD Biosciences). Chromogenic reaction and reading of plates was 
performed as described above. Unknown PrPC concentrations were interpolated from the 
linear range of the calibration curve.  
The Human IgG ELISA Kit (Abcam, ab100547) was used to measure whole IgG levels in 
human blood. 
Fluorescence-activated cell sorting 
Cell monolayers were detached by scraping in 1 mM EDTA in PBS and spun down for 5 min 
at 800 x g. Cells were washed twice in FACS buffer (PBS with 3% FBS and 1 mM EDTA), 
counted and resuspended at concentrations of at least 1x106 cells per 100 µl. The following 
primary antibodies were added for 30 min at 4°C in the dark: PE-conjugated monoclonal 
  
  
KARL FRONTZEK, 2017 114 
 
mouse anti-human CD19 clone HIB19 (BD Biosciences), PerCP-Cy™5.5-conjugated 
monoclonal mouse anti-human IgD clone IA6-2 (BD Biosciences). When creating tetramers of 
BrilliantViolet421-Streptavidin (BV421-SA, BD Biosciences) with biotinylated human PrP-
Avitag (hPrP-ATbiotin), a ratio of 1:4 of BV421-SA:hPrP-ATbiotin was mixed at room temperature 
for 1 h. Tetramer solution was spun down at 23’000 x g for 10 min, and 0.35 µg of complex 
were added per reaction for 30 min at 4°C. Viable cells were visualized by incubating cells with 
Live/Dead® near-IR dead cell stain kit (Thermo Fisher Scientific). Cells were washed twice in 
FACS buffer for 5 min at 800 x g. FACS was performed using LSR II Fortessa (BD 
Biosciences).  
Immunohistochemistry and NeuN morphometry 
Organotypic slices were washed twice in PBS and fixed in 4% formalin for at least 2 days at 
4°C. Membrane inserts were washed and incubated for 1 h in blocking buffer (0.05% vol/vol 
Triton X-100 and 3% vol/vol goat serum dissolved in PBS) and incubated with primary 
antibodies diluted in blocking buffer at 4°C for 3 d. Primary antibodies used were as follows: 
Alexa-488-conjugated mouse anti-neuronal nuclei (NeuN) monoclonal antibody clone A60 (1.6 
µg/ml, Millipore), polyclonal rabbit anti-GFAP (1:1’000, DAKO),  rat anti-mouse F4/80 clone 
CI:A3-1 (1:1’000, Bio-Rad). Fluorescent detection of primary antibodies was undertaken using 
Alexa-conjugated secondary antibodies and counterstained with 4,6-diamidino-2-phenylindole 
(DAPI, 1 mg/ml) or Hoechst 33342 (H33342, 10 µg/ml). For NeuN morphometry, images were 
recorded at 10x magnification on a fluorescence microscope (BX-61, Olympus) equipped with 
a cooled black&white CCD camera. NeuN images were acquired at identical exposure times, 
and the area of immunoreactivity was determined by morphometry with image analysis 
software analySIS v5.0 (Soft Imaging System) using identical grey-scale threshold settings for 
identifying positive pixels.  
Glass bottom µ-slide chamber slides (Ibidi) were used to image cell monolayers. For staining 
of membranal epitopes, cells were washed twice in PBS and fixed with 4% formalin for 30 min 
at room temperature. For staining of intracellular epitopes, cells were washed twice in PBS 
  
  
KARL FRONTZEK, 2017 115 
 
and fixed in ice-cold acetone for 30 min. Cells were again washed twice and blocked for 1 h at 
room temperature with 10% goat serum (DAKO) and 5% bovine serum albumin (BSA) in PBS. 
Blocking buffer was discarded and anti-PrP mouse monoclonal POM primary antibodies were 
added at 1:1’000 in PBS overnight at 4°C diluted in PBS with 1% BSA. Cells were washed 
twice in PBS and fluorescent Alexa-conjugated secondary antibodies were added at 1:1’000 
in PBS with 1% BSA and incubated for 1 h at room temperature. Cells were washed twice in 
PBS and nuclei were counterstained with DAPI (1mg/ml) in PBS for 5 minutes at room 
temperature. Imaging of cells was done after another two washes in PBS.  
For live imaging of HEK PRNP0/0 cells transfected with pCAG.SypI-hPrP-IRES-GFP (HEKPrP-
GFP) and HEK PRNP0/0 cells transfected with pCAG.DsRed (HEK-Prnp0/0DsRed), cells were 
plated in 1:1 ratio and human plasma was diluted 1:50 into OptiMEM (Invitrogen). Cells were 
incubated for 30 min at 37°C, 5% CO2 for with OptiMEM-plasma and then washed three times 
in PBS. Cells were fixed using 4% formalin for 30 min and washed twice with PBS. Blocking, 
secondary antibodies and counterstainings were performed as described above.  
For immunohistochemistry of mice brains, prion-inoculated, formalin-fixed tissues were 
incubated in concentrated formic acid to inactivate prions, following by embedding in paraffin, 
sectioning of paraffin tissue (2 µm) and staining with hematoxylin and eosin (H&E). 
Deparaffinized sections were stained with primary antibodies as follows: polyclonal rabbit anti-
GFAP (1:300; DAKO), rabbit anti-Iba1 (1:1’000; Wako), monoclonal mouse anti-PrPSc clone 
SAF-84 (1:200; SPI bio). Sections were developed with IVIEW DAB Detection kit (Ventana) 
and were then counterstained with hematoxylin as described. Representative images were 
acquired using the digital camera UC30 (Olympus).  
In vitro bioassay 
In vitro assessment of prion propagation was performed with subclones of the murine 
neuroblastoma cell line CAD5 as described before (Enari, Flechsig, and Weissmann 2001). 
Herein, the cells were exposed to 0.001% RML6 (12 ng in 1 mL), 0.001% non-infectious brain 
homogenate (NBH, 11 ng in 1 mL) and 0.001% scFvPOM1- or scFvPOM1+recPrP23-230 COCS 
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homogenate (6 ng in 1 mL). Prions were allowed to propagate for 3 days followed by a 1:7 
split, with three further 3-day growth periods and 1:7 splits. Cells were harvested, lysed in PBS 
with 1% Triton-X 100, phosSTOPTM Phosphatase Inhibitor Cocktail (Roche), cOmpleteTM Mini 
Protease Inhibitor Cocktail (Roche). 
Live-imaging based neuronal cell quantification 
Z-stacks were recorded in ∆z steps as indicated and automated stitching was performed by 
LAS AF (Leica) or Fv10i-LIV (Olympus) software. Merged YFP+ CA1 z-stacks were imported 
into IMARIS software (Bitplane) for quantification of absolute YFP-positive hippocampal CA1 
pyramidal neuron number.  IMARIS Spots function with automatically determined black&white 
thresholds was used for automated neuron cell detection with subsequent manual adjustment 
for falsely labeled neurons. Correlation of blinded semi-automated counting through 2 readers 
in untreated YFP16 HOCS yielded a Pearson’s r=0.91 (n=6, 95% CI 0.38 - 0.99, p=0.01). YFP+ 
slices were randomly assigned to treatment groups; absolute cell numbers between treatment 
groups did not differ at baseline and are expressed as percentage of baseline counts per slice. 
Colocalization of YFP/NeuN double stained neurons on immunohistochemistry was 
determined using Colocalization Threshold for ImageJ.  
Live-imaging confocal microscopy 
PTFE-membranes with attached OCS were excised and placed in a glass bottom petri dish 
(MatTek) with 1.5 mL of organotypic slice culture medium. Live-imaging of fluorescently 
labeled OCS for quantification of hippocampal CA1 pyramidal neurons or CGL neurons was 
undertaken using a Fluoview Fv10i CLSM (Olympus) using a 10x dry objective (NA 0.4) at 2x 
optical zoom or a SP5 confocal microscopy (Leica) using a 10x dry objective (NA 0.4 at 1.7x 
optical zoom. Laser intensities were kept constant across treatment groups during imaging.  
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Patients and blood samples 
Ethics approval for patient studies was given by the local institutional review board (IRB), e.g. 
the Cantonal Ethics Committee of Zurich (KEK-ZH). These patients gave blood during their 
hospital stay at the University Hospital Zurich (UHZ) for diagnostic purposes (application 
number KEK-ZH 2015-0561). For genetic prion disease (gPrD), CIDP and APECED patients, 
IRB approval was given to further re-use their biological specimen obtained by external 
collaborators (application number KEK-ZH 2015-0514). For gPrD, CIDP and APECED 
patients, all participants have signed an informed consent according to their local jurisdiction 
and local IRB approvals are in place, where applicable.  
In the UHZ patient cohort, blood was tested only from patients who signed an informed 
consent for secondary use of diagnostic specimen for research purposes (“Generalkonsent 
2.0”). Physical interventions on UHZ patients were only performed during routine diagnostics 
and no additional blood was drawn for the purpose of this study. For gPrD, APECED and CIDP 
patients, phlebotomies were performed by qualified medical personnel (medical doctors, 
nurses) according to their local jurisdiction. No physical interventions were performed on Swiss 
gPrD patients (blood from one Swiss gPrD patient is included and IRB approval for this patient 
was given under the application number KEK-ZH 2015-0561). 
Pharmacological treatment of OCS 
Antibody treatment was initiated 10-14 days after dissection of OCS and was re-added with 
every medium change. Under live-imaging conditions, treatments were initiated and/or re-
added after imaging with every medium change. When combined with recPrP, antibodies were 
pre-incubated at 4°C for 1 hour with recPrP before administration.  
Preparation of organotypic slice cultures 
400 µm thick HOCS were prepared from 5-7 day-old pups and 350 µm thick COCS were 
prepared from 9-12 day-old pups according to previously published protocols (Stoppini, Buchs, 
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and Muller 1991; Falsig and Aguzzi 2008). Herein, animals were decapitated and the brains 
were immediately transferred into ice-cold Geys balanced salt solution (i.e. NaCl [137 mM], 
KCl [5 mM], Na2HPO4 [0.845 mM], CaCl2·2H2O [1.5 mM], KH2PO4 [0.66 mM], MgSO4·7H2O 
[0.28 mM], MgCl2·6H2O [1.0 mM] and NaHCO3 [2.7 mM]) with 33.33 mM glucose and 1 mM 
of the glutamate receptor antagonist kynurenic acid. The activation of the Thy1.2 expression 
cassette in neural tissue exhibits diverse variations depending amongst others on age, region 
and cell type (Porrero et al. 2010). Hence, only fluorescent brains were dissected for slices 
cultures despite the appearance of an YFP-allele on genotyping. Usually, 4-6 HOCS and 6-9 
COCS were plated per PTFE-coated cell culture insert (Millipore) in organotypic slice culture 
medium. Cultures were kept in a standard cell incubator (37°C, 5% CO2, 95% humidity). OCS 
culture medium was exchanged three times weekly. 
PRNP genotyping 
PRNP genotyping from gPrD patients was performed using a modified version of the DNeasy 
Blood & Tissue Kit (Qiagen). 20 µl of PK (600 mAU/ml) and 200 µl of guanidine hydrochloride 
(GdnHCl) with 1% Triton-X100 at pH=5.0 were added to 200 µl of anticoagualted blood, 
vortexed thoroughly and incubated for 24 h at room temperature. 200 µl EtOH (96-100%) were 
added to the reaction and the rest of the DNA purification was performed according to the 
manufacturer’s guidelines. The primer pair PRNP_up and PRNP_low (see also appendix a)) 
was used in combination with Q5 high-fidelity DNA polymerase to amplify the open reading 
frame from exon 2 of PRNP. Sanger sequencing was performed at the Department of 
Molecular Pathology (Institute of Surgical Pathology, University Hospital Zurich). Sequencing 
traces were aligned to reference DNA from the Reference Sequence (RefSeq) Database 
(O'Leary et al. 2016) using CLC Main Workbench (Qiagen).  
Recombinant proteins 
Bacterial expression of mouse and human recPrP and fragments thereof was performed as 
described in (Zahn, von Schroetter, and Wuthrich 1997; Hornemann et al. 2009; Sonati et al. 
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2013; Kuffer et al. 2016). For generation of hPrP-ATbiotin, a synthetic gene fragment (gBlock, 
IDT, see sequence in appendix b)) was designed harboring a N-terminal 6xHistidine-Tag 
followed by full-length human PrP23-231 linked by a GSGS-linker to the Avitag®-coding 
sequence (GLNDIFEAQKIEWHE, (Fairhead and Howarth 2015)). The hPrP-AT gene fragment 
was PCR amplified (primers hPrP-ATgbl_5’ and hPrP-ATgbl_5’, see also appendix a)) and 
DNA was excised and purified from the agarose gel using NucleoSpin Gel and PCR Clean-up 
kit (Macherey-Nagel). Cloning of hPrP-AT gBlock was done into the BamHI and EcoRI sites of 
a modified pREST-A-mini-T vector described in (Sonati et al. 2013) yielding pRSET-A-mini-
T.hPrP-AT. The plasmid pBirAcm (Avidity) containing the biotin ligase birA was used for in vivo 
biotinylation of hPrP-AT. Lysogeny broth (LB) agar containing 50 µg/ml Carbenicillin and 30 
µg/ml Chloramphenicol were plated with BL21 DE3 pLySs chemically competent E. coli 
(Invitrogen) co-transfected with pRSET-A-mini-T.hPrP-AT and pBirAcm and incubated 
overnight at 37°C. A single colony was picked and grown at 37°C overnight in LB liquid medium 
(“pre-culture”) containing 50 µg/ml Carbenicillin and 30 µg/ml Chloramphenicol. For protein 
expression, the pre-culture was diluted 1:20 in 2xYT medium (16 g Tryptone, 10 g Yeast, 5 g 
NaCl dissolved in 1 l ddH2O) supplemented with 50 µg/ml Carbenicillin, 30 µg/ml 
Chloramphenicol and 50 mM D-biotin and incubated at 25°C. When the optical density at 
𝜆𝜆=600 nm (OD600) reached 0.6 - 1.0, 1 mM of Isopropyl-β-D-thiogalactopyranosid (IPTG), and 
the cells were grown overnight at 25°C. For expression tests, cells were subsequently spun 
down at 23’000 x g for 5 min and 1 ml of cell equivalents of OD600=0.8 was lysed in NuPAGE 
LDS Sample Buffer (Thermo Fisher) in the presence and absence of 200 mM DTT. For large-
scale protein purification, hPrP-ATbiotin was purified on a Ni-Nitrilotriacetic acid (Ni-NTA) column 
as already described (Hornemann et al. 2009; Zahn, von Schroetter, and Wuthrich 1997). 
Purified protein was visualized using SDS-PAGE gels stained with InstaBlue (Sigma) and 
correct biotinylation was tested in Western Blot using Streptavidin-HRP (Abcam).  
Custom peptide synthesis of PrP fragments PrP106-126A117V (KTNMKHMAGAAVAGAVVGGLG) 
and PrP106-126scrambled (NGAKALMGGHGATKVMVGAAA) was performed by EZbiolabs.   
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Statistical analyses 
Statistical tests were performed as indicated and computed by GraphPad Prism 7 (GraphPad). 
GraphPad Prism 7, SPSS (IBM) and MATLAB (MathWorks) were used for data visualization. 
For statistical determination of differences in variance, an F-test of equality of variances was 
used. All data are given as mean ± S.D. unless stated otherwise.  
Three-dimensional neuron modeling and computation of time-lapse neuronal 
loss 
All computations from live-imaging derived data were performed using SPSS (IBM) and 
custom-written scripts in MATLAB (MathWorks). For three-dimensional visualization of 
neurons, x/y/z coordinates of YFP-positive CA1 pyramidal neurons were exported from 
IMARIS Spots and visualized using the plot3-function for MATLAB. The same neuronal three-
dimensional point clouds were used for slice-based calculations of cell-to-encompassing YFP-
positive volume ratios through application of a convex hull function (i.e. the convhull-function 
in MATLAB), where each neuron of a YFP+-slice is assigned a coefficient that is eventually 
used to compute a weighted average of all neuronal coefficients in three-dimensional space. 
For re-construction of time-lapse neuronal loss, I chose 9 putatively suitable curve estimation 
models with one regression coefficient (Table 1). Relative quality of estimated models was 
calculated using Akaike’s Information Criteria (AIC) corrected for finite sample sizes (AICc):  
knRSSnAIC 2)/ln(* +=  
1
)1(2
−−
+
+=
kn
kkAICAICc  
where n  = number of data points, RSS = residual sum of squares, k = number of parameters 
in the statistical model. 
The best candidate model was chosen by its smallest difference in AICc values when 
compared to other AICc values, ∆i: 
AICcAICcii min−=∆  
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where iAICc is AICc for model i and AICcmin is the minimum AIC value of all models. 
Western blot  
OCS were washed twice in PBS and scraped off the membrane using sterile PBS per slice, 
spun down at 1’000 x g for 5 min, followed by homogenization in lysis buffer (0.5% Triton-X 
100, phosSTOPTM Phosphatase Inhibitor Cocktail (Roche), cOmpleteTM Mini Protease Inhibitor 
Cocktail (Roche) in PBS) using the TissueLyser LT (Qiagen) at 50 Hz for 2 min. For PNGaseF 
digestion, 20 µg of samples were processed using a commercially available kit (New England 
Biolabs). Protein concentration of samples was determined using a bicinchoninic acid assay 
(Pierce Biotechnology). For determination of PrPSc, cell homogenates were digested with 5 
μg/mL, Tga20 COCS and C57BL/6 whole brain homogenates were digested with 25 μg/mL 
Proteinase K (Roche) at a final volume of 20 μL in PBS for 30 minutes at 37°C. Tga20 whole 
brain homogenates were digested with 50 μg/mL PK at a final volume of 20 μL in PBS for 45 
minutes at 37°C. Loading buffer was added and samples were boiled at 95°C for 5 minutes to 
deactivate PK. Western blotting was performed using the monoclonal anti-PrP antibody POM1 
as described before (Herrmann et al. 2015). For SDS-PAGE analysis, protein samples from 
OCS homogenates (10-20 µg per lane) were diluted in 20 µL of PBS and were separated using 
a 12% Bis-Tris polyacrylamide gel or for higher molecular weight proteins on a 4–12% gradient 
gel (NuPAGE, Invitrogen) with subsequent blotting onto a nitrocellulose membrane. 
Membranes were blocked with 5% wt/vol Top-Block (Fluka) in Tris-buffered saline 
supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) for 30 
minutes and incubated with primary antibodies in 1% Top-Block. Primary antibodies used were 
as follows: mouse monoclonal IgG1 raised against PrPC POM1 (400 ng/ml, see (Polymenidou 
et al. 2008)), monoclonal rabbit anti-ATF4 clone D4B8 (1:1’000, Cell Signalling Technologies), 
monoclonal rabbit anti-CHOP clone D46F1 (1:1’000, Cell Signalling Technologies), 
monoclonal mouse anti-gp91[phox] (833 ng/ml, BD Biosciences), polyclonal rabbit anti-NeuN 
(1:1’000, Abcam),  monoclonal mouse anti-actin clone C4 (1:10’000, Chemicon), mouse 
monoclonal anti-GAPDH clone 6C5 (200 ng/ml, Millipore). Secondary antibodies used were 
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horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:10’000, Chemicon) and 
HRP-conjugated goat anti-mouse IgG (1:10’000, Jackson ImmunoResearch). Blots were 
developed using Luminata Crescendo Western HRP substrate (Millipore) and visualized using 
the Stella chemilumniscence detection system (Raytest). Protein levels were normalized to 
actin and/or GAPDH as loading control and analyzed semi-quantitatively using the 
QuantityONE software (Bio-Rad).  
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Appendix 
 
a) Primer DNA and sgRNA sequences 
 
Name 
(forward/reverse) 
Sequence 5’ -> 3’ 
Genotyping of YFP16 animals 
oIMR1258 
(forward) 
TCT GAG TGG CAA AGG ACC TTA GG 
oIMR1260 
(reverse) 
CGC TGA ACT TGT GGC CGT TTA CG 
Creation of CAD5 Prnp0/0 
sgRNA TCA GTC ATC ATG GCG AAC CT 
Oligo 4 F 
(forward) 
ACA CCG CAG TCA TCA TGG CGA ACC TG 
Oligo 4 R 
(reverse) 
AAA ACA GGT TCG CCA TGA TGA CTG CG 
Prn-ko F1 
(forward) 
TGC AGG TGA CTT TCT GCA TTC TGG 
P10 rev 
(reverse) 
GCT GGG CTT GTT CCA CTG ATT ATG GGT AC 
MscI2594 restriction enzyme site mutagenesis of pFUSE2.CH-Ig1 
MscI(2594)-fwd 
(forward) 
CGG CAC TGG TCA ACT TCG CCA TGA TGG CTC CTC C 
MscI(2594)-rev 
(reverse) 
GGA GGA GCC ATC ATG GCG AAG TTG ACC AGT GCC G 
PCR amplification of hPOM1- and hPOM2-variable chain gene blocks 
POM1 
variable light 
(forward) 
ATA TAA CCG GTG CCA CCA TGT ACA GGA 
POM1 
variable light 
(reverse) 
TAT ATC GTA CGA CGT TTC AGC TCT AGC TTG GT 
POM2 
variable light 
(forward) 
ATA TAA CCG GTG CCA CCA TGT ACA GGA T 
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POM2 
variable light 
(reverse) 
TAT ATC GTA CGT TTG ATT TCC AGC TTG GTA CCT CC 
Generation of hPrP-ATbiotin 
hPrP-ATgbl_5’ 
(forward) 
ATA TAT GGA TCC AAG AAA CGC CCT AAA C 
hPrP-ATgbl_3’ 
(reverse) 
ATA TAT GAA TTC TCA TTA TTC ATG CCA CTC GA 
b) Gene blocks DNA sequences 
 
Name Sequence 5’ -> 3’ 
hPOM1 
Variable light 
chain 
ACCGGTGCCACCATGTACAGGATGCAACTCCTGTCTTGCATTGC
ACTAAGTCTTGCACTTGTCACGAATTCGGATATTGTGCTGACCCA
ATCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGTTT
CTCCTGCAGGGCCAGTCAGAACATTGGCACAAGCATACACTGGT
ATCAGCAAAGAACAAATGAATCTCCAAGGCTTATCATAAAGTATG
CTTCTGAGTCTATCTCTGGGATCCCTTCCAGGTTTAGTGGCAGTG
GATCAGGGACAGATTTTACTCTTAGCATCAACAGTGTGGAGTCTG
AAGATATTGCAGATTATTACTGTCAACAAAGTAATACCTGGCCGT
ACACGTTCGGAGGGGGGACCAAGCTAGAGCTGAAACGTCGTAC
G 
Variable + 
constant heavy 
chain 
GATATCGCCACCATGTACAGGATGCAACTCCTGTCTTGCATTGCA
CTAAGTCTTGCACTTGTCACGAATTCGCAGGTCCAGCTCCAGCAA
TCTGGGACTGAGCTTGTGATGCCTGGGGCTTCAGTGAAGATGTC
CTGCAAGGCTTCTGGCTACACATTCACTGACTACTGGATGCACTG
GGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATCGGATCG
ATTGATCCTTCTGATAGTTATACTAGTCACAATGAAAAGTTCAAGG
GCAAGGCCACATTGACTGTAGACGAATCCTCCAGCACAGCCTAC
ATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTT
CTGTTCAAGATCCGGCTACGGATATTATGCTATGGAGTACTGGG
GTCAAGGAACCTCAGTCACCGTCTCCTCGGCTAGCACCAAGGGC
CCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGG
GGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG
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GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTAC
TCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCA
CCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACC
AAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCAC
ACATGCCCACCGTGCCCAGCACCTGAAGCAGCCGGGGGACCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCT
CCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCA
CGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG
GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
AGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAG
GGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG
GGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA
TGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTG
GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGA
CAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC
CTGTCTCCGGGTAAACATCACCATCACCATCACTGATGGCCA 
hPOM2 
Variable light 
chain 
ACCGGTGCCACCATGTACAGGATGCAACTCCTGTCTTGCATTGC
ACTAAGTCTTGCACTTGTCACGAATTCGGATATTGTGATGACACA
GTCTCACAAATTCATGTCCACTTCAGTAGGAGACAGGGTCAGCAT
CACCTGCAAGGCCAGTCAGGATGTGGGTACTGCTCTAGCCTGGT
ATCAACAGAAACCAGGGCAATCTCCTAAACTACTGATTTACTGGG
CATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGT
GGATCTGGGACAGATTTCACTCTCACCATTAGCAATGTGCAGTCT
GAAGACTTGTCAGATTATTTCTGTCAGCAATATAGCAGCTATCCG
ACGTTCGGTGGAGGTACCAAGCTGGAAATCAAACGTACG 
Variable + 
constant heavy 
chain 
GATATCGCCACCATGTACAGGATGCAACTCCTGTCTTGCATTGCA
CTAAGTCTTGCACTTGTCACGAATTCGGAGGTAAAGCTTCAGGAG
TCTGGAGGTGAGGTGGTAAGGCCTGGGACTTCAGTGAAGGTGTC
CTGCAAGGCTTCTGGATATGCCTTCACTAATTACTTAATAGAGTG
GGTAAAGCAGAGGCCTGGACAGGGCCTTGAGTGGATTGGAGTG
ATTAATCCTGGAAGTGGTGATACTAACTACAATGAGAAGTTCAAG
GGCAAGGCAACACTGACTGCAGACAAGTCCTCCAGCACTGCCTA
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TATGCAGCTCAACAGCCTGACATCTGATGACTCTGCGGTCTATTT
CTGTGCAAGATCAGGGGTAGCTGCCCCTTATTACTATGCTATGGA
CTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCGGCTAGCA
CCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACT
ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT
GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAG
GACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC
TTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAG
CAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACA
AAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCAGCCGG
GGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCC
TCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGA
CGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCT
GCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCT
CCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA
GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC
CATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTG
CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG
AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCA
CCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATG
CTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGA
GCCTCTCCCTGTCTCCGGGTAAACATCACCATCACCATCACTGAT
GGCCA 
Generation of hPrP-ATbiotin 
hPrP-AT 
ATATATGGATCCAAGAAACGCCCTAAACCGGGAGGGTGGAATAC
AGGTGGTAGCCGTTACCCCGGGCAAGGAAGCCCGGGGGGTAAT
CGTTACCCTCCTCAAGGCGGGGGTGGATGGGGCCAACCCCATG
GCGGGGGTTGGGGCCAGCCGCATGGTGGAGGTTGGGGCCAAC
CTCATGGAGGCGGGTGGGGTCAGCCGCACGGAGGAGGCTGGG
GGCAGGGAGGCGGCACACACTCCCAATGGAATAAACCCAGTAA
GCCCAAAACCAATATGAAGCATATGGCTGGAGCAGCAGCGGCAG
GGGCCGTTGTTGGGGGACTGGGGGGTTATGTTCTTGGATCAGC
CATGTCCCGCCCCATCATTCACTTTGGGTCTGATTATGAAGACCG
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CTACTATCGTGAAAATATGCACCGTTACCCCAACCAAGTCTACTA
TCGCCCGATGGACGAGTACAGCAATCAGAACAACTTTGTTCACG
ACTGCGTGAACATTACAATTAAACAGCACACTGTCACCACTACAA
CCAAAGGGGAGAATTTTACCGAAACTGATGTCAAGATGATGGAG
CGTGTCGTGGAACAGATGTGCATCACTCAATATGAGCGTGAATC
CCAAGCATATTACAAACGTGGTAGCGGTTCGGGCAGTGGTCTGA
ACGACATCTTCGAGGCCCAGAAAATCGAGTGGCATGAATAATGA
GAATTCATATAT 
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